1
|
Abdel-Razek O, Jung RG, Di Santo P, Mathew R, Hibbert B. Impact of hypoxic hepatitis in cardiogenic shock: a substudy of the DOREMI trial. Eur Heart J Open 2024; 4:oeae024. [PMID: 38708291 PMCID: PMC11065344 DOI: 10.1093/ehjopen/oeae024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/28/2023] [Revised: 01/21/2024] [Accepted: 02/02/2024] [Indexed: 05/07/2024]
Affiliation(s)
- Omar Abdel-Razek
- Division of Cardiovascular Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA 02446, USA
- CAPITAL Research Group, University of Ottawa Heart Institute, 40 Ruskin Street, Ottawa, K1Y4W7 Ontario, Canada
| | - Richard G Jung
- CAPITAL Research Group, University of Ottawa Heart Institute, 40 Ruskin Street, Ottawa, K1Y4W7 Ontario, Canada
- Vascular Biology and Experimental Medicine Laboratory, University of Ottawa Heart Institute, 40 Ruskin Street, Ottawa, K1Y4W7 Ontario, Canada
- Department of Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa, 501 Smyth Road, Ottawa, K1H8L6 Ontario, Canada
- Division of Internal Medicine, The Ottawa Hospital, 501 Smyth Road, Ottawa, K1H8L6 Ontario, Canada
| | - Pietro Di Santo
- CAPITAL Research Group, University of Ottawa Heart Institute, 40 Ruskin Street, Ottawa, K1Y4W7 Ontario, Canada
- School of Epidemiology and Public Health, University of Ottawa, 501 Smyth Road, Ottawa, K1H8L6 Ontario, Canada
- Division of Cardiology, University of Ottawa Heart Institute, 40 Ruskin Street, Ottawa, K1Y4W7 Ontario, Canada
| | - Rebecca Mathew
- CAPITAL Research Group, University of Ottawa Heart Institute, 40 Ruskin Street, Ottawa, K1Y4W7 Ontario, Canada
- Division of Cardiology, University of Ottawa Heart Institute, 40 Ruskin Street, Ottawa, K1Y4W7 Ontario, Canada
| | - Benjamin Hibbert
- CAPITAL Research Group, University of Ottawa Heart Institute, 40 Ruskin Street, Ottawa, K1Y4W7 Ontario, Canada
- Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN 55905, USA
| |
Collapse
|
2
|
Mesnier J, Simard T, Jung RG, Lehenbauer KR, Piayda K, Pracon R, Jackson GG, Flores-Umanzor E, Faroux L, Korsholm K, Chun JKR, Chen S, Maarse M, Montrella K, Chaker Z, Spoon JN, Pastormerlo LE, Meincke F, Sawant AC, Moldovan CM, Qintar M, Aktas MK, Branca L, Radinovic A, Ram P, El-Zein RS, Flautt T, Ding WY, Sayegh B, Benito-González T, Lee OH, Badejoko SO, Paitazoglou C, Karim N, Zaghloul AM, Agarwal H, Kaplan RM, Alli O, Ahmed A, Suradi HS, Knight BP, Alla VM, Panaich SS, Wong T, Bergmann MW, Chothia R, Kim JS, Pérez de Prado A, Bazaz R, Gupta D, Valderrábano M, Sanchez CE, El Chami MF, Mazzone P, Adamo M, Ling F, Wang DD, O'Neill W, Wojakowski W, Pershad A, Berti S, Spoon DB, Kawsara A, Jabbour G, Boersma LVA, Schmidt B, Nielsen-Kudsk JE, Freixa X, Ellis CR, Fauchier L, Demkow M, Sievert H, Main ML, Hibbert B, Holmes DR, Alkhouli M, Rodés-Cabau J. Persistent and Recurrent Device-Related Thrombus After Left Atrial Appendage Closure: Incidence, Predictors, and Outcomes. JACC Cardiovasc Interv 2023; 16:2722-2732. [PMID: 38030358 DOI: 10.1016/j.jcin.2023.09.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/14/2023] [Revised: 09/05/2023] [Accepted: 09/11/2023] [Indexed: 12/01/2023]
Abstract
BACKGROUND Scarce data exist on the evolution of device-related thrombus (DRT) after left atrial appendage closure (LAAC). OBJECTIVES This study sought to assess the incidence, predictors, and clinical impact of persistent and recurrent DRT in LAAC recipients. METHODS Data were obtained from an international multicenter registry including 237 patients diagnosed with DRT after LAAC. Of these, 214 patients with a subsequent imaging examination after the initial diagnosis of DRT were included. Unfavorable evolution of DRT was defined as either persisting or recurrent DRT. RESULTS DRT resolved in 153 (71.5%) cases and persisted in 61 (28.5%) cases. Larger DRT size (OR per 1-mm increase: 1.08; 95% CI: 1.02-1.15; P = 0.009) and female (OR: 2.44; 95% CI: 1.12-5.26; P = 0.02) were independently associated with persistent DRT. After DRT resolution, 82 (53.6%) of 153 patients had repeated device imaging, with 14 (17.1%) cases diagnosed with recurrent DRT. Overall, 75 (35.0%) patients had unfavorable evolution of DRT, and the sole predictor was average thrombus size at initial diagnosis (OR per 1-mm increase: 1.09; 95% CI: 1.03-1.16; P = 0.003), with an optimal cutoff size of 7 mm (OR: 2.51; 95% CI: 1.39-4.52; P = 0.002). Unfavorable evolution of DRT was associated with a higher rate of thromboembolic events compared with resolved DRT (26.7% vs 15.1%; HR: 2.13; 95% CI: 1.15-3.94; P = 0.02). CONCLUSIONS About one-third of DRT events had an unfavorable evolution (either persisting or recurring), with a larger initial thrombus size (particularly >7 mm) portending an increased risk. Unfavorable evolution of DRT was associated with a 2-fold higher risk of thromboembolic events compared with resolved DRT.
Collapse
Affiliation(s)
- Jules Mesnier
- Quebec Heart and Lung Institute, Laval University, Quebec City, Quebec, Canada
| | - Trevor Simard
- Department of Cardiovascular Diseases, Mayo Clinic School of Medicine, Rochester, Minnesota, USA
| | - Richard G Jung
- Capital Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Kyle R Lehenbauer
- Division of Cardiology, Saint Luke's Mid America Heart Institute, Kansas City, Missouri, USA
| | - Kerstin Piayda
- CardioVascular Center Frankfurt, Frankfurt, Germany; Department of Cardiology and Angiology, Universitätsklinikum Gießen und Marburg, Gießen, Germany
| | - Radoslaw Pracon
- Coronary and Structural Heart Diseases Department, National Institute of Cardiology, Warsaw, Poland
| | | | - Eduardo Flores-Umanzor
- Department of Cardiology, Hospital Clínic of Barcelona, August Pi i Sunyer Biomedical Research Institute, University of Barcelona, Barcelona, Spain
| | - Laurent Faroux
- Quebec Heart and Lung Institute, Laval University, Quebec City, Quebec, Canada
| | - Kasper Korsholm
- Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark
| | - Julian K R Chun
- Cardioangiologisches Centrum Bethanien, Medizinische Klinik III, Markuskrankenhaus, Frankfurt, Germany
| | - Shaojie Chen
- Cardioangiologisches Centrum Bethanien, Medizinische Klinik III, Markuskrankenhaus, Frankfurt, Germany
| | - Moniek Maarse
- Cardiology, St Antonius Hospital, Nieuwegein, the Netherlands; LB Amsterdam University Medical Center, Amsterdam, the Netherlands
| | - Kristi Montrella
- Heart and Vascular Institute, University of Pittsburgh Medical Center, University of Pittsburgh, Altoona, Pennsylvania, USA
| | - Zakeih Chaker
- Division of Cardiology, West Virginia School of Medicine, Morgantown, West Virginia, USA
| | - Jocelyn N Spoon
- International Heart Institute of Montana, Missoula, Montana, USA
| | - Luigi E Pastormerlo
- Fondazione Toscana Gabriele Monasterio Massa, Scuola Superiore Sant'Anna, Pisa, Italy
| | | | | | - Carmen M Moldovan
- Division of Cardiology and Structural Heart Diseases, Medical University of Silesia, Katowice, Poland
| | - Mohammed Qintar
- Division of Cardiology, Henry Ford Health System, Detroit, Michigan, USA; Department of Cardiology, Sparrow Hospital, Michigan State University, Lansing, Michigan
| | - Mehmet K Aktas
- Division of Cardiology, University of Rochester Medical Center, Rochester, New York, USA
| | - Luca Branca
- Cardiac Catheterization Laboratory and Cardiology, ASST Spedali Civili di Brescia, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy
| | - Andrea Radinovic
- Arrhythmology Department, San Raffaele University Hospital, Milan, Italy
| | - Pradhum Ram
- Emory University Hospital, Atlanta, Georgia, USA
| | - Rayan S El-Zein
- Division of Cardiology, OhioHealth Doctors Hospital/OhioHealth Riverside Methodist Hospital, Columbus, Ohio, USA
| | | | - Wern Yew Ding
- Liverpool Heart and Chest Hospital, Liverpool, United Kingdom
| | - Bassel Sayegh
- Heart, Lung and Vascular Institute, Excela Health, Independence Health System, Pittsburgh, Pennsylvania, USA
| | | | - Oh-Hyun Lee
- Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea
| | - Solomon O Badejoko
- Division of Internal Medicine, St Joseph's Medical Center (Dignity Health), Stockton, California, USA
| | | | - Nabeela Karim
- Royal Brompton and Harefield Hospitals, Part of Guys' and St Thomas' National Health Service Foundation Trust, London, United Kingdom
| | - Ahmed M Zaghloul
- Division of Cardiovascular Medicine, Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, Iowa, USA
| | | | - Rachel M Kaplan
- Bluhm Cardiovascular Institute, Northwestern University, Chicago, Illinois, USA
| | - Oluseun Alli
- Division of Cardiology, Novant Health Heart and Vascular Institute, Charlotte, North Carolina, USA
| | - Aamir Ahmed
- Rush University Medical Center, Chicago, Illinois, USA
| | | | - Bradley P Knight
- Bluhm Cardiovascular Institute, Northwestern University, Chicago, Illinois, USA
| | - Venkata M Alla
- Creighton University School of Medicine, Omaha, Nebraska, USA
| | - Sidakpal S Panaich
- Division of Cardiovascular Medicine, Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, Iowa, USA
| | - Tom Wong
- Royal Brompton and Harefield Hospitals, Part of Guys' and St Thomas' National Health Service Foundation Trust, London, United Kingdom
| | | | - Rashaad Chothia
- Division of Internal Medicine, St Joseph's Medical Center (Dignity Health), Stockton, California, USA
| | - Jung-Sun Kim
- Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea
| | | | - Raveen Bazaz
- Heart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA
| | - Dhiraj Gupta
- Liverpool Heart and Chest Hospital, Liverpool, United Kingdom
| | | | - Carlos E Sanchez
- Division of Cardiology, OhioHealth Doctors Hospital/OhioHealth Riverside Methodist Hospital, Columbus, Ohio, USA
| | | | - Patrizio Mazzone
- Electrophysiology Unit, Cardio-Thoraco-Vascular Department, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy
| | - Marianna Adamo
- Cardiac Catheterization Laboratory and Cardiology, ASST Spedali Civili di Brescia, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy
| | - Fred Ling
- Division of Cardiology, University of Rochester Medical Center, Rochester, New York, USA
| | - Dee Dee Wang
- Division of Cardiology, Henry Ford Health System, Detroit, Michigan, USA
| | - William O'Neill
- Division of Cardiology, Henry Ford Health System, Detroit, Michigan, USA
| | - Wojtek Wojakowski
- Division of Cardiology and Structural Heart Diseases, Medical University of Silesia, Katowice, Poland
| | - Ashish Pershad
- Chandler Regional Medical Center, Chandler, Arizona, USA
| | - Sergio Berti
- Fondazione Toscana Gabriele Monasterio Massa, Scuola Superiore Sant'Anna, Pisa, Italy
| | - Daniel B Spoon
- International Heart Institute of Montana, Missoula, Montana, USA
| | - Akram Kawsara
- Division of Cardiology, West Virginia School of Medicine, Morgantown, West Virginia, USA
| | - George Jabbour
- Heart and Vascular Institute, University of Pittsburgh Medical Center, University of Pittsburgh, Altoona, Pennsylvania, USA
| | - Lucas V A Boersma
- Cardiology, St Antonius Hospital, Nieuwegein, the Netherlands; LB Amsterdam University Medical Center, Amsterdam, the Netherlands
| | - Boris Schmidt
- Cardioangiologisches Centrum Bethanien, Medizinische Klinik III, Markuskrankenhaus, Frankfurt, Germany
| | | | - Xavier Freixa
- Department of Cardiology, Hospital Clínic of Barcelona, August Pi i Sunyer Biomedical Research Institute, University of Barcelona, Barcelona, Spain
| | | | - Laurent Fauchier
- Service de Cardiologie, Centre Hospitalier Universitaire Trousseau Faculté de Médecine, Université François Rabelais, Tours, France
| | - Marcin Demkow
- Coronary and Structural Heart Diseases Department, National Institute of Cardiology, Warsaw, Poland
| | - Horst Sievert
- Heart, Lung and Vascular Institute, Excela Health, Independence Health System, Pittsburgh, Pennsylvania, USA
| | - Michael L Main
- Division of Cardiology, Saint Luke's Mid America Heart Institute, Kansas City, Missouri, USA
| | - Benjamin Hibbert
- Capital Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - David R Holmes
- Department of Cardiovascular Diseases, Mayo Clinic School of Medicine, Rochester, Minnesota, USA
| | - Mohamad Alkhouli
- Department of Cardiovascular Diseases, Mayo Clinic School of Medicine, Rochester, Minnesota, USA.
| | - Josep Rodés-Cabau
- Quebec Heart and Lung Institute, Laval University, Quebec City, Quebec, Canada; Department of Cardiology, Hospital Clínic of Barcelona, August Pi i Sunyer Biomedical Research Institute, University of Barcelona, Barcelona, Spain.
| |
Collapse
|
3
|
Jung RG, Kipshidze N, Duchez AC. Editorial: Thrombo-inflammation in cardiovascular disease and health. Front Cardiovasc Med 2023; 10:1294874. [PMID: 37900561 PMCID: PMC10600444 DOI: 10.3389/fcvm.2023.1294874] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2023] [Accepted: 09/26/2023] [Indexed: 10/31/2023] Open
Affiliation(s)
- Richard G. Jung
- CAPITAL research group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, ON, Canada
- Division of Internal Medicine, The Ottawa Hospital, Ottawa, ON, Canada
| | - Nicholas Kipshidze
- Division of Interventional Therapy, New York Cardiovascular Research, New York, NY, United States
- Hemostasis and Thrombosis Research Laboratories, Loyola University Medical Center, Chicago, IL, United States
| | - Anne-Claire Duchez
- INSERM, U 1059 SAINBIOSE, Université Jean Monnet, Mines Saint-Étienne, Saint-Etienne, France
- Etablissement Français du Sang Auvergne-Rhône-Alpes, Research Department, Saint-Etienne, France
| |
Collapse
|
4
|
Sterling LH, Fernando SM, Talarico R, Qureshi D, van Diepen S, Herridge MS, Price S, Brodie D, Fan E, Di Santo P, Jung RG, Parlow S, Basir MB, Scales DC, Combes A, Mathew R, Thiele H, Tanuseputro P, Hibbert B. Long-Term Outcomes of Cardiogenic Shock Complicating Myocardial Infarction. J Am Coll Cardiol 2023; 82:985-995. [PMID: 37648357 DOI: 10.1016/j.jacc.2023.06.026] [Citation(s) in RCA: 7] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/23/2023] [Revised: 05/24/2023] [Accepted: 06/12/2023] [Indexed: 09/01/2023]
Abstract
BACKGROUND Cardiogenic shock secondary to acute myocardial infarction (AMI-CS) is associated with substantial short-term mortality; however, there are limited data on long-term outcomes and trends. OBJECTIVES This study sought to examine long-term outcomes of AMI-CS patients. METHODS This was a population-based, retrospective cohort study in Ontario, Canada of critically ill adult patients with AMI-CS who were admitted to hospitals between April 1, 2009 and March 31, 2019. Outcome data were captured using linked health administrative databases. RESULTS A total of 9,789 consecutive patients with AMI-CS from 135 centers were included. The mean age was 70.5 ± 12.3 years, and 67.7% were male. The incidence of AMI-CS was 8.2 per 100,000 person-years, and it increased over the study period. Critical care interventions were common, with 5,422 (55.4%) undergoing invasive mechanical ventilation, 1,425 (14.6%) undergoing renal replacement therapy, and 1,484 (15.2%) receiving mechanical circulatory support. A total of 2,961 patients (30.2%) died in the hospital, and 4,004 (40.9%) died by 1 year. Mortality at 5 years was 58.9%. Small improvements in short- and long-term mortality were seen over the study period. Among survivors to discharge, 2,870 (42.0%) required increased support in care from their preadmission baseline, 3,244 (47.5%) were readmitted to the hospital within 1 year, and 1,047 (15.3%) died within 1 year. The mean number of days at home in the year following discharge was 307.9 ± 109.6. CONCLUSIONS Short- and long-term mortality among patients with AMI-CS is high, with minimal improvement over time. AMI-CS survivors experience significant morbidity, with high risks of readmission and death. Future studies should evaluate interventions to minimize postdischarge morbidity and mortality among AMI-CS survivors.
Collapse
Affiliation(s)
- Lee H Sterling
- CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Shannon M Fernando
- CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; Division of Critical Care, Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada; Department of Critical Care, Lakeridge Health Corporation, Oshawa, Ontario, Canada; Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
| | - Robert Talarico
- Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; ICES, Toronto, Ontario, Canada
| | - Danial Qureshi
- Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; ICES, Toronto, Ontario, Canada; Bruyère Research Institute, Ottawa, Ontario, Canada
| | - Sean van Diepen
- Department of Critical Care Medicine, University of Alberta, Edmonton, Alberta, Canada; Division of Cardiology, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada; VIGOUR Centre, University of Alberta, Edmonton, Alberta, Canada
| | - Margaret S Herridge
- Interdepartmental Division of Critical Care Medicine, University of Toronto, Toronto, Ontario, Canada; Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada; Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada
| | - Susanna Price
- Royal Brompton & Harefield Hospitals, London, United Kingdom; National Heart and Lung Institute, Imperial College, London, United Kingdom
| | - Daniel Brodie
- Division of Pulmonary and Critical Care Medicine, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
| | - Eddy Fan
- Interdepartmental Division of Critical Care Medicine, University of Toronto, Toronto, Ontario, Canada; Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada; Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada
| | - Pietro Di Santo
- CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; Division of Critical Care, Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada
| | - Richard G Jung
- CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Simon Parlow
- CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Mir B Basir
- Division of Cardiology, Henry Ford Hospital, Detroit, Michigan, USA
| | - Damon C Scales
- ICES, Toronto, Ontario, Canada; Interdepartmental Division of Critical Care Medicine, University of Toronto, Toronto, Ontario, Canada; Department of Critical Care Medicine, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; Li Ka Shing Knowledge Institute, St Michael's Hospital, Toronto, Ontario, Canada
| | - Alain Combes
- Institute of Cardiometabolism and Nutrition, Sorbonne University, Paris, France; Service de Médecine Intensive-Réanimation, Hôpitaux Universitaires Pitié Salpêtrière, Assistance Publique-Hôpitaux de Paris, Institut de Cardiologie, Paris, France
| | - Rebecca Mathew
- CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Holger Thiele
- Department of Internal Medicine/Cardiology, Heart Center Leipzig at the University of Leipzig and Leipzig Heart Institute, Leipzig, Germany
| | - Peter Tanuseputro
- Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; ICES, Toronto, Ontario, Canada; Bruyère Research Institute, Ottawa, Ontario, Canada; Division of Palliative Care, Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada
| | - Benjamin Hibbert
- CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA
| |
Collapse
|
5
|
Abdel-Razek O, Di Santo P, Jung RG, Parlow S, Motazedian P, Prosperi-Porta G, Visintini S, Marbach JA, Ramirez FD, Simard T, Labinaz M, Mathew R, Hibbert B. Efficacy of Milrinone and Dobutamine in Cardiogenic Shock: An Updated Systematic Review and Meta-Analysis. Crit Care Explor 2023; 5:e0962. [PMID: 37649849 PMCID: PMC10465094 DOI: 10.1097/cce.0000000000000962] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/01/2023] Open
Abstract
OBJECTIVES Inotropic support is commonly used in patients with cardiogenic shock (CS). High-quality data guiding the use of dobutamine or milrinone among this patient population is limited. We compared the efficacy and safety of these two inotropes among patients with low cardiac output states (LCOS) or CS. DATA SOURCES MEDLINE, Embase, and Cochrane Central Register of Controlled Trials were searched up to February 1, 2023, using key terms and index headings related to LCOS or CS and inotropes. DATA EXTRACTION Two independent reviewers included studies that compared dobutamine to milrinone on all-cause in-hospital mortality, length of ICU stay, length of hospital stay, and significant arrhythmias in hospitalized patients. DATA SYNTHESIS A total of eleven studies with 21,084 patients were included in the meta-analysis. Only two randomized controlled trials were identified. The primary outcome, all-cause mortality, favored milrinone in observational studies only (odds ratio [OR] 1.19 (95% CI, 1.02-1.39; p = 0.02). In-hospital length of stay (LOS) was reduced with dobutamine in observational studies only (mean difference -1.85 d; 95% CI -3.62 to -0.09; p = 0.04). There was no difference in the prevalence of significant arrhythmias or in ICU LOS. CONCLUSIONS Only limited data exists supporting the use of one inotropic agent over another exists. Dobutamine may be associated with a shorter hospital LOS; however, there is also a potential for increased all-cause mortality. Larger randomized studies sufficiently powered to detect a difference in these outcomes are required to confirm these findings.
Collapse
Affiliation(s)
- Omar Abdel-Razek
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
- Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Pietro Di Santo
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
- Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
- Vascular Biology and Experimental Medicine Laboratory, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
- School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada
| | - Richard G Jung
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
- Vascular Biology and Experimental Medicine Laboratory, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
- Department of Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada
- Division of Internal Medicine, The Ottawa Hospital, Ottawa, Ontario, Canada
| | - Simon Parlow
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
- Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Pouya Motazedian
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
- Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Graeme Prosperi-Porta
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
- Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Sarah Visintini
- Berkman Library, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Jeffrey A Marbach
- Division of Cardiovascular Medicine, Knight Cardiovascular Center, Oregon Health and Science University, Portland, OR
| | - F Daniel Ramirez
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
- Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Trevor Simard
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
- Vascular Biology and Experimental Medicine Laboratory, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
- Department of Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada
- Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN
| | - Marino Labinaz
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
- Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Rebecca Mathew
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
- Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Benjamin Hibbert
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
- Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN
| |
Collapse
|
6
|
Parlow S, Santo PD, Sterling LH, Goodliffe L, Motazedian P, Prosperi-Porta G, Morgan B, Koopman Z, Jung RG, Lepage-Ratte MF, Robinson L, Feagan H, Simard T, Wells GA, Kyeremanteng K, Ainsworth C, Amin F, Marbach JA, Fernando SM, Labinaz M, Belley-Cote EP, Hibbert B, Mathew R. Inotrope versus Placebo Therapy in Cardiogenic Shock: Rationale and Study Design of the CAPITAL DOREMI2 Trial. Am Heart J 2023; 262:83-89. [PMID: 37094667 DOI: 10.1016/j.ahj.2023.04.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/08/2023] [Revised: 04/17/2023] [Accepted: 04/19/2023] [Indexed: 05/03/2023]
Abstract
BACKGROUND Cardiogenic shock (CS) is a state of end-organ hypoperfusion related to cardiac dysfunction. Current guidelines recommend consideration of inotrope therapy in patients with CS, however no robust data support their use. The purpose of the CAPITAL DOREMI2 trial is to examine the efficacy and safety of inotrope therapy against placebo in the initial resuscitation of patients with CS. METHODS AND DESIGN This is a multi-center, double-blind, randomized, placebo-controlled trial comparing single-agent inotrope therapy to placebo in patients with CS. A total of 346 participants with Society for Cardiovascular Angiography and Interventions class C or D CS will be randomized in a 1:1 fashion to inotrope or placebo therapy, which will be administered over a 12-hour period. After this period, participants will continue open-label therapies at the discretion of the treating team. The primary outcome is a composite of all-cause in-hospital death, and, as measured during the 12-hour intervention period, any of: sustained hypotension or high dose vasopressor requirements, lactate greater than 3.5 mmol/L at 6 hours or thereafter, need for mechanical circulatory support, arrhythmia leading to emergent electrical cardioversion, and resuscitated cardiac arrest. All participants will be followed for the duration of their hospitalization, and secondary outcomes will be assessed at the time of discharge. IMPLICATION This trial will be the first to establish the safety and efficacy of inotrope therapy against placebo in a population of patients with CS and has the potential to alter the standard care provided to this group of patients.
Collapse
Affiliation(s)
- Simon Parlow
- Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Pietro Di Santo
- Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; Division of Critical Care Medicine, Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada; School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada
| | - Lee H Sterling
- Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Laura Goodliffe
- Division of Cardiology, Department of Medicine, McMaster University, Hamilton, Ontario, Canada
| | - Pouya Motazedian
- Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Graeme Prosperi-Porta
- Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Baylie Morgan
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Zandra Koopman
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Richard G Jung
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada
| | - Melissa Fay Lepage-Ratte
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada
| | - Lisa Robinson
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Hannah Feagan
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Trevor Simard
- Department of Cardiovascular Diseases, Mayo Clinic School of Medicine, Rochester, Minnesota
| | - George A Wells
- School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada; Cardiovascular Research Methods Center, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Kwadwo Kyeremanteng
- Division of Critical Care Medicine, Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada
| | - Craig Ainsworth
- Division of Cardiology, Department of Medicine, McMaster University, Hamilton, Ontario, Canada
| | - Faizan Amin
- Division of Cardiology, Department of Medicine, McMaster University, Hamilton, Ontario, Canada
| | - Jeffrey A Marbach
- Division of Cardiology, Knight Cardiovascular Institute, Oregon Health & Sciences University, Portland, Oregon, USA
| | - Shannon M Fernando
- Department of Critical Care, Lakeridge Health Corporation, Oshawa, Ontario, Canada
| | - Marino Labinaz
- Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Emilie P Belley-Cote
- Division of Cardiology, Department of Medicine, McMaster University, Hamilton, Ontario, Canada; Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada
| | - Benjamin Hibbert
- Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Rebecca Mathew
- Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.
| |
Collapse
|
7
|
Parlow S, Di Santo P, Abdel-Razek O, Jung RG, Motazedian P, Robinson L, Feagan H, Morgan B, Wade J, Toeg H, Al-Atassi T, Ruel M, Kuhar P, Bernick J, Wells GA, Simard T, Marbach JA, Froeschl M, Mathew R, Labinaz M, Chan V, Hibbert B. Utility of a Smartphone Application in Assessing Palmar Circulation Before Radial Artery Harvesting for Coronary Artery Bypass Grafting. Circulation 2023; 147:1183-1185. [PMID: 37036908 DOI: 10.1161/circulationaha.122.063795] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 04/12/2023]
Affiliation(s)
- Simon Parlow
- CAPITAL (Cardiovascular Percutaneous Intervention Trials) Research Group (S.P., P.D.S., O.A.-R., R.G.J., P.M., L.R., H.F., B.M., J.W., R.M., B.H.), University of Ottawa, Canada
- Division of Cardiology (S.P., P.D.S., O.A.-R., P.M., M.F., R.M., M.L., B.H.), University of Ottawa, Canada
| | - Pietro Di Santo
- CAPITAL (Cardiovascular Percutaneous Intervention Trials) Research Group (S.P., P.D.S., O.A.-R., R.G.J., P.M., L.R., H.F., B.M., J.W., R.M., B.H.), University of Ottawa, Canada
- Division of Cardiology (S.P., P.D.S., O.A.-R., P.M., M.F., R.M., M.L., B.H.), University of Ottawa, Canada
- Heart Institute, School of Epidemiology, Public Health and Preventative Medicine (P.D.S., R.G.J., P.M., J.B., G.A.W.), University of Ottawa, Canada
- Division of Critical Care Medicine (P.D.S.), Ottawa Hospital, Canada
| | - Omar Abdel-Razek
- CAPITAL (Cardiovascular Percutaneous Intervention Trials) Research Group (S.P., P.D.S., O.A.-R., R.G.J., P.M., L.R., H.F., B.M., J.W., R.M., B.H.), University of Ottawa, Canada
- Division of Cardiology (S.P., P.D.S., O.A.-R., P.M., M.F., R.M., M.L., B.H.), University of Ottawa, Canada
| | - Richard G Jung
- CAPITAL (Cardiovascular Percutaneous Intervention Trials) Research Group (S.P., P.D.S., O.A.-R., R.G.J., P.M., L.R., H.F., B.M., J.W., R.M., B.H.), University of Ottawa, Canada
- Heart Institute, School of Epidemiology, Public Health and Preventative Medicine (P.D.S., R.G.J., P.M., J.B., G.A.W.), University of Ottawa, Canada
- Division of Internal Medicine (R.G.J.), Ottawa Hospital, Canada
| | - Pouya Motazedian
- CAPITAL (Cardiovascular Percutaneous Intervention Trials) Research Group (S.P., P.D.S., O.A.-R., R.G.J., P.M., L.R., H.F., B.M., J.W., R.M., B.H.), University of Ottawa, Canada
- Division of Cardiology (S.P., P.D.S., O.A.-R., P.M., M.F., R.M., M.L., B.H.), University of Ottawa, Canada
- Heart Institute, School of Epidemiology, Public Health and Preventative Medicine (P.D.S., R.G.J., P.M., J.B., G.A.W.), University of Ottawa, Canada
| | - Lisa Robinson
- CAPITAL (Cardiovascular Percutaneous Intervention Trials) Research Group (S.P., P.D.S., O.A.-R., R.G.J., P.M., L.R., H.F., B.M., J.W., R.M., B.H.), University of Ottawa, Canada
| | - Hannah Feagan
- CAPITAL (Cardiovascular Percutaneous Intervention Trials) Research Group (S.P., P.D.S., O.A.-R., R.G.J., P.M., L.R., H.F., B.M., J.W., R.M., B.H.), University of Ottawa, Canada
| | - Baylie Morgan
- CAPITAL (Cardiovascular Percutaneous Intervention Trials) Research Group (S.P., P.D.S., O.A.-R., R.G.J., P.M., L.R., H.F., B.M., J.W., R.M., B.H.), University of Ottawa, Canada
| | - Jilliane Wade
- CAPITAL (Cardiovascular Percutaneous Intervention Trials) Research Group (S.P., P.D.S., O.A.-R., R.G.J., P.M., L.R., H.F., B.M., J.W., R.M., B.H.), University of Ottawa, Canada
| | - Hadi Toeg
- Division of Cardiac Surgery (H.T., T.A.-A., M.R., V.C.), University of Ottawa, Canada
| | - Talal Al-Atassi
- Division of Cardiac Surgery (H.T., T.A.-A., M.R., V.C.), University of Ottawa, Canada
| | - Marc Ruel
- Division of Cardiac Surgery (H.T., T.A.-A., M.R., V.C.), University of Ottawa, Canada
| | | | - Jordan Bernick
- Cardiovascular Research Methods Centre (J.B., G.A.W.), University of Ottawa, Canada
- Heart Institute, School of Epidemiology, Public Health and Preventative Medicine (P.D.S., R.G.J., P.M., J.B., G.A.W.), University of Ottawa, Canada
| | - George A Wells
- Cardiovascular Research Methods Centre (J.B., G.A.W.), University of Ottawa, Canada
- Heart Institute, School of Epidemiology, Public Health and Preventative Medicine (P.D.S., R.G.J., P.M., J.B., G.A.W.), University of Ottawa, Canada
| | - Trevor Simard
- Department of Cardiovascular Diseases, Mayo Clinic School of Medicine, Rochester, MN (T.S.)
| | - Jeffrey A Marbach
- Division of Cardiology, Knight Cardiovascular Institute, Oregon Health & Sciences University, Portland (J.A.M.)
| | - Michael Froeschl
- Division of Cardiology (S.P., P.D.S., O.A.-R., P.M., M.F., R.M., M.L., B.H.), University of Ottawa, Canada
| | - Rebecca Mathew
- CAPITAL (Cardiovascular Percutaneous Intervention Trials) Research Group (S.P., P.D.S., O.A.-R., R.G.J., P.M., L.R., H.F., B.M., J.W., R.M., B.H.), University of Ottawa, Canada
- Division of Cardiology (S.P., P.D.S., O.A.-R., P.M., M.F., R.M., M.L., B.H.), University of Ottawa, Canada
| | - Marino Labinaz
- Division of Cardiology (S.P., P.D.S., O.A.-R., P.M., M.F., R.M., M.L., B.H.), University of Ottawa, Canada
| | - Vincent Chan
- Division of Cardiac Surgery (H.T., T.A.-A., M.R., V.C.), University of Ottawa, Canada
| | - Benjamin Hibbert
- CAPITAL (Cardiovascular Percutaneous Intervention Trials) Research Group (S.P., P.D.S., O.A.-R., R.G.J., P.M., L.R., H.F., B.M., J.W., R.M., B.H.), University of Ottawa, Canada
- Division of Cardiology (S.P., P.D.S., O.A.-R., P.M., M.F., R.M., M.L., B.H.), University of Ottawa, Canada
| |
Collapse
|
8
|
Parlow S, Di Santo P, Jung RG, Fam N, Czarnecki A, Horlick E, Abdel-Razek O, Chan V, Hynes M, Nicholson D, Dryden A, Fernando SM, Wells GA, Bernick J, Labinaz M, Mathew R, Simard T, Hibbert B. Transcatheter mitral valve repair for inotrope dependent cardiogenic shock - Design and rationale of the CAPITAL MINOS trial. Am Heart J 2022; 254:81-87. [PMID: 36002047 DOI: 10.1016/j.ahj.2022.08.008] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/18/2022] [Revised: 08/11/2022] [Accepted: 08/13/2022] [Indexed: 06/15/2023]
Abstract
BACKGROUND Functional mitral regurgitation (MR) is an important clinical consideration in patients with heart failure. Transcatheter edge-to-edge repair (TEER) has emerged as a useful therapeutic tool for patients with chronic heart failure, however the role of TEER in patients with cardiogenic shock (CS) and MR has not yet been studied in a randomized trial. The Transcatheter Mitral Valve Repair for Inotrope Dependent Cardiogenic Shock (CAPITAL MINOS) trial was therefore designed to determine if TEER improves clinical outcomes in the CS population. METHODS AND DESIGN The CAPITAL MINOS trial is an open-label, multi-center randomized clinical trial comparing TEER to medical therapy in patients with CS and MR. A total of 144 patients with Society for Cardiovascular Angiography and Interventions (SCAI) class C or D CS and at least 3+ MR will be randomized in a 1:1 ratio to TEER or medical therapy alone. The primary outcome will be a composite of in-hospital all-cause mortality, cardiac transplantation, implantation of durable left ventricular assist device, or discharge on palliative inotropic therapy. Patients will be followed for the duration of their index hospitalization for the primary outcome. Secondary outcomes include 6 month mortality. IMPLICATIONS The CAPITAL MINOS trial will determine whether TEER improves outcomes in patients with CS and MR and will be an important step in optimizing treatment for this high-risk patient population.
Collapse
Affiliation(s)
- Simon Parlow
- Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Pietro Di Santo
- Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada
| | - Richard G Jung
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; Vascular Biology and Experimental Medicine Laboratory, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada
| | - Neil Fam
- Division of Cardiology, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada
| | - Andrew Czarnecki
- Division of Cardiology, Sunnybrook Hospital, University of Toronto, Toronto, Ontario, Canada
| | - Eric Horlick
- Division of Cardiology, Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada
| | - Omar Abdel-Razek
- Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Vincent Chan
- Division of Cardiac Surgery, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Mark Hynes
- Division of Cardiac Anesthesiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Donna Nicholson
- Division of Cardiac Anesthesiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Adam Dryden
- Division of Cardiac Anesthesiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Shannon M Fernando
- Division of Critical Care Medicine, Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada; Clinical Epidemiology Program, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada
| | - George A Wells
- School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada; Cardiovascular Research Methods Center, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Jordan Bernick
- Cardiovascular Research Methods Center, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Marino Labinaz
- Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Rebecca Mathew
- Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Trevor Simard
- Department of Cardiovascular Diseases, Mayo Clinic School of Medicine, Rochester, Minnesota
| | - Benjamin Hibbert
- Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; Vascular Biology and Experimental Medicine Laboratory, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.
| |
Collapse
|
9
|
Gillmore T, Jung RG, Moreland R, Di Santo P, Stotts C, Makwana D, Abdel-Razek O, Ahmed Z, Chung K, Parlow S, Simard T, Froeschl M, Labinaz M, Hibbert B. Impact of intracoronary assessments on revascularization decisions: A contemporary evaluation. Catheter Cardiovasc Interv 2022; 100:955-963. [PMID: 36259740 DOI: 10.1002/ccd.30417] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/21/2022] [Accepted: 09/06/2022] [Indexed: 11/07/2022]
Abstract
OBJECTIVES To investigate the real-world implementation of intracoronary assessment (ICA) techniques and evaluate their impact on clinical decisions regarding the management of coronary artery disease (CAD) in contemporary practice. BACKGROUND Coronary angiogram is the gold standard used to diagnose vessel stenosis and guide percutaneous coronary intervention (PCI); however, it is limited by its two-dimensional imaging capabilities. ICA techniques like intravascular ultrasound and optical coherence tomography capture the vessel in three-dimensional images. Comparatively, fractional flow reserve provides information on the physiologic significance of coronary stenosis. Both techniques may improve PCI outcomes if they routinely change physician behavior. METHODS Patients who underwent ICA between August 2015 and March 2020 were included in the study. The primary outcome was the clinical impact of ICA on physician clinical decision making of a stenotic vessel. The secondary outcome was the clinical changes that occurred following ICA. RESULTS A total of 1135 patients were included in the study. Physiologic assessment (PA) and image assessment (IA) were performed in 61.4% and 38.6% respectively. Management plans were changed in 38.1% and 23.9% of patients who received PA and IA. Over half of the management change resulted in physicians deciding to not intervene on the stenotic vessel. One-year outcome of these decisions showed no significant increase in major adverse cardiac events (hazard ratio [HR], 0.68; 95% confidence interval [CI], 0.40-1.15; p = 0.15) or unplanned revascularization (HR, 0.78; 95% CI, 0.35-1.74; p = 0.55) suggesting reliance on PA/IA data did not increase risk. CONCLUSION Selected ICA alters physician management of CAD in one-third of patients being evaluated for revascularization-typically leading to fewer interventions. All cause death is numerally lower in patients that received a change in management. However, the 1-year outcome of these altered decisions does not appear to be significantly different.
Collapse
Affiliation(s)
- Taylor Gillmore
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.,Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada
| | - Richard G Jung
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.,Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada.,Vascular Biology and Experimental Medicine Laboratory, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.,Department of Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada
| | - Robert Moreland
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Pietro Di Santo
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.,Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada.,Department of Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada.,Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.,School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada
| | - Cameron Stotts
- Department of Biochemistry, Microbiology, and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada
| | - Dwipen Makwana
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Omar Abdel-Razek
- Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Zeeshan Ahmed
- Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Kevin Chung
- Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Simon Parlow
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.,Department of Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada
| | - Trevor Simard
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.,Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada.,Vascular Biology and Experimental Medicine Laboratory, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Michael Froeschl
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.,Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Marino Labinaz
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.,Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Benjamin Hibbert
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.,Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada.,Vascular Biology and Experimental Medicine Laboratory, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.,Department of Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada
| |
Collapse
|
10
|
Jung RG, Di Santo P, Mathew R, Simard T, Parlow S, Weng W, Abdel-Razek O, Malhotra N, Cheung M, Hutson JH, Marbach JA, Motazedian P, Thibert MJ, Fernando SM, Nery PB, Nair GM, Russo JJ, Hibbert B, Ramirez FD. Arrhythmic events and mortality in patients with cardiogenic shock on inotropic support: results of the DOREMI randomized trial. Can J Cardiol 2022; 39:394-402. [PMID: 36150583 DOI: 10.1016/j.cjca.2022.09.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2022] [Revised: 09/14/2022] [Accepted: 09/15/2022] [Indexed: 11/02/2022] Open
Abstract
BACKGROUND Inotropic support is widely used in the management of cardiogenic shock (CS). Existing data on the incidence and significance of arrhythmic events in patients with CS on inotropic support is at high risk of bias. METHODS The DObutamine compaREd to MIlrinone (DOREMI) trial randomized patients to receive dobutamine or milrinone in a double-blind fashion. Patients with and without arrhythmic events (defined as arrhythmias requiring intervention or sustained ventricular arrhythmias) were compared to (1) identify factors associated with their occurrence and (2) examine their association with in-hospital mortality and secondary outcomes. RESULTS Ninety-two patients (47.9%) had arrhythmic events, occurring equally with dobutamine and milrinone (P=0.563). The need for vasopressor support at inotrope initiation and a history of atrial fibrillation were positively associated with arrhythmic events whereas predominant right ventricular dysfunction, previous myocardial infarction, and increasing left ventricular ejection fraction were negatively associated with them. Supraventricular arrhythmic events were not associated with mortality (RR 0.97, 95% CI 0.68-1.40, P=0.879) but were positively associated with resuscitated cardiac arrests and hospital length of stay. Ventricular arrhythmic events were positively associated with mortality (RR 1.66, 95% CI 1.13-2.43; P=0.026) and resuscitated cardiac arrests. Arrhythmic events were most often treated with amiodarone (97%) and electrical cardioversion (27%), which were not associated with mortality. CONCLUSIONS Clinically relevant arrhythmic events occur in approximately half of patients with CS treated with dobutamine or milrinone and are associated with adverse clinical outcomes. Five factors may help identify patients most at risk of arrhythmic events.
Collapse
Affiliation(s)
- Richard G Jung
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Ontario Canada
| | - Pietro Di Santo
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada
| | - Rebecca Mathew
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Trevor Simard
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; Division of Cardiology, Mayo Clinic, Rochester, Minnesota, USA
| | - Simon Parlow
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Willy Weng
- Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Omar Abdel-Razek
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Nikita Malhotra
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Matthew Cheung
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Jordan H Hutson
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; Division of Critical Care, University of Ottawa, Ottawa, Ontario, Canada
| | - Jeffrey A Marbach
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; Division of Cardiology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
| | - Pouya Motazedian
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Michael J Thibert
- Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Shannon M Fernando
- Division of Critical Care, University of Ottawa, Ottawa, Ontario, Canada
| | - Pablo B Nery
- Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Girish M Nair
- Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Juan J Russo
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Benjamin Hibbert
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Ontario Canada
| | - F Daniel Ramirez
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada.
| |
Collapse
|
11
|
Simard T, Vemulapalli S, Jung RG, Vekstein A, Stebbins A, Holmes DR, Czarnecki A, Hibbert B, Alkhouli M. Transcatheter Edge-to-Edge Repair in Patients with Severe Mitral Regurgitation and Cardiogenic Shock: TVT Registry Analysis. J Am Coll Cardiol 2022; 80:2072-2084. [PMID: 36126766 DOI: 10.1016/j.jacc.2022.09.006] [Citation(s) in RCA: 25] [Impact Index Per Article: 12.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/30/2022] [Revised: 09/08/2022] [Accepted: 09/09/2022] [Indexed: 11/25/2022]
Abstract
BACKGROUND Data on the efficacy of transcatheter edge-to-edge repair (TEER) in patients with cardiogenic shock (CS) are limited. OBJECTIVES We investigated the characteristics and outcomes of consecutive patients with significant MR and CS who underwent TEER. METHODS The STS/ACC/TVT Registry was assessed from November 22, 2013, to December 31, 2021. CS was defined as [i] CS, [ii] inotrope-use or [iii] mechanical circulatory support prior to TEER. Device success was defined as MR reduction of >1 grade and a final MR grade<2+. The primary outcome was the impact of device success on 1-year mortality or heart failure (HF) re-admissions. Cox proportional hazards model were used to report the risk-adjusted association between device success and 1-year outcomes. RESULTS A total of 3,797 patients met the inclusion criteria. Mean age was 73.0±11.9 and 59.5% were male. Mean STS-score (MV repair) was 14.9±15.3. MR etiology was degenerative (53.4%) and functional (27.5%). Device success was achieved in 3,249(85.6%) patients given successful achievement of [i] final MR grade <2+(88.2%) and [ii] MR reduction >1 absolute grade(91.4%). At one-year after TEER, device success was associated with significantly lower all-cause mortality (34.6% vs.55.5%, adjusted-HR 0.49,95%CI 0.41-0.59,p<0.001), and a composite of mortality or HF admissions (29.6% vs. 45.2%, adjusted HR 0.51,95%CI 0.42-0.62,p<0.001). CONCLUSION Successful MR reduction is achievable in most patients with CS and is associated with significantly lower mortality and HF hospitalization at 1-year. Randomized trials assessing TEER in CS are needed to establish this potential therapeutic approach. CONDENSED ABSTRACT We examined the role of transcatheter edge-to-edge repair (TEER) in patients with cardiogenic shock and mitral regurgitation (MR). We identified 3,797 patients with cardiogenic shock who underwent TEER between 2013-2021 in the STS/ACC/TVT registry. Mean age was 73.0±11.9 and 59.5% were males. Mean STS was 14.9±15.3. Device success (defined as MR reduction of >1 grade and a final MR <2+) was achieved in 3,249 patients (85.6%). At one-year, device success was associated with lower all-cause mortality (34.6% vs.55.5%,adjusted-HR 0.49,95%CI 0.41-0.58, p<0.001), and a composite of mortality and HF admissions (29.6% vs. 45.2%, adjusted HR 0.51,95%CI 0.42-0.62, p<0.001).
Collapse
Affiliation(s)
- Trevor Simard
- Department of Cardiovascular Disease, Mayo Clinic, Rochester, Minnesota
| | - Sreek Vemulapalli
- Department of Medicine, Duke University, Durham, North Carolina; Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina
| | - Richard G Jung
- University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Andrew Vekstein
- Department of Medicine, Duke University, Durham, North Carolina; Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina
| | - Amanda Stebbins
- Department of Medicine, Duke University, Durham, North Carolina; Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina
| | - David R Holmes
- Department of Cardiovascular Disease, Mayo Clinic, Rochester, Minnesota
| | | | | | - Mohamad Alkhouli
- Department of Cardiovascular Disease, Mayo Clinic, Rochester, Minnesota.
| |
Collapse
|
12
|
Jung RG, Duchez AC, Simard T, Dhaliwal S, Gillmore T, Di Santo P, Labinaz A, Ramirez FD, Rasheed A, Robichaud S, Ouimet M, Short S, Clifford C, Xiao F, Lordkipanidzé M, Burger D, Gadde S, Rayner KJ, Hibbert B. Plasminogen Activator Inhibitor-1–Positive Platelet-Derived Extracellular Vesicles Predicts MACE and the Proinflammatory SMC Phenotype. JACC Basic Transl Sci 2022; 7:985-997. [PMID: 36337926 PMCID: PMC9626902 DOI: 10.1016/j.jacbts.2022.05.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/18/2022] [Revised: 05/02/2022] [Accepted: 05/02/2022] [Indexed: 12/01/2022]
Abstract
This study shows the existence of PAI-1+ PEVs. Approximately 20% of plasma PAI-1 is composed of PAI-1+ PEVs. Elevated PAI-1+ PEV levels were predictive of 1-year major adverse cardiac events in both the discovery and the validation cohort, with larger effect sizes than other clinical biomarkers. High PAI-1+ PEV levels did not affect thrombogenicity. Increasing doses of PAI-1+ PEVs promoted the proinflammatory VSMC state by enhancing proliferation and migration. Inhibition of the PAI-1:low-density lipoprotein–related receptor-1 pathway dampened the proinflammatory VSMC changes. PAI-1+ PEV is a promising biomarker for major adverse cardiac events, and targeting the PAI-1+ PEV–VSMC interaction may offer a novel target to modulate cardiac events in patients with coronary artery disease.
Patients with established coronary artery disease remain at elevated risk of major adverse cardiac events. The goal of this study was to evaluate the utility of plasminogen activator inhibitor-1–positive platelet-derived extracellular vesicles as a biomarker for major adverse cardiac events and to explore potential underlying mechanisms. Our study suggests these extracellular vesicles as a potential biomarker to identify and a therapeutic target to ameliorate neointimal formation of high-risk patients.
Collapse
Affiliation(s)
- Richard G. Jung
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
- Vascular Biology and Experimental Medicine Laboratory, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
- Department of Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada
| | - Anne-Claire Duchez
- Department of Biochemistry, Microbiology, and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada
| | - Trevor Simard
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
- Vascular Biology and Experimental Medicine Laboratory, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
- Department of Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada
- Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Shan Dhaliwal
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
- Vascular Biology and Experimental Medicine Laboratory, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
- Department of Biochemistry, Microbiology, and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada
- School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada
| | - Taylor Gillmore
- Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada
| | - Pietro Di Santo
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
- Vascular Biology and Experimental Medicine Laboratory, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
- Department of Biochemistry, Microbiology, and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada
- School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada
| | - Alisha Labinaz
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
- Vascular Biology and Experimental Medicine Laboratory, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - F. Daniel Ramirez
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
- Vascular Biology and Experimental Medicine Laboratory, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
- Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Adil Rasheed
- Department of Biochemistry, Microbiology, and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada
| | - Sabrina Robichaud
- Department of Biochemistry, Microbiology, and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada
| | - Mireille Ouimet
- Department of Biochemistry, Microbiology, and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada
| | - Spencer Short
- Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada
| | - Cole Clifford
- Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada
| | - Fengxia Xiao
- Kidney Research Centre, Department of Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada
| | - Marie Lordkipanidzé
- Faculté de Pharmacie, Université de Montréal, Montréal, Québec, Canada
- Research Center, Montreal Heart Institute, Montréal, Québec, Canada
| | - Dylan Burger
- Kidney Research Centre, Department of Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada
| | - Suresh Gadde
- Department of Biochemistry, Microbiology, and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada
| | - Katey J. Rayner
- Department of Biochemistry, Microbiology, and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada
| | - Benjamin Hibbert
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
- Vascular Biology and Experimental Medicine Laboratory, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
- Department of Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada
- Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
- Address for correspondence: Dr Benjamin Hibbert, University of Ottawa Heart Institute, 40 Ruskin Street, H-4238, Ottawa, Ontario K1Y 4W7, Canada.
| |
Collapse
|
13
|
Jung RG, Abdel-Razek O, Di Santo P, Gillmore T, Stotts C, Makwana D, Soriano J, Moreland R, Verreault-Julien L, Goh CY, Parlow S, Sypkes C, Ramirez DF, Sadek M, Chan V, Toeg H, Simard T, Froeschl MPV, Labinaz M, Hibbert B. Impact of atrial fibrillation on the risk of major adverse cardiac events following coronary revascularisation. Open Heart 2022; 9:openhrt-2022-002012. [PMID: 36150746 PMCID: PMC9511650 DOI: 10.1136/openhrt-2022-002012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/06/2022] [Accepted: 08/05/2022] [Indexed: 11/04/2022] Open
Abstract
OBJECTIVE Atrial fibrillation (AF) remains a highly prevalent arrhythmia with significant burden on morbidity and mortality. The impact of AF in the revascularised population remains incompletely described. Given the high prevalence of AF in the revascularised population, we sought to evaluate the incidence and prognosis in patients with pre-existing and new-onset AF following revascularisation. METHODS We used the University of Ottawa Heart Institute Revascularisation Registry to identify patients who underwent revascularisation between August 2015 and March 2020, who were prospectively followed for an average of one year. We conducted a retrospective cohort study analysing the association between AF and clinical outcomes. The primary outcome of interest was 1-year major adverse cardiac events (MACE) defined as a composite of death, myocardial infarction, unplanned revascularisation and cerebrovascular accidents. Moreover, secondary outcomes include the individual components of MACE and bleeding. RESULTS A total of 6704 patients underwent revascularisation and completed 1-year clinical follow-up. Median time to follow-up was 12.8 (IQR 11.2-15.9) months. One-year MACE occurred in 166 (21.8%) and 683 (11.5%) patients in AF and non-AF groups, respectively (adjusted HR, 1.61; 95% CI 1.29 to 2.01; p<0.0001). AF was independently predictive of 1-year mortality, myocardial infarction, unplanned revascularisation, cerebrovascular accident and bleeding. Within 1 year, 299 (4.5%) episodes of new-onset AF was observed. New-onset AF following revascularisation was also associated with 1-year MACE, mortality, myocardial infarction, cerebrovascular accident and unplanned revascularisation. CONCLUSIONS Preprocedural and new-onset AF following revascularisation remains highly predictive 1-year MACE. AF should be considered in addition to traditional risk factors for adverse outcomes following revascularisation.
Collapse
Affiliation(s)
- Richard G Jung
- Department of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Omar Abdel-Razek
- Department of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Pietro Di Santo
- Department of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | | | | | | | | | - Robert Moreland
- University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | | | - Cheng Yee Goh
- University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Simon Parlow
- Department of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | | | - Daniel F Ramirez
- Department of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Mouhannad Sadek
- Department of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Vincent Chan
- Department of Surgery, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Hadi Toeg
- Department of Surgery, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | | | - Michael P V Froeschl
- Department of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Marino Labinaz
- Department of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Benjamin Hibbert
- Department of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| |
Collapse
|
14
|
Prosperi-Porta G, Motazedian P, Di Santo P, Jung RG, Parlow S, Abdel-Razek O, Simard T, Hutson J, Malhotra N, Fu A, Ramirez FD, Froeschl M, Mathew R, Hibbert B. No sex-based difference in cardiogenic shock: A post-hoc analysis of the DOREMI trial. J Cardiol 2022; 80:358-364. [PMID: 35725945 DOI: 10.1016/j.jjcc.2022.06.001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/18/2022] [Revised: 05/19/2022] [Accepted: 06/02/2022] [Indexed: 12/12/2022]
Abstract
BACKGROUND Cardiogenic shock (CS) is associated with significant morbidity and mortality; however, there are limited randomized data evaluating the association between sex and clinical outcomes in patients with CS. Patients with CS enrolled in the DObutamine compaREd with MIlrinone (DOREMI) trial were evaluated in this post-hoc analysis. METHODS The primary outcome was a composite of all-cause mortality, resuscitated cardiac arrest, cardiac transplant or mechanical circulatory support, non-fatal myocardial infarction, transient ischemic attack or stroke, or initiation of renal replacement therapy. Secondary outcomes included the individual components of the primary outcome. We analyzed the primary and secondary outcomes using unadjusted relative risks and performed adjusted analysis for the primary outcome and all-cause mortality using the covariates mean arterial pressure <70 mmHg at inotrope initiation, age, and acute myocardial infarction CS. RESULTS Among 192 participants in the DOREMI study, 70 patients (36 %) were female. The primary outcome occurred in 38 female patients (54 %) compared to 61 male patients (50 %) [adjusted relative risk (aRR) 1.23; 95 % CI 0.78-1.95, p = 0.97]. When stratified by inotrope, there was no difference in the primary outcome comparing females to males receiving dobutamine (RR 1.14; 95 % CI 0.79-1.65, p = 0.50) nor milrinone (RR 1.03; 95 % CI 0.68-1.57, p = 0.87). There was no difference in all-cause mortality comparing females to males (aRR 1.51; 95 % CI 0.78-2.94, p = 0.88). Additionally, there were no differences in any secondary outcomes between males and females (p > 0.05 for all endpoints). CONCLUSION In patients presenting with CS treated with milrinone or dobutamine, no differences in clinical outcomes were observed between males and females.
Collapse
Affiliation(s)
- Graeme Prosperi-Porta
- CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Pouya Motazedian
- CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Pietro Di Santo
- CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada
| | - Richard G Jung
- CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Ontario, Canada; Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada
| | - Simon Parlow
- CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Omar Abdel-Razek
- CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Trevor Simard
- Department of Cardiovascular Diseases, Mayo Clinic School of Medicine, Rochester, MN, USA
| | - Jordan Hutson
- Division of Critical Care, University of Ottawa, Ottawa, Ontario, Canada
| | - Nikita Malhotra
- Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Angel Fu
- Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - F Daniel Ramirez
- Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Michael Froeschl
- CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Rebecca Mathew
- CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Benjamin Hibbert
- CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Ontario, Canada.
| | | |
Collapse
|
15
|
Parlow S, Fay Lepage-Ratte M, Jung RG, Fernando SM, Visintini S, Sterling LH, Di Santo P, Simard T, Russo JJ, Labinaz M, Hibbert B, Nolan JP, Rochwerg B, Mathew R. Inhaled anaesthesia compared with conventional sedation in post cardiac arrest patients undergoing temperature control: a systematic review and meta-analysis. Resuscitation 2022; 176:74-79. [DOI: 10.1016/j.resuscitation.2022.05.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2022] [Revised: 05/19/2022] [Accepted: 05/21/2022] [Indexed: 10/18/2022]
|
16
|
Parlow S, Weng W, Di Santo P, Jung RG, Lepage-Ratte MF, Motazedian P, Prosperi-Porta G, Abdel-Razek O, Simard T, Chan V, Labinaz M, Froeschl M, Mathew R, Hibbert B. Significant valvular dysfunction and outcomes in cardiogenic shock: insights from the randomized DOREMI trial. Can J Cardiol 2022; 38:1211-1219. [DOI: 10.1016/j.cjca.2022.04.004] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2021] [Revised: 04/02/2022] [Accepted: 04/03/2022] [Indexed: 12/15/2022] Open
|
17
|
Marbach JA, Di Santo P, Kapur NK, Thayer KL, Simard T, Jung RG, Parlow S, Abdel-Razek O, Fernando SM, Labinaz M, Froeschl M, Mathew R, Hibbert B. Lactate Clearance as a Surrogate for Mortality in Cardiogenic Shock: Insights From the DOREMI Trial. J Am Heart Assoc 2022; 11:e023322. [PMID: 35261289 PMCID: PMC9075306 DOI: 10.1161/jaha.121.023322] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Abstract
Background Recent studies have shown improved outcomes in cardiogenic shock through protocols directed toward early identification and initiation of mechanical circulatory support. However, objective therapeutic targets—based on clinical and/or laboratory data—to guide real‐time clinical decision making are lacking. Lactate clearance has been suggested as a potential treatment target because of its independent association with mortality. Methods and Results In a post hoc analysis of the DOREMI (Dobutamine Compared to Milrinone in the Treatment of Cardiogenic Shock) trial—a randomized, double‐blind, controlled trial comparing milrinone to dobutamine in the treatment of cardiogenic shock—we used prospectively collected lactate data to evaluate lactate clearance as a surrogate marker for in‐hospital mortality. In total, 82 (57.7%) patients survived to hospital discharge (survivors). In multivariate logistic regression analysis, complete lactate clearance, percentage lactate clearance, and percentage lactate clearance per hour were independently associated with survival beginning as early as 8 hours after enrollment. Complete lactate clearance was the strongest predictor of survival at all time points, with odds ratios ranging between 2.46 (95% CI, 1.09–5.55; P=0.03) at 8 hours to 5.44 (95% CI, 2.14–13.8; P<0.01) at 24 hours. Conclusions Complete lactate clearance is a strong and independent predictor of in‐hospital survival in patients with cardiogenic shock. Together with previously published data, these results further support the validity of lactate clearance as an appropriate surrogate for mortality and as a potential therapeutic target in future cardiogenic shock trials. Registration URL: https://www.clinicaltrials.gov; Unique identifier: NCT03207165.
Collapse
Affiliation(s)
- Jeffrey A Marbach
- CAPITAL Research Group Division of Cardiology Department of Medicine University of Ottawa Heart Institute Ottawa Canada.,Division of Pulmonary Critical Care and Sleep Medicine Tufts Medical Center and Tufts University School of Medicine Boston MA.,Division of Cardiology Beth Israel Deaconess Medical Center Boston MA
| | - Pietro Di Santo
- CAPITAL Research Group Division of Cardiology Department of Medicine University of Ottawa Heart Institute Ottawa Canada.,Faculty of Medicine University of Ottawa Canada.,School of Epidemiology and Public Health University of Ottawa Canada
| | - Navin K Kapur
- Department of Medicine Tufts Medical Center and Tufts University School of Medicine Boston MA.,The Cardiovascular Center Tufts Medical Center and Tufts University School of Medicine Boston MA
| | - Katherine L Thayer
- The Cardiovascular Center Tufts Medical Center and Tufts University School of Medicine Boston MA
| | - Trevor Simard
- CAPITAL Research Group Division of Cardiology Department of Medicine University of Ottawa Heart Institute Ottawa Canada.,Division of Cardiology Mayo Clinic Rochester MN
| | - Richard G Jung
- CAPITAL Research Group Division of Cardiology Department of Medicine University of Ottawa Heart Institute Ottawa Canada.,Faculty of Medicine University of Ottawa Canada.,Department of Cellular and Molecular Medicine University of Ottawa Canada
| | - Simon Parlow
- CAPITAL Research Group Division of Cardiology Department of Medicine University of Ottawa Heart Institute Ottawa Canada.,Faculty of Medicine University of Ottawa Canada
| | - Omar Abdel-Razek
- CAPITAL Research Group Division of Cardiology Department of Medicine University of Ottawa Heart Institute Ottawa Canada.,Faculty of Medicine University of Ottawa Canada
| | - Shannon M Fernando
- Faculty of Medicine University of Ottawa Canada.,Division of Critical Care Department of Medicine University of Ottawa Canada
| | - Marino Labinaz
- CAPITAL Research Group Division of Cardiology Department of Medicine University of Ottawa Heart Institute Ottawa Canada.,Faculty of Medicine University of Ottawa Canada
| | - Michael Froeschl
- CAPITAL Research Group Division of Cardiology Department of Medicine University of Ottawa Heart Institute Ottawa Canada.,Faculty of Medicine University of Ottawa Canada
| | - Rebecca Mathew
- CAPITAL Research Group Division of Cardiology Department of Medicine University of Ottawa Heart Institute Ottawa Canada.,Faculty of Medicine University of Ottawa Canada.,Division of Critical Care Department of Medicine University of Ottawa Canada
| | - Benjamin Hibbert
- CAPITAL Research Group Division of Cardiology Department of Medicine University of Ottawa Heart Institute Ottawa Canada.,Faculty of Medicine University of Ottawa Canada.,Department of Cellular and Molecular Medicine University of Ottawa Canada
| |
Collapse
|
18
|
Verreault-Julien L, Bhatt DL, Jung RG, Di Santo P, Simard T, Avram R, Hibbert B. Predictors of angina resolution after percutaneous coronary intervention in stable coronary artery disease. Coron Artery Dis 2022; 33:98-104. [PMID: 34148973 DOI: 10.1097/mca.0000000000001081] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Abstract
BACKGROUND Elective percutaneous coronary intervention (PCI) is performed to relieve symptoms of angina. Identifying patients who will benefit symptomatically after PCI would be clinically advantageous but robust predictors of symptom resolution are ill-defined. METHODS Prospective indexing of baseline angina status, clinical, and procedural characteristics were collected over a 5-year period in a regional revascularization registry. At 1-year follow-up, angina resolution was assessed. We performed a stepwise selection algorithm to identify predictors of persistent angina at 1 year. RESULTS A total of 777 patients were included in the analysis and the median follow-up was 387 days. Mean age of the cohort was 66.6 years, 23.8% were female and 23.3% had baseline Canadian Cardiovascular Society class 3 or 4 angina. Overall, 13.1% had persistent angina. The only predictor of persistent angina was the presence of a residual chronic total occlusion after PCI with odds ratio of 3.06 (95% confidence interval, 1.81-5.17). Residual stenoses 50-69%, 70-89%, and 90-99% were not associated with residual angina after PCI. CONCLUSION Most patients achieved symptom resolution with PCI and optimal medical therapy. A residual chronic total occlusion after PCI was associated with persistent angina. Other degrees of stenoses were not associated with persistent angina.
Collapse
Affiliation(s)
- Louis Verreault-Julien
- CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
- Harvard T.H. Chan School of Public Health, Harvard University
| | - Deepak L Bhatt
- Department of Medicine, Brigham and Women's Hospital Heart & Vascular Center
- Harvard Medical School, Boston, MA, USA
| | - Richard G Jung
- CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
- Faculty of Medicine
| | - Pietro Di Santo
- CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
- Faculty of Medicine
- School of Epidemiology and Public Health
| | - Trevor Simard
- CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
- Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Ontario, Canada
- Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA
| | - Robert Avram
- CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Benjamin Hibbert
- CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
- Faculty of Medicine
- School of Epidemiology and Public Health
- Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA
| |
Collapse
|
19
|
Jung RG, Simard T, Hibbert B, Harris AH, Hohmann SF, Giri JS, Bashir R, Alkhouli M. Association of annual volume and in-hospital outcomes of catheter-directed thrombolysis for pulmonary embolism. Catheter Cardiovasc Interv 2022; 99:440-446. [PMID: 35083846 DOI: 10.1002/ccd.30080] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/24/2021] [Revised: 12/02/2021] [Accepted: 01/05/2022] [Indexed: 11/06/2022]
Abstract
OBJECTIVE We sought to evaluate the association between the institutional volume of catheter-directed thrombolysis (CDT) for pulmonary embolism and in-hospital mortality. BACKGROUND CDT is an increasingly utilized therapy in patients with intermediate/high-risk PE. However, data on the relationship between hospital volume and clinical outcomes remain limited. METHODS Patients who underwent CDT between October 1, 2015, and March 31, 2021, were identified in the Vizient Clinical Database. The primary outcome was in-hospital mortality. Secondary outcome were major complications, length of stay, and cost. Hospitals were dichotomized into <8 and ≥ 8 cases/year following restricted cubic spline analysis. RESULTS A total of 6741 CDT procedures at 171 hospitals were included with a median annual hospital volume of 4.1 cases (IQR = 1.9-8.3). A total of 44 hospitals (25.7%) were classified as high-volume ( ≥ 8 cases/year) and performed 60.9% of all CDT cases. CDT at high-volume centers was associated with lower in-hospital mortality (6.0% vs. 11.3%; p < 0.0001). Stroke and bleeding rates were similar, but pulmonary complications were more frequent at low-volume centers. CDT at high volume centers was associated with a significantly shorter length of stay and lower cost. The association between high CDT volume and in-hospital mortality persisted after adjustment for demographics (odds ratio [OR] = 0.49, [0.41-0.58]), demographics and risk factors (OR = 0.52 [0.44-0.62]), and demographics, risk factors, and troponin elevation (OR = 0.51 [0.40-0.66]). CONCLUSION In a large contemporary cohort of patients undergoing CDT in the United States, low annual institutional volume of CDT was associated with higher in-hospital mortality.
Collapse
Affiliation(s)
- Richard G Jung
- Division of Cardiology, CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Trevor Simard
- Department of Cardiovascular Diseases, Mayo Clinic School of Medicine, Rochester, Minnesota, USA
| | - Benjamin Hibbert
- Division of Cardiology, CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Alyssa H Harris
- Center for Advanced Analytics and Informatics, Chicago, Illinois, USA
| | - Samuel F Hohmann
- Center for Advanced Analytics and Informatics, Chicago, Illinois, USA
| | - Jay S Giri
- Cardiovascular Medicine Division, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.,Penn Cardiovascular Outcomes, Quality, and Evaluative Research Center and the Leonard Davis Institute of Health Economics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA
| | - Riyaz Bashir
- Department of Medicine, Section of Cardiology, Temple University, Philadelphia, Pennsylvania, USA
| | - Mohamad Alkhouli
- Department of Cardiovascular Diseases, Mayo Clinic School of Medicine, Rochester, Minnesota, USA
| |
Collapse
|
20
|
Jung RG, Simard T, Killu A, Harris AA, Hohmann SF, Holmes DR, Alkhouli M. Learning Curve and Outcomes of Left Atrial Appendage Closure. JACC Cardiovasc Interv 2021; 14:2750-2752. [PMID: 34949401 DOI: 10.1016/j.jcin.2021.08.067] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/10/2021] [Revised: 08/09/2021] [Accepted: 08/24/2021] [Indexed: 11/28/2022]
|
21
|
Parlow S, Cheung M, Verreault-Julien L, Wu KY, Berardi P, Nair V, Di Santo P, Jung RG, Mathew R, Hibbert B. An Unusual Case of Obstructive Shock. JACC Case Rep 2021; 3:1913-1917. [PMID: 34984352 PMCID: PMC8693255 DOI: 10.1016/j.jaccas.2021.10.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2021] [Revised: 10/20/2021] [Accepted: 10/29/2021] [Indexed: 11/18/2022]
Abstract
A 54-year-old man presented in profound obstructive shock. Investigations revealed a right atrial mass causing severe right ventricular inflow obstruction and compromised cardiac output. The patient was treated with emergency balloon catheter intervention to relieve the obstruction, with resulting hemodynamic stability. The pathology report later returned a positive result for diffuse large B-cell lymphoma. (Level of Difficulty: Intermediate.).
Collapse
Affiliation(s)
- Simon Parlow
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
- Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Matthew Cheung
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
- Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Louis Verreault-Julien
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
- Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Kai Yi Wu
- Department of Medicine, University of Alberta, Edmonton, Alberta, Canada
| | - Philip Berardi
- Department of Pathology and Laboratory Medicine, University of Ottawa and Ottawa Hospital Research Institute, The Ottawa Hospital, Ottawa, Ontario, Canada
| | - Vidhya Nair
- Department of Pathology and Laboratory Medicine, University of Ottawa and Ottawa Hospital Research Institute, The Ottawa Hospital, Ottawa, Ontario, Canada
| | - Pietro Di Santo
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
- Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
- School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada
| | - Richard G. Jung
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
- Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada
| | - Rebecca Mathew
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
- Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Benjamin Hibbert
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
- Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
- Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Ontario, Canada
| |
Collapse
|
22
|
Simard T, Jung RG, Di Santo P, Harnett DT, Abdel-Razek O, Ramirez FD, Motazedian P, Parlow S, Labinaz A, Moreland R, Marbach J, Poulin A, Levi A, Majeed K, Boland P, Couture E, Sarathy K, Promislow S, Russo JJ, Chong AY, So D, Froeschl M, Dick A, Labinaz M, Le May M, Holmes DR, Hibbert B. Modifiable Risk Factors and Residual Risk Following Coronary Revascularization: Insights From a Regionalized Dedicated Follow-Up Clinic. Mayo Clin Proc Innov Qual Outcomes 2021; 5:1138-1152. [PMID: 34934904 PMCID: PMC8654638 DOI: 10.1016/j.mayocpiqo.2021.09.001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
Abstract
OBJECTIVE To ensure compliance with optimal secondary prevention strategies and document the residual risk of patients following revascularization, we established a postrevascularization clinic for risk-factor optimization at 1 year, with outcomes recorded in a web-based registry. Although coronary revascularization can reduce ischemia, medical treatment of coronary artery disease (CAD) remains the cornerstone of ongoing risk reduction. While standardized referral pathways and protocols for revascularization are prevalent and well studied, post-revascularization care is often less formalized. PATIENTS AND METHODS The University of Ottawa Heart Institute is a tertiary-care center providing coronary revascularization services. From 2015 to 2019, data were prospectively recorded in the CAPITAL revascularization registry, and patient-level procedural, clinical, and outcome data are collected in the year following revascularization. Major adverse cardiovascular event (MACE) was defined as death, myocardial infarction, unplanned revascularization, or cerebrovascular accident. Kaplan-Meier curves were generated to evaluate time-to-event data for clinical outcomes by risk-factor management, and comparisons were performed using log-rank tests and reported by hazard ratio (HR) and 95% confidence intervals (CIs). RESULTS A cohort of 4147 patients completed 1-year follow-up after revascularization procedure that included 3462 undergoing percutaneous coronary intervention (PCI), 589 undergoing coronary artery bypass graft (CABG), and 96 undergoing both PCI and CABG. In the year following revascularization (median follow-up 13.3 months-interquartile range [IQR]: 11.9-16.5) 11% of patients experienced MACE, with female patients being disproportionately at risk. Moreover, 47.7% of patients had ≥2 risk factors (diabetes, dyslipidemia, overweight, active smoker) at the time of follow-up, with 45.0% of patients with diabetes failing to achieve target hemoglobin (Hb) A1c, 54.8% of smokers continuing to smoke, and 27.1% of patients failing to achieve guideline-directed lipid targets. CONCLUSION Patients who have undergone revascularization procedures remain at elevated risk for MACE, and inadequately controlled risk factors are prevalent in follow-up. This highlights the need for aggressive secondary prevention strategies and implementation of programs to optimize postrevascularization care.
Collapse
Key Words
- ACS, acute coronary syndrome
- CABG, coronary artery bypass grafting
- CAD, coronary artery disease
- CAPITAL, Cardiovascular And Percutaneous clinical TriALs
- DM, diabetes mellitus
- HR, hazard ratio
- HbA1c, hemoglobin A1C
- MACE, major adverse cardiovascular event
- MI, myocardial infarction
- NSTEMI, non-ST elevation MI
- PCI, percutaneous coronary intervention
- STEMI, ST elevation MI
- UA, unstable angina
Collapse
Affiliation(s)
- Trevor Simard
- CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
- Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Ontario, Canada
- Department of Cardiovascular Diseases, Mayo Clinic College of Medicine, Rochester, Minnesota
| | - Richard G. Jung
- CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
- Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Ontario, Canada
| | - Pietro Di Santo
- CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - David T. Harnett
- CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Omar Abdel-Razek
- CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - F. Daniel Ramirez
- CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
- Hôpital Cardiologique du Haut-Lévêque, CHU Bordeaux, Bordeaux-Pessac, France
- L’Institut de Rythmologie et Modélisation Cardiaque (LIRYC), Université de Bordeaux, Bordeaux-Pessac, France
| | - Pouya Motazedian
- CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
- Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
| | - Simon Parlow
- CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Alisha Labinaz
- CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Robert Moreland
- CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Jeffrey Marbach
- CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Anthony Poulin
- CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Amos Levi
- CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Kamran Majeed
- CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
- Department of Cardiology, Royal Perth Hospital, Perth, Western Australia
- School of Medicine, University of Western Australia, Perth, Western Australia
| | - Paul Boland
- CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Etienne Couture
- CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Kiran Sarathy
- CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Steven Promislow
- CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Juan J. Russo
- CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Aun Yeong Chong
- CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Derek So
- CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Michael Froeschl
- CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Alexander Dick
- CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Marino Labinaz
- CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Michel Le May
- CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - David R. Holmes
- Department of Cardiovascular Diseases, Mayo Clinic College of Medicine, Rochester, Minnesota
| | - Benjamin Hibbert
- CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
- Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Ontario, Canada
| |
Collapse
|
23
|
Simard T, Jung RG, Hibbert B, Holmes DR, Alkhouli M. Reply: Left Atrial Appendage Occlusion in Hypertrophic Cardiomyopathy Patients Should Be Taken Into Account. J Am Coll Cardiol 2021; 78:e159. [PMID: 34736571 DOI: 10.1016/j.jacc.2021.09.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/30/2021] [Accepted: 09/02/2021] [Indexed: 10/20/2022]
|
24
|
Jung RG, Di Santo P, Mathew R, Abdel-Razek O, Parlow S, Simard T, Marbach JA, Gillmore T, Mao B, Bernick J, Theriault-Lauzier P, Fu A, Lau L, Motazedian P, Russo JJ, Labinaz M, Hibbert B. Implications of Myocardial Infarction on Management and Outcome in Cardiogenic Shock. J Am Heart Assoc 2021; 10:e021570. [PMID: 34713704 PMCID: PMC8751815 DOI: 10.1161/jaha.121.021570] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
Background The randomized DOREMI (Dobutamine Compared to Milrinone) clinical trial evaluated the efficacy and safety of milrinone and dobutamine in patients with cardiogenic shock. Whether the results remain consistent when stratified by acute myocardial infarction remains unknown. In this substudy, we sought to evaluate differences in clinical management and outcomes of acute myocardial infarction complicated by cardiogenic shock (AMICS) versus non-AMICS. Methods and Results Patients in cardiogenic shock (n=192) were randomized 1:1 to dobutamine or milrinone. The primary composite end point in this subgroup analysis was all-cause in-hospital mortality, cardiac arrest, non-fatal myocardial infarction, cerebrovascular accident, the need for mechanical circulatory support, or initiation of renal replacement therapy (RRT) at 30-days. Outcomes were evaluated in patients with (n=65) and without (n=127) AMICS. The primary composite end point was significantly higher in AMICS versus non-AMICS (hazard ratio [HR], 2.21; 95% CI, 1.47-3.30; P=0.0001). The primary end point was driven by increased rates of all-cause mortality, mechanical circulatory support, and RRT. No differences in other secondary outcomes including cardiac arrest or cerebrovascular accident were observed. AMICS remained associated with the primary composite outcome, 30-day mortality, and RRT after adjustment for age, sex, procedural contrast use, multivessel disease, and inotrope type. Conclusions AMI was associated with increased rates of adverse clinical outcomes in cardiogenic shock along with increased rates of mortality and initiation of mechanical circulatory support and RRT. Contrast administration during revascularization likely contributes to increased rates of RRT. Heterogeneity of outcomes in AMICS versus non-AMICS highlights the need to study interventions in specific subgroups of cardiogenic shock. Registration URL: https://www.clinicaltrials.gov; Unique identifier: NCT03207165.
Collapse
Affiliation(s)
- Richard G Jung
- CAPITAL Research Group Division of Cardiology University of Ottawa Heart Institute Ottawa Ontario Canada.,Faculty of Medicine University of Ottawa Ontario Canada.,Department of Cellular and Molecular Medicine University of Ottawa Ontario Canada
| | - Pietro Di Santo
- CAPITAL Research Group Division of Cardiology University of Ottawa Heart Institute Ottawa Ontario Canada.,School of Epidemiology and Public Health University of Ottawa Ontario Canada.,Division of Cardiology University of Ottawa Heart Institute Ottawa Ontario Canada
| | - Rebecca Mathew
- CAPITAL Research Group Division of Cardiology University of Ottawa Heart Institute Ottawa Ontario Canada.,Division of Cardiology University of Ottawa Heart Institute Ottawa Ontario Canada.,Division of Critical Care Department of Medicine University of Ottawa Ontario Canada
| | - Omar Abdel-Razek
- CAPITAL Research Group Division of Cardiology University of Ottawa Heart Institute Ottawa Ontario Canada.,Division of Cardiology University of Ottawa Heart Institute Ottawa Ontario Canada
| | - Simon Parlow
- CAPITAL Research Group Division of Cardiology University of Ottawa Heart Institute Ottawa Ontario Canada.,Division of Cardiology University of Ottawa Heart Institute Ottawa Ontario Canada
| | - Trevor Simard
- CAPITAL Research Group Division of Cardiology University of Ottawa Heart Institute Ottawa Ontario Canada.,Department of Cellular and Molecular Medicine University of Ottawa Ontario Canada.,Division of Cardiology University of Ottawa Heart Institute Ottawa Ontario Canada.,Department of Cardiovascular Medicine Mayo Clinic Rochester MN
| | - Jeffrey A Marbach
- CAPITAL Research Group Division of Cardiology University of Ottawa Heart Institute Ottawa Ontario Canada.,Division of Critical Care Tufts Medical Center Boston MA
| | | | - Brennan Mao
- Faculty of Medicine University of Ottawa Ontario Canada
| | - Jordan Bernick
- Cardiovascular Research Methods Centre University of Ottawa Heart Institute Ottawa Canada
| | - Pascal Theriault-Lauzier
- CAPITAL Research Group Division of Cardiology University of Ottawa Heart Institute Ottawa Ontario Canada.,Division of Cardiology University of Ottawa Heart Institute Ottawa Ontario Canada
| | - Angel Fu
- CAPITAL Research Group Division of Cardiology University of Ottawa Heart Institute Ottawa Ontario Canada.,Division of Cardiology University of Ottawa Heart Institute Ottawa Ontario Canada
| | - Lawrence Lau
- CAPITAL Research Group Division of Cardiology University of Ottawa Heart Institute Ottawa Ontario Canada.,Division of Cardiology University of Ottawa Heart Institute Ottawa Ontario Canada
| | | | - Juan J Russo
- CAPITAL Research Group Division of Cardiology University of Ottawa Heart Institute Ottawa Ontario Canada.,Division of Cardiology University of Ottawa Heart Institute Ottawa Ontario Canada
| | - Marino Labinaz
- CAPITAL Research Group Division of Cardiology University of Ottawa Heart Institute Ottawa Ontario Canada.,Division of Cardiology University of Ottawa Heart Institute Ottawa Ontario Canada
| | - Benjamin Hibbert
- CAPITAL Research Group Division of Cardiology University of Ottawa Heart Institute Ottawa Ontario Canada.,Department of Cellular and Molecular Medicine University of Ottawa Ontario Canada.,School of Epidemiology and Public Health University of Ottawa Ontario Canada.,Division of Cardiology University of Ottawa Heart Institute Ottawa Ontario Canada
| |
Collapse
|
25
|
Jung RG, Stotts C, Makwana D, Motazedian P, Di Santo P, Goh CY, Verreault-Julien L, Simard T, Ramirez FD, Hibbert B. Methodological Rigor in Preclinical Cardiovascular Research: Contemporary Performance of AHA Scientific Publications. Circ Res 2021; 129:887-889. [PMID: 34521221 DOI: 10.1161/circresaha.121.319921] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Affiliation(s)
- Richard G Jung
- CAPITAL Research Group (R.G.J., C.S., D.M., P.M., P.D.S., C.-Y.G., L.V.-J., T.S., F.D.R., B.H.), University of Ottawa Heart Institute, Ontario, Canada.,Vascular Biology and Experimental Medicine Laboratory (R.G.J., P.M., P.D.S., T.S., B.H.), University of Ottawa Heart Institute, Ontario, Canada.,Cellular and Molecular Medicine, Faculty of Medicine (R.G.J., T.S., B.H.), University of Ottawa, Ontario, Canada
| | - Cameron Stotts
- CAPITAL Research Group (R.G.J., C.S., D.M., P.M., P.D.S., C.-Y.G., L.V.-J., T.S., F.D.R., B.H.), University of Ottawa Heart Institute, Ontario, Canada.,Department of Biochemistry, Microbiology, and Immunology, Faculty of Medicine (C.S.), University of Ottawa, Ontario, Canada
| | - Dwipen Makwana
- CAPITAL Research Group (R.G.J., C.S., D.M., P.M., P.D.S., C.-Y.G., L.V.-J., T.S., F.D.R., B.H.), University of Ottawa Heart Institute, Ontario, Canada
| | - Pouya Motazedian
- CAPITAL Research Group (R.G.J., C.S., D.M., P.M., P.D.S., C.-Y.G., L.V.-J., T.S., F.D.R., B.H.), University of Ottawa Heart Institute, Ontario, Canada.,Vascular Biology and Experimental Medicine Laboratory (R.G.J., P.M., P.D.S., T.S., B.H.), University of Ottawa Heart Institute, Ontario, Canada.,Division of Cardiology (P.M., P.D.S., C.-Y.G., L.V.-J., F.D.R., B.H.), University of Ottawa Heart Institute, Ontario, Canada.,Cumming School of Medicine, University of Calgary, Alberta, Canada (P.M.)
| | - Pietro Di Santo
- CAPITAL Research Group (R.G.J., C.S., D.M., P.M., P.D.S., C.-Y.G., L.V.-J., T.S., F.D.R., B.H.), University of Ottawa Heart Institute, Ontario, Canada.,Vascular Biology and Experimental Medicine Laboratory (R.G.J., P.M., P.D.S., T.S., B.H.), University of Ottawa Heart Institute, Ontario, Canada.,Division of Cardiology (P.M., P.D.S., C.-Y.G., L.V.-J., F.D.R., B.H.), University of Ottawa Heart Institute, Ontario, Canada.,School of Epidemiology (P.D.S.), University of Ottawa, Ontario, Canada
| | - Cheng-Yee Goh
- CAPITAL Research Group (R.G.J., C.S., D.M., P.M., P.D.S., C.-Y.G., L.V.-J., T.S., F.D.R., B.H.), University of Ottawa Heart Institute, Ontario, Canada.,Division of Cardiology (P.M., P.D.S., C.-Y.G., L.V.-J., F.D.R., B.H.), University of Ottawa Heart Institute, Ontario, Canada
| | - Louis Verreault-Julien
- CAPITAL Research Group (R.G.J., C.S., D.M., P.M., P.D.S., C.-Y.G., L.V.-J., T.S., F.D.R., B.H.), University of Ottawa Heart Institute, Ontario, Canada.,Division of Cardiology (P.M., P.D.S., C.-Y.G., L.V.-J., F.D.R., B.H.), University of Ottawa Heart Institute, Ontario, Canada
| | - Trevor Simard
- CAPITAL Research Group (R.G.J., C.S., D.M., P.M., P.D.S., C.-Y.G., L.V.-J., T.S., F.D.R., B.H.), University of Ottawa Heart Institute, Ontario, Canada.,Vascular Biology and Experimental Medicine Laboratory (R.G.J., P.M., P.D.S., T.S., B.H.), University of Ottawa Heart Institute, Ontario, Canada.,Division of Cardiology (P.M., P.D.S., C.-Y.G., L.V.-J., F.D.R., B.H.), University of Ottawa Heart Institute, Ontario, Canada.,Cellular and Molecular Medicine, Faculty of Medicine (R.G.J., T.S., B.H.), University of Ottawa, Ontario, Canada.,Department of Cardiovascular Diseases, Mayo Clinic School of Medicine, Rochester, MN (T.S.)
| | - F Daniel Ramirez
- CAPITAL Research Group (R.G.J., C.S., D.M., P.M., P.D.S., C.-Y.G., L.V.-J., T.S., F.D.R., B.H.), University of Ottawa Heart Institute, Ontario, Canada.,Division of Cardiology (P.M., P.D.S., C.-Y.G., L.V.-J., F.D.R., B.H.), University of Ottawa Heart Institute, Ontario, Canada
| | - Benjamin Hibbert
- CAPITAL Research Group (R.G.J., C.S., D.M., P.M., P.D.S., C.-Y.G., L.V.-J., T.S., F.D.R., B.H.), University of Ottawa Heart Institute, Ontario, Canada.,Vascular Biology and Experimental Medicine Laboratory (R.G.J., P.M., P.D.S., T.S., B.H.), University of Ottawa Heart Institute, Ontario, Canada.,Division of Cardiology (P.M., P.D.S., C.-Y.G., L.V.-J., F.D.R., B.H.), University of Ottawa Heart Institute, Ontario, Canada.,Cellular and Molecular Medicine, Faculty of Medicine (R.G.J., T.S., B.H.), University of Ottawa, Ontario, Canada
| |
Collapse
|
26
|
Parlow S, Di Santo P, Mathew R, Jung RG, Simard T, Gillmore T, Mao B, Abdel-Razek O, Ramirez FD, Marbach JA, Dick A, Glover C, Russo JJ, Froeschl M, Labinaz M, Fernando SM, Hibbert B. The association between mean arterial pressure and outcomes in patients with cardiogenic shock: insights from the DOREMI trial. Eur Heart J Acute Cardiovasc Care 2021; 10:712-720. [PMID: 34382063 DOI: 10.1093/ehjacc/zuab052] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Received: 03/08/2021] [Revised: 05/18/2021] [Accepted: 06/26/2021] [Indexed: 11/14/2022]
Abstract
AIMS Cardiogenic shock (CS) is a state of low cardiac output resulting in end-organ hypoperfusion. Despite high in-hospital mortality rates, little evidence exists regarding the optimal mean arterial pressure (MAP) target in CS. We therefore evaluated the relationship between achieved MAP and clinical outcomes in patients with CS. METHODS AND RESULTS We performed a post hoc analysis of the CAPITAL DOREMI trial: a randomized, double-blind trial comparing dobutamine to milrinone in patients with CS. We divided patients into a high MAP group (average MAP ≥ 70 mmHg over the 36 h following randomization), and a low MAP group (average MAP < 70 mmHg). Our primary outcome included in-hospital all-cause mortality, resuscitated cardiac arrest, need for cardiac transplantation or mechanical circulatory support, non-fatal myocardial infarction, transient ischaemic attack or stroke, or initiation of renal replacement therapy. In total, 71 (37.0%) patients achieved an average MAP < 70 mmHg, and 121 (63.0%) achieved an average MAP ≥ 70 mmHg. The primary outcome occurred in 48 (67.6%) patients in the low MAP group and 51 (42.2%) patients in the high MAP group [adjusted relative risk (aRR) 0.70; 95% confidence interval (CI) 0.53-0.92; P = 0.01]. All-cause mortality occurred in 41 (57.8%) and 35 (28.9%) patients in the low and high MAP groups, respectively (aRR 0.56; 95% CI 0.40-0.79; P < 0.01). There were no significant differences in any secondary outcomes between each group. CONCLUSIONS In patients with CS treated with inotrope therapy, low MAP is associated with worse clinical outcomes. Randomized data evaluating optimal MAP targets in CS is needed to guide medical therapy.
Collapse
Affiliation(s)
- Simon Parlow
- CAPITAL Research Group, University of Ottawa Heart Institute, 40 Ruskin Street, H-4238, Ottawa, Ontario K1Y 4W7, Canada.,Division of Cardiology, University of Ottawa Heart Institute, 40 Ruskin Street, H-4238, Ottawa, Ontario K1Y 4W7, Canada
| | - Pietro Di Santo
- CAPITAL Research Group, University of Ottawa Heart Institute, 40 Ruskin Street, H-4238, Ottawa, Ontario K1Y 4W7, Canada.,Division of Cardiology, University of Ottawa Heart Institute, 40 Ruskin Street, H-4238, Ottawa, Ontario K1Y 4W7, Canada.,School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, 600 Peter Morand Crescent, Room 101, Ottawa, Ontario, K1G 5Z3, Canada
| | - Rebecca Mathew
- CAPITAL Research Group, University of Ottawa Heart Institute, 40 Ruskin Street, H-4238, Ottawa, Ontario K1Y 4W7, Canada.,Division of Cardiology, University of Ottawa Heart Institute, 40 Ruskin Street, H-4238, Ottawa, Ontario K1Y 4W7, Canada
| | - Richard G Jung
- CAPITAL Research Group, University of Ottawa Heart Institute, 40 Ruskin Street, H-4238, Ottawa, Ontario K1Y 4W7, Canada.,Faculty of Medicine, University of Ottawa, Roger Guindon Hall, 451 Smyth Rd #2044, Ottawa, Ontario, K1H 8M5, Canada.,Department of Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa, 451 Smyth Road, Room #3206, Ottawa, Ontario, K1H 8M5, Canada
| | - Trevor Simard
- CAPITAL Research Group, University of Ottawa Heart Institute, 40 Ruskin Street, H-4238, Ottawa, Ontario K1Y 4W7, Canada.,Department of Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa, 451 Smyth Road, Room #3206, Ottawa, Ontario, K1H 8M5, Canada.,Department of Cardiovascular Diseases, Mayo Clinic School of Medicine, 200 First St. SW, Rochester, Minnesota, 55905, USA
| | - Taylor Gillmore
- Faculty of Medicine, University of Ottawa, Roger Guindon Hall, 451 Smyth Rd #2044, Ottawa, Ontario, K1H 8M5, Canada
| | - Brennan Mao
- Faculty of Medicine, University of Ottawa, Roger Guindon Hall, 451 Smyth Rd #2044, Ottawa, Ontario, K1H 8M5, Canada
| | - Omar Abdel-Razek
- CAPITAL Research Group, University of Ottawa Heart Institute, 40 Ruskin Street, H-4238, Ottawa, Ontario K1Y 4W7, Canada.,Division of Cardiology, University of Ottawa Heart Institute, 40 Ruskin Street, H-4238, Ottawa, Ontario K1Y 4W7, Canada
| | - F Daniel Ramirez
- CAPITAL Research Group, University of Ottawa Heart Institute, 40 Ruskin Street, H-4238, Ottawa, Ontario K1Y 4W7, Canada.,Division of Cardiology, University of Ottawa Heart Institute, 40 Ruskin Street, H-4238, Ottawa, Ontario K1Y 4W7, Canada
| | - Jeffrey A Marbach
- CAPITAL Research Group, University of Ottawa Heart Institute, 40 Ruskin Street, H-4238, Ottawa, Ontario K1Y 4W7, Canada.,Division of Pulmonary, Critical Care, and Sleep Medicine, Tufts Medical Center, 800 Washington Street, Boston, Massachusetts, 02111, USA
| | - Alexander Dick
- CAPITAL Research Group, University of Ottawa Heart Institute, 40 Ruskin Street, H-4238, Ottawa, Ontario K1Y 4W7, Canada.,Division of Cardiology, University of Ottawa Heart Institute, 40 Ruskin Street, H-4238, Ottawa, Ontario K1Y 4W7, Canada
| | - Christopher Glover
- CAPITAL Research Group, University of Ottawa Heart Institute, 40 Ruskin Street, H-4238, Ottawa, Ontario K1Y 4W7, Canada.,Division of Cardiology, University of Ottawa Heart Institute, 40 Ruskin Street, H-4238, Ottawa, Ontario K1Y 4W7, Canada
| | - Juan J Russo
- CAPITAL Research Group, University of Ottawa Heart Institute, 40 Ruskin Street, H-4238, Ottawa, Ontario K1Y 4W7, Canada.,Division of Cardiology, University of Ottawa Heart Institute, 40 Ruskin Street, H-4238, Ottawa, Ontario K1Y 4W7, Canada
| | - Michael Froeschl
- CAPITAL Research Group, University of Ottawa Heart Institute, 40 Ruskin Street, H-4238, Ottawa, Ontario K1Y 4W7, Canada.,Division of Cardiology, University of Ottawa Heart Institute, 40 Ruskin Street, H-4238, Ottawa, Ontario K1Y 4W7, Canada
| | - Marino Labinaz
- CAPITAL Research Group, University of Ottawa Heart Institute, 40 Ruskin Street, H-4238, Ottawa, Ontario K1Y 4W7, Canada.,Division of Cardiology, University of Ottawa Heart Institute, 40 Ruskin Street, H-4238, Ottawa, Ontario K1Y 4W7, Canada
| | - Shannon M Fernando
- CAPITAL Research Group, University of Ottawa Heart Institute, 40 Ruskin Street, H-4238, Ottawa, Ontario K1Y 4W7, Canada.,Division of Critical Care, Department of Medicine, University of Ottawa, 501 Smyth Road, Ottawa, Ontario, K1H 8L6, Canada
| | - Benjamin Hibbert
- CAPITAL Research Group, University of Ottawa Heart Institute, 40 Ruskin Street, H-4238, Ottawa, Ontario K1Y 4W7, Canada.,Division of Cardiology, University of Ottawa Heart Institute, 40 Ruskin Street, H-4238, Ottawa, Ontario K1Y 4W7, Canada.,Department of Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa, 451 Smyth Road, Room #3206, Ottawa, Ontario, K1H 8M5, Canada
| |
Collapse
|
27
|
Di Santo P, Mathew R, Jung RG, Simard T, Skanes S, Mao B, Ramirez FD, Marbach JA, Abdel-Razek O, Motazedian P, Parlow S, Boczar KE, D'Egidio G, Hawken S, Bernick J, Wells GA, Dick A, So DY, Glover C, Russo JJ, McGuinty C, Hibbert B. Impact of baseline beta-blocker use on inotrope response and clinical outcomes in cardiogenic shock: a subgroup analysis of the DOREMI trial. Crit Care 2021; 25:289. [PMID: 34376218 PMCID: PMC8356445 DOI: 10.1186/s13054-021-03706-2] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 10/29/2020] [Accepted: 02/19/2021] [Indexed: 12/29/2022]
Abstract
Background Cardiogenic shock (CS) is associated with significant morbidity and mortality. The impact of beta-blocker (BB) use on patients who develop CS remains unknown. We sought to evaluate the clinical outcomes and hemodynamic response profiles in patients treated with BB in the 24 h prior to the development of CS. Methods Patients with CS enrolled in the DObutamine compaREd to MIlrinone trial were analyzed. The primary outcome was a composite of all-cause mortality, resuscitated cardiac arrest, need for cardiac transplant or mechanical circulatory support, non-fatal myocardial infarction, transient ischemic attack or stroke, or initiation of renal replacement therapy. Secondary outcomes included the individual components of the primary composite and hemodynamic response profiles derived from pulmonary artery catheters. Results Among 192 participants, 93 patients (48%) had received BB therapy. The primary outcome occurred in 47 patients (51%) in the BB group and in 52 (53%) in the no BB group (RR 0.96; 95% CI 0.73–1.27; P = 0.78) throughout the in-hospital period. There were fewer early deaths in the BB group (RR 0.41; 95% CI 0.18–0.95; P = 0.03). There were no differences in other individual components of the primary outcome or in hemodynamic response between the two groups throughout the remainder of the hospitalization. Conclusions BB therapy in the 24 h preceding the development of CS did not negatively influence clinical outcomes or hemodynamic parameters. On the contrary, BB use was associated with fewer deaths in the early resuscitation period, suggesting a paradoxically protective effect in patients with CS. Trial registration ClinicalTrials.gov Identifier: NCT03207165
Collapse
Affiliation(s)
- Pietro Di Santo
- CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, 40 Ruskin Street, H-4238, Ottawa, ON, K1Y 4W7, Canada.,Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.,School of Epidemiology and Public Health, University of Ottawa, Ottawa, ON, Canada
| | - Rebecca Mathew
- CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, 40 Ruskin Street, H-4238, Ottawa, ON, K1Y 4W7, Canada.,Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.,Division of Critical Care, Department of Medicine, University of Ottawa, Ottawa, ON, Canada
| | - Richard G Jung
- CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, 40 Ruskin Street, H-4238, Ottawa, ON, K1Y 4W7, Canada.,Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.,Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, ON, Canada
| | - Trevor Simard
- CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, 40 Ruskin Street, H-4238, Ottawa, ON, K1Y 4W7, Canada.,Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA
| | | | - Brennan Mao
- Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada
| | - F Daniel Ramirez
- CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, 40 Ruskin Street, H-4238, Ottawa, ON, K1Y 4W7, Canada.,Hôpital Cardiologique du Haut Lévêque, CHU Bordeaux, Bordeaux-Pessac, France.,LIRYC (L'Institut de Rythmologie Et Modélisation Cardiaque), Bordeaux-Pessac, France
| | - Jeffrey A Marbach
- CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, 40 Ruskin Street, H-4238, Ottawa, ON, K1Y 4W7, Canada.,Division of Critical Care, Tufts Medical Center, Boston, MA, USA
| | - Omar Abdel-Razek
- CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, 40 Ruskin Street, H-4238, Ottawa, ON, K1Y 4W7, Canada.,Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada
| | - Pouya Motazedian
- CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, 40 Ruskin Street, H-4238, Ottawa, ON, K1Y 4W7, Canada.,Department of Medicine, Cumming School of Medicine, Calgary, AB, Canada
| | - Simon Parlow
- CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, 40 Ruskin Street, H-4238, Ottawa, ON, K1Y 4W7, Canada.,Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada
| | - Kevin E Boczar
- CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, 40 Ruskin Street, H-4238, Ottawa, ON, K1Y 4W7, Canada.,Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.,School of Epidemiology and Public Health, University of Ottawa, Ottawa, ON, Canada
| | - Gianni D'Egidio
- Division of Critical Care, Department of Medicine, University of Ottawa, Ottawa, ON, Canada
| | - Steven Hawken
- Ottawa Hospital Research Institute, Ottawa, ON, Canada
| | - Jordan Bernick
- Cardiovascular Research Methods Centre, University of Ottawa Heart Institute, Ottawa, ON, Canada
| | - George A Wells
- Cardiovascular Research Methods Centre, University of Ottawa Heart Institute, Ottawa, ON, Canada
| | - Alexander Dick
- CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, 40 Ruskin Street, H-4238, Ottawa, ON, K1Y 4W7, Canada.,Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada
| | - Derek Y So
- CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, 40 Ruskin Street, H-4238, Ottawa, ON, K1Y 4W7, Canada.,Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada
| | - Christopher Glover
- CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, 40 Ruskin Street, H-4238, Ottawa, ON, K1Y 4W7, Canada.,Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada
| | - Juan J Russo
- CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, 40 Ruskin Street, H-4238, Ottawa, ON, K1Y 4W7, Canada.,Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada
| | - Caroline McGuinty
- CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, 40 Ruskin Street, H-4238, Ottawa, ON, K1Y 4W7, Canada.,Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada
| | - Benjamin Hibbert
- CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, 40 Ruskin Street, H-4238, Ottawa, ON, K1Y 4W7, Canada. .,Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada. .,Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, ON, Canada.
| | | |
Collapse
|
28
|
Mathew R, Di Santo P, Jung RG, Marbach JA, Hutson J, Simard T, Ramirez FD, Harnett DT, Merdad A, Almufleh A, Weng W, Abdel-Razek O, Fernando SM, Kyeremanteng K, Bernick J, Wells GA, Chan V, Froeschl M, Labinaz M, Le May MR, Russo JJ, Hibbert B. Milrinone as Compared with Dobutamine in the Treatment of Cardiogenic Shock. N Engl J Med 2021; 385:516-525. [PMID: 34347952 DOI: 10.1056/nejmoa2026845] [Citation(s) in RCA: 88] [Impact Index Per Article: 29.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
BACKGROUND Cardiogenic shock is associated with substantial morbidity and mortality. Although inotropic support is a mainstay of medical therapy for cardiogenic shock, little evidence exists to guide the selection of inotropic agents in clinical practice. METHODS We randomly assigned patients with cardiogenic shock to receive milrinone or dobutamine in a double-blind fashion. The primary outcome was a composite of in-hospital death from any cause, resuscitated cardiac arrest, receipt of a cardiac transplant or mechanical circulatory support, nonfatal myocardial infarction, transient ischemic attack or stroke diagnosed by a neurologist, or initiation of renal replacement therapy. Secondary outcomes included the individual components of the primary composite outcome. RESULTS A total of 192 participants (96 in each group) were enrolled. The treatment groups did not differ significantly with respect to the primary outcome; a primary outcome event occurred in 47 participants (49%) in the milrinone group and in 52 participants (54%) in the dobutamine group (relative risk, 0.90; 95% confidence interval [CI], 0.69 to 1.19; P = 0.47). There were also no significant differences between the groups with respect to secondary outcomes, including in-hospital death (37% and 43% of the participants, respectively; relative risk, 0.85; 95% CI, 0.60 to 1.21), resuscitated cardiac arrest (7% and 9%; hazard ratio, 0.78; 95% CI, 0.29 to 2.07), receipt of mechanical circulatory support (12% and 15%; hazard ratio, 0.78; 95% CI, 0.36 to 1.71), or initiation of renal replacement therapy (22% and 17%; hazard ratio, 1.39; 95% CI, 0.73 to 2.67). CONCLUSIONS In patients with cardiogenic shock, no significant difference between milrinone and dobutamine was found with respect to the primary composite outcome or important secondary outcomes. (Funded by the Innovation Fund of the Alternative Funding Plan for the Academic Health Sciences Centres of Ontario; ClinicalTrials.gov number, NCT03207165.).
Collapse
Affiliation(s)
- Rebecca Mathew
- From the CAPITAL Research Group, Division of Cardiology (R.M., P.D.S., R.G.J., J.A.M., T.S., F.D.R., D.T.H., O.A.-R., M.F., M.L., M.R.L.M., J.J.R., B.H.), the Cardiovascular Research Methods Centre (J.B., G.A.W.), and the Division of Cardiac Surgery (V.C.), University of Ottawa Heart Institute, and the Faculty of Medicine (R.M., P.D.S., R.G.J., J.H., D.T.H., W.W., O.A.-R., S.M.F., K.K., M.F., M.L., M.R.L.M., J.J.R., B.H.), the Division of Critical Care, Department of Medicine (R.M., J.H., S.M.F., K.K.), the School of Epidemiology and Public Health (P.D.S.), and the Department of Cellular and Molecular Medicine (R.G.J., T.S., B.H.), University of Ottawa, Ottawa, the Division of Cardiology, University of Toronto, Toronto (A.M.), and the Division of Cardiology, University of British Columbia, Vancouver (A.A.) - all in Canada; the Division of Critical Care, Tufts Medical Center, Boston (J.A.M.); the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (T.S.); and Hôpital Cardiologique du Haut Lévêque, Centre Hospitalier Universitaire Bordeaux (F.D.R.), and LIRYC (L'Institut de Rythmologie et Modélisation Cardiaque) (F.D.R.) - both in Bordeaux-Pessac, France
| | - Pietro Di Santo
- From the CAPITAL Research Group, Division of Cardiology (R.M., P.D.S., R.G.J., J.A.M., T.S., F.D.R., D.T.H., O.A.-R., M.F., M.L., M.R.L.M., J.J.R., B.H.), the Cardiovascular Research Methods Centre (J.B., G.A.W.), and the Division of Cardiac Surgery (V.C.), University of Ottawa Heart Institute, and the Faculty of Medicine (R.M., P.D.S., R.G.J., J.H., D.T.H., W.W., O.A.-R., S.M.F., K.K., M.F., M.L., M.R.L.M., J.J.R., B.H.), the Division of Critical Care, Department of Medicine (R.M., J.H., S.M.F., K.K.), the School of Epidemiology and Public Health (P.D.S.), and the Department of Cellular and Molecular Medicine (R.G.J., T.S., B.H.), University of Ottawa, Ottawa, the Division of Cardiology, University of Toronto, Toronto (A.M.), and the Division of Cardiology, University of British Columbia, Vancouver (A.A.) - all in Canada; the Division of Critical Care, Tufts Medical Center, Boston (J.A.M.); the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (T.S.); and Hôpital Cardiologique du Haut Lévêque, Centre Hospitalier Universitaire Bordeaux (F.D.R.), and LIRYC (L'Institut de Rythmologie et Modélisation Cardiaque) (F.D.R.) - both in Bordeaux-Pessac, France
| | - Richard G Jung
- From the CAPITAL Research Group, Division of Cardiology (R.M., P.D.S., R.G.J., J.A.M., T.S., F.D.R., D.T.H., O.A.-R., M.F., M.L., M.R.L.M., J.J.R., B.H.), the Cardiovascular Research Methods Centre (J.B., G.A.W.), and the Division of Cardiac Surgery (V.C.), University of Ottawa Heart Institute, and the Faculty of Medicine (R.M., P.D.S., R.G.J., J.H., D.T.H., W.W., O.A.-R., S.M.F., K.K., M.F., M.L., M.R.L.M., J.J.R., B.H.), the Division of Critical Care, Department of Medicine (R.M., J.H., S.M.F., K.K.), the School of Epidemiology and Public Health (P.D.S.), and the Department of Cellular and Molecular Medicine (R.G.J., T.S., B.H.), University of Ottawa, Ottawa, the Division of Cardiology, University of Toronto, Toronto (A.M.), and the Division of Cardiology, University of British Columbia, Vancouver (A.A.) - all in Canada; the Division of Critical Care, Tufts Medical Center, Boston (J.A.M.); the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (T.S.); and Hôpital Cardiologique du Haut Lévêque, Centre Hospitalier Universitaire Bordeaux (F.D.R.), and LIRYC (L'Institut de Rythmologie et Modélisation Cardiaque) (F.D.R.) - both in Bordeaux-Pessac, France
| | - Jeffrey A Marbach
- From the CAPITAL Research Group, Division of Cardiology (R.M., P.D.S., R.G.J., J.A.M., T.S., F.D.R., D.T.H., O.A.-R., M.F., M.L., M.R.L.M., J.J.R., B.H.), the Cardiovascular Research Methods Centre (J.B., G.A.W.), and the Division of Cardiac Surgery (V.C.), University of Ottawa Heart Institute, and the Faculty of Medicine (R.M., P.D.S., R.G.J., J.H., D.T.H., W.W., O.A.-R., S.M.F., K.K., M.F., M.L., M.R.L.M., J.J.R., B.H.), the Division of Critical Care, Department of Medicine (R.M., J.H., S.M.F., K.K.), the School of Epidemiology and Public Health (P.D.S.), and the Department of Cellular and Molecular Medicine (R.G.J., T.S., B.H.), University of Ottawa, Ottawa, the Division of Cardiology, University of Toronto, Toronto (A.M.), and the Division of Cardiology, University of British Columbia, Vancouver (A.A.) - all in Canada; the Division of Critical Care, Tufts Medical Center, Boston (J.A.M.); the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (T.S.); and Hôpital Cardiologique du Haut Lévêque, Centre Hospitalier Universitaire Bordeaux (F.D.R.), and LIRYC (L'Institut de Rythmologie et Modélisation Cardiaque) (F.D.R.) - both in Bordeaux-Pessac, France
| | - Jordan Hutson
- From the CAPITAL Research Group, Division of Cardiology (R.M., P.D.S., R.G.J., J.A.M., T.S., F.D.R., D.T.H., O.A.-R., M.F., M.L., M.R.L.M., J.J.R., B.H.), the Cardiovascular Research Methods Centre (J.B., G.A.W.), and the Division of Cardiac Surgery (V.C.), University of Ottawa Heart Institute, and the Faculty of Medicine (R.M., P.D.S., R.G.J., J.H., D.T.H., W.W., O.A.-R., S.M.F., K.K., M.F., M.L., M.R.L.M., J.J.R., B.H.), the Division of Critical Care, Department of Medicine (R.M., J.H., S.M.F., K.K.), the School of Epidemiology and Public Health (P.D.S.), and the Department of Cellular and Molecular Medicine (R.G.J., T.S., B.H.), University of Ottawa, Ottawa, the Division of Cardiology, University of Toronto, Toronto (A.M.), and the Division of Cardiology, University of British Columbia, Vancouver (A.A.) - all in Canada; the Division of Critical Care, Tufts Medical Center, Boston (J.A.M.); the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (T.S.); and Hôpital Cardiologique du Haut Lévêque, Centre Hospitalier Universitaire Bordeaux (F.D.R.), and LIRYC (L'Institut de Rythmologie et Modélisation Cardiaque) (F.D.R.) - both in Bordeaux-Pessac, France
| | - Trevor Simard
- From the CAPITAL Research Group, Division of Cardiology (R.M., P.D.S., R.G.J., J.A.M., T.S., F.D.R., D.T.H., O.A.-R., M.F., M.L., M.R.L.M., J.J.R., B.H.), the Cardiovascular Research Methods Centre (J.B., G.A.W.), and the Division of Cardiac Surgery (V.C.), University of Ottawa Heart Institute, and the Faculty of Medicine (R.M., P.D.S., R.G.J., J.H., D.T.H., W.W., O.A.-R., S.M.F., K.K., M.F., M.L., M.R.L.M., J.J.R., B.H.), the Division of Critical Care, Department of Medicine (R.M., J.H., S.M.F., K.K.), the School of Epidemiology and Public Health (P.D.S.), and the Department of Cellular and Molecular Medicine (R.G.J., T.S., B.H.), University of Ottawa, Ottawa, the Division of Cardiology, University of Toronto, Toronto (A.M.), and the Division of Cardiology, University of British Columbia, Vancouver (A.A.) - all in Canada; the Division of Critical Care, Tufts Medical Center, Boston (J.A.M.); the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (T.S.); and Hôpital Cardiologique du Haut Lévêque, Centre Hospitalier Universitaire Bordeaux (F.D.R.), and LIRYC (L'Institut de Rythmologie et Modélisation Cardiaque) (F.D.R.) - both in Bordeaux-Pessac, France
| | - F Daniel Ramirez
- From the CAPITAL Research Group, Division of Cardiology (R.M., P.D.S., R.G.J., J.A.M., T.S., F.D.R., D.T.H., O.A.-R., M.F., M.L., M.R.L.M., J.J.R., B.H.), the Cardiovascular Research Methods Centre (J.B., G.A.W.), and the Division of Cardiac Surgery (V.C.), University of Ottawa Heart Institute, and the Faculty of Medicine (R.M., P.D.S., R.G.J., J.H., D.T.H., W.W., O.A.-R., S.M.F., K.K., M.F., M.L., M.R.L.M., J.J.R., B.H.), the Division of Critical Care, Department of Medicine (R.M., J.H., S.M.F., K.K.), the School of Epidemiology and Public Health (P.D.S.), and the Department of Cellular and Molecular Medicine (R.G.J., T.S., B.H.), University of Ottawa, Ottawa, the Division of Cardiology, University of Toronto, Toronto (A.M.), and the Division of Cardiology, University of British Columbia, Vancouver (A.A.) - all in Canada; the Division of Critical Care, Tufts Medical Center, Boston (J.A.M.); the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (T.S.); and Hôpital Cardiologique du Haut Lévêque, Centre Hospitalier Universitaire Bordeaux (F.D.R.), and LIRYC (L'Institut de Rythmologie et Modélisation Cardiaque) (F.D.R.) - both in Bordeaux-Pessac, France
| | - David T Harnett
- From the CAPITAL Research Group, Division of Cardiology (R.M., P.D.S., R.G.J., J.A.M., T.S., F.D.R., D.T.H., O.A.-R., M.F., M.L., M.R.L.M., J.J.R., B.H.), the Cardiovascular Research Methods Centre (J.B., G.A.W.), and the Division of Cardiac Surgery (V.C.), University of Ottawa Heart Institute, and the Faculty of Medicine (R.M., P.D.S., R.G.J., J.H., D.T.H., W.W., O.A.-R., S.M.F., K.K., M.F., M.L., M.R.L.M., J.J.R., B.H.), the Division of Critical Care, Department of Medicine (R.M., J.H., S.M.F., K.K.), the School of Epidemiology and Public Health (P.D.S.), and the Department of Cellular and Molecular Medicine (R.G.J., T.S., B.H.), University of Ottawa, Ottawa, the Division of Cardiology, University of Toronto, Toronto (A.M.), and the Division of Cardiology, University of British Columbia, Vancouver (A.A.) - all in Canada; the Division of Critical Care, Tufts Medical Center, Boston (J.A.M.); the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (T.S.); and Hôpital Cardiologique du Haut Lévêque, Centre Hospitalier Universitaire Bordeaux (F.D.R.), and LIRYC (L'Institut de Rythmologie et Modélisation Cardiaque) (F.D.R.) - both in Bordeaux-Pessac, France
| | - Anas Merdad
- From the CAPITAL Research Group, Division of Cardiology (R.M., P.D.S., R.G.J., J.A.M., T.S., F.D.R., D.T.H., O.A.-R., M.F., M.L., M.R.L.M., J.J.R., B.H.), the Cardiovascular Research Methods Centre (J.B., G.A.W.), and the Division of Cardiac Surgery (V.C.), University of Ottawa Heart Institute, and the Faculty of Medicine (R.M., P.D.S., R.G.J., J.H., D.T.H., W.W., O.A.-R., S.M.F., K.K., M.F., M.L., M.R.L.M., J.J.R., B.H.), the Division of Critical Care, Department of Medicine (R.M., J.H., S.M.F., K.K.), the School of Epidemiology and Public Health (P.D.S.), and the Department of Cellular and Molecular Medicine (R.G.J., T.S., B.H.), University of Ottawa, Ottawa, the Division of Cardiology, University of Toronto, Toronto (A.M.), and the Division of Cardiology, University of British Columbia, Vancouver (A.A.) - all in Canada; the Division of Critical Care, Tufts Medical Center, Boston (J.A.M.); the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (T.S.); and Hôpital Cardiologique du Haut Lévêque, Centre Hospitalier Universitaire Bordeaux (F.D.R.), and LIRYC (L'Institut de Rythmologie et Modélisation Cardiaque) (F.D.R.) - both in Bordeaux-Pessac, France
| | - Aws Almufleh
- From the CAPITAL Research Group, Division of Cardiology (R.M., P.D.S., R.G.J., J.A.M., T.S., F.D.R., D.T.H., O.A.-R., M.F., M.L., M.R.L.M., J.J.R., B.H.), the Cardiovascular Research Methods Centre (J.B., G.A.W.), and the Division of Cardiac Surgery (V.C.), University of Ottawa Heart Institute, and the Faculty of Medicine (R.M., P.D.S., R.G.J., J.H., D.T.H., W.W., O.A.-R., S.M.F., K.K., M.F., M.L., M.R.L.M., J.J.R., B.H.), the Division of Critical Care, Department of Medicine (R.M., J.H., S.M.F., K.K.), the School of Epidemiology and Public Health (P.D.S.), and the Department of Cellular and Molecular Medicine (R.G.J., T.S., B.H.), University of Ottawa, Ottawa, the Division of Cardiology, University of Toronto, Toronto (A.M.), and the Division of Cardiology, University of British Columbia, Vancouver (A.A.) - all in Canada; the Division of Critical Care, Tufts Medical Center, Boston (J.A.M.); the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (T.S.); and Hôpital Cardiologique du Haut Lévêque, Centre Hospitalier Universitaire Bordeaux (F.D.R.), and LIRYC (L'Institut de Rythmologie et Modélisation Cardiaque) (F.D.R.) - both in Bordeaux-Pessac, France
| | - Willy Weng
- From the CAPITAL Research Group, Division of Cardiology (R.M., P.D.S., R.G.J., J.A.M., T.S., F.D.R., D.T.H., O.A.-R., M.F., M.L., M.R.L.M., J.J.R., B.H.), the Cardiovascular Research Methods Centre (J.B., G.A.W.), and the Division of Cardiac Surgery (V.C.), University of Ottawa Heart Institute, and the Faculty of Medicine (R.M., P.D.S., R.G.J., J.H., D.T.H., W.W., O.A.-R., S.M.F., K.K., M.F., M.L., M.R.L.M., J.J.R., B.H.), the Division of Critical Care, Department of Medicine (R.M., J.H., S.M.F., K.K.), the School of Epidemiology and Public Health (P.D.S.), and the Department of Cellular and Molecular Medicine (R.G.J., T.S., B.H.), University of Ottawa, Ottawa, the Division of Cardiology, University of Toronto, Toronto (A.M.), and the Division of Cardiology, University of British Columbia, Vancouver (A.A.) - all in Canada; the Division of Critical Care, Tufts Medical Center, Boston (J.A.M.); the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (T.S.); and Hôpital Cardiologique du Haut Lévêque, Centre Hospitalier Universitaire Bordeaux (F.D.R.), and LIRYC (L'Institut de Rythmologie et Modélisation Cardiaque) (F.D.R.) - both in Bordeaux-Pessac, France
| | - Omar Abdel-Razek
- From the CAPITAL Research Group, Division of Cardiology (R.M., P.D.S., R.G.J., J.A.M., T.S., F.D.R., D.T.H., O.A.-R., M.F., M.L., M.R.L.M., J.J.R., B.H.), the Cardiovascular Research Methods Centre (J.B., G.A.W.), and the Division of Cardiac Surgery (V.C.), University of Ottawa Heart Institute, and the Faculty of Medicine (R.M., P.D.S., R.G.J., J.H., D.T.H., W.W., O.A.-R., S.M.F., K.K., M.F., M.L., M.R.L.M., J.J.R., B.H.), the Division of Critical Care, Department of Medicine (R.M., J.H., S.M.F., K.K.), the School of Epidemiology and Public Health (P.D.S.), and the Department of Cellular and Molecular Medicine (R.G.J., T.S., B.H.), University of Ottawa, Ottawa, the Division of Cardiology, University of Toronto, Toronto (A.M.), and the Division of Cardiology, University of British Columbia, Vancouver (A.A.) - all in Canada; the Division of Critical Care, Tufts Medical Center, Boston (J.A.M.); the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (T.S.); and Hôpital Cardiologique du Haut Lévêque, Centre Hospitalier Universitaire Bordeaux (F.D.R.), and LIRYC (L'Institut de Rythmologie et Modélisation Cardiaque) (F.D.R.) - both in Bordeaux-Pessac, France
| | - Shannon M Fernando
- From the CAPITAL Research Group, Division of Cardiology (R.M., P.D.S., R.G.J., J.A.M., T.S., F.D.R., D.T.H., O.A.-R., M.F., M.L., M.R.L.M., J.J.R., B.H.), the Cardiovascular Research Methods Centre (J.B., G.A.W.), and the Division of Cardiac Surgery (V.C.), University of Ottawa Heart Institute, and the Faculty of Medicine (R.M., P.D.S., R.G.J., J.H., D.T.H., W.W., O.A.-R., S.M.F., K.K., M.F., M.L., M.R.L.M., J.J.R., B.H.), the Division of Critical Care, Department of Medicine (R.M., J.H., S.M.F., K.K.), the School of Epidemiology and Public Health (P.D.S.), and the Department of Cellular and Molecular Medicine (R.G.J., T.S., B.H.), University of Ottawa, Ottawa, the Division of Cardiology, University of Toronto, Toronto (A.M.), and the Division of Cardiology, University of British Columbia, Vancouver (A.A.) - all in Canada; the Division of Critical Care, Tufts Medical Center, Boston (J.A.M.); the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (T.S.); and Hôpital Cardiologique du Haut Lévêque, Centre Hospitalier Universitaire Bordeaux (F.D.R.), and LIRYC (L'Institut de Rythmologie et Modélisation Cardiaque) (F.D.R.) - both in Bordeaux-Pessac, France
| | - Kwadwo Kyeremanteng
- From the CAPITAL Research Group, Division of Cardiology (R.M., P.D.S., R.G.J., J.A.M., T.S., F.D.R., D.T.H., O.A.-R., M.F., M.L., M.R.L.M., J.J.R., B.H.), the Cardiovascular Research Methods Centre (J.B., G.A.W.), and the Division of Cardiac Surgery (V.C.), University of Ottawa Heart Institute, and the Faculty of Medicine (R.M., P.D.S., R.G.J., J.H., D.T.H., W.W., O.A.-R., S.M.F., K.K., M.F., M.L., M.R.L.M., J.J.R., B.H.), the Division of Critical Care, Department of Medicine (R.M., J.H., S.M.F., K.K.), the School of Epidemiology and Public Health (P.D.S.), and the Department of Cellular and Molecular Medicine (R.G.J., T.S., B.H.), University of Ottawa, Ottawa, the Division of Cardiology, University of Toronto, Toronto (A.M.), and the Division of Cardiology, University of British Columbia, Vancouver (A.A.) - all in Canada; the Division of Critical Care, Tufts Medical Center, Boston (J.A.M.); the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (T.S.); and Hôpital Cardiologique du Haut Lévêque, Centre Hospitalier Universitaire Bordeaux (F.D.R.), and LIRYC (L'Institut de Rythmologie et Modélisation Cardiaque) (F.D.R.) - both in Bordeaux-Pessac, France
| | - Jordan Bernick
- From the CAPITAL Research Group, Division of Cardiology (R.M., P.D.S., R.G.J., J.A.M., T.S., F.D.R., D.T.H., O.A.-R., M.F., M.L., M.R.L.M., J.J.R., B.H.), the Cardiovascular Research Methods Centre (J.B., G.A.W.), and the Division of Cardiac Surgery (V.C.), University of Ottawa Heart Institute, and the Faculty of Medicine (R.M., P.D.S., R.G.J., J.H., D.T.H., W.W., O.A.-R., S.M.F., K.K., M.F., M.L., M.R.L.M., J.J.R., B.H.), the Division of Critical Care, Department of Medicine (R.M., J.H., S.M.F., K.K.), the School of Epidemiology and Public Health (P.D.S.), and the Department of Cellular and Molecular Medicine (R.G.J., T.S., B.H.), University of Ottawa, Ottawa, the Division of Cardiology, University of Toronto, Toronto (A.M.), and the Division of Cardiology, University of British Columbia, Vancouver (A.A.) - all in Canada; the Division of Critical Care, Tufts Medical Center, Boston (J.A.M.); the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (T.S.); and Hôpital Cardiologique du Haut Lévêque, Centre Hospitalier Universitaire Bordeaux (F.D.R.), and LIRYC (L'Institut de Rythmologie et Modélisation Cardiaque) (F.D.R.) - both in Bordeaux-Pessac, France
| | - George A Wells
- From the CAPITAL Research Group, Division of Cardiology (R.M., P.D.S., R.G.J., J.A.M., T.S., F.D.R., D.T.H., O.A.-R., M.F., M.L., M.R.L.M., J.J.R., B.H.), the Cardiovascular Research Methods Centre (J.B., G.A.W.), and the Division of Cardiac Surgery (V.C.), University of Ottawa Heart Institute, and the Faculty of Medicine (R.M., P.D.S., R.G.J., J.H., D.T.H., W.W., O.A.-R., S.M.F., K.K., M.F., M.L., M.R.L.M., J.J.R., B.H.), the Division of Critical Care, Department of Medicine (R.M., J.H., S.M.F., K.K.), the School of Epidemiology and Public Health (P.D.S.), and the Department of Cellular and Molecular Medicine (R.G.J., T.S., B.H.), University of Ottawa, Ottawa, the Division of Cardiology, University of Toronto, Toronto (A.M.), and the Division of Cardiology, University of British Columbia, Vancouver (A.A.) - all in Canada; the Division of Critical Care, Tufts Medical Center, Boston (J.A.M.); the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (T.S.); and Hôpital Cardiologique du Haut Lévêque, Centre Hospitalier Universitaire Bordeaux (F.D.R.), and LIRYC (L'Institut de Rythmologie et Modélisation Cardiaque) (F.D.R.) - both in Bordeaux-Pessac, France
| | - Vincent Chan
- From the CAPITAL Research Group, Division of Cardiology (R.M., P.D.S., R.G.J., J.A.M., T.S., F.D.R., D.T.H., O.A.-R., M.F., M.L., M.R.L.M., J.J.R., B.H.), the Cardiovascular Research Methods Centre (J.B., G.A.W.), and the Division of Cardiac Surgery (V.C.), University of Ottawa Heart Institute, and the Faculty of Medicine (R.M., P.D.S., R.G.J., J.H., D.T.H., W.W., O.A.-R., S.M.F., K.K., M.F., M.L., M.R.L.M., J.J.R., B.H.), the Division of Critical Care, Department of Medicine (R.M., J.H., S.M.F., K.K.), the School of Epidemiology and Public Health (P.D.S.), and the Department of Cellular and Molecular Medicine (R.G.J., T.S., B.H.), University of Ottawa, Ottawa, the Division of Cardiology, University of Toronto, Toronto (A.M.), and the Division of Cardiology, University of British Columbia, Vancouver (A.A.) - all in Canada; the Division of Critical Care, Tufts Medical Center, Boston (J.A.M.); the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (T.S.); and Hôpital Cardiologique du Haut Lévêque, Centre Hospitalier Universitaire Bordeaux (F.D.R.), and LIRYC (L'Institut de Rythmologie et Modélisation Cardiaque) (F.D.R.) - both in Bordeaux-Pessac, France
| | - Michael Froeschl
- From the CAPITAL Research Group, Division of Cardiology (R.M., P.D.S., R.G.J., J.A.M., T.S., F.D.R., D.T.H., O.A.-R., M.F., M.L., M.R.L.M., J.J.R., B.H.), the Cardiovascular Research Methods Centre (J.B., G.A.W.), and the Division of Cardiac Surgery (V.C.), University of Ottawa Heart Institute, and the Faculty of Medicine (R.M., P.D.S., R.G.J., J.H., D.T.H., W.W., O.A.-R., S.M.F., K.K., M.F., M.L., M.R.L.M., J.J.R., B.H.), the Division of Critical Care, Department of Medicine (R.M., J.H., S.M.F., K.K.), the School of Epidemiology and Public Health (P.D.S.), and the Department of Cellular and Molecular Medicine (R.G.J., T.S., B.H.), University of Ottawa, Ottawa, the Division of Cardiology, University of Toronto, Toronto (A.M.), and the Division of Cardiology, University of British Columbia, Vancouver (A.A.) - all in Canada; the Division of Critical Care, Tufts Medical Center, Boston (J.A.M.); the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (T.S.); and Hôpital Cardiologique du Haut Lévêque, Centre Hospitalier Universitaire Bordeaux (F.D.R.), and LIRYC (L'Institut de Rythmologie et Modélisation Cardiaque) (F.D.R.) - both in Bordeaux-Pessac, France
| | - Marino Labinaz
- From the CAPITAL Research Group, Division of Cardiology (R.M., P.D.S., R.G.J., J.A.M., T.S., F.D.R., D.T.H., O.A.-R., M.F., M.L., M.R.L.M., J.J.R., B.H.), the Cardiovascular Research Methods Centre (J.B., G.A.W.), and the Division of Cardiac Surgery (V.C.), University of Ottawa Heart Institute, and the Faculty of Medicine (R.M., P.D.S., R.G.J., J.H., D.T.H., W.W., O.A.-R., S.M.F., K.K., M.F., M.L., M.R.L.M., J.J.R., B.H.), the Division of Critical Care, Department of Medicine (R.M., J.H., S.M.F., K.K.), the School of Epidemiology and Public Health (P.D.S.), and the Department of Cellular and Molecular Medicine (R.G.J., T.S., B.H.), University of Ottawa, Ottawa, the Division of Cardiology, University of Toronto, Toronto (A.M.), and the Division of Cardiology, University of British Columbia, Vancouver (A.A.) - all in Canada; the Division of Critical Care, Tufts Medical Center, Boston (J.A.M.); the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (T.S.); and Hôpital Cardiologique du Haut Lévêque, Centre Hospitalier Universitaire Bordeaux (F.D.R.), and LIRYC (L'Institut de Rythmologie et Modélisation Cardiaque) (F.D.R.) - both in Bordeaux-Pessac, France
| | - Michel R Le May
- From the CAPITAL Research Group, Division of Cardiology (R.M., P.D.S., R.G.J., J.A.M., T.S., F.D.R., D.T.H., O.A.-R., M.F., M.L., M.R.L.M., J.J.R., B.H.), the Cardiovascular Research Methods Centre (J.B., G.A.W.), and the Division of Cardiac Surgery (V.C.), University of Ottawa Heart Institute, and the Faculty of Medicine (R.M., P.D.S., R.G.J., J.H., D.T.H., W.W., O.A.-R., S.M.F., K.K., M.F., M.L., M.R.L.M., J.J.R., B.H.), the Division of Critical Care, Department of Medicine (R.M., J.H., S.M.F., K.K.), the School of Epidemiology and Public Health (P.D.S.), and the Department of Cellular and Molecular Medicine (R.G.J., T.S., B.H.), University of Ottawa, Ottawa, the Division of Cardiology, University of Toronto, Toronto (A.M.), and the Division of Cardiology, University of British Columbia, Vancouver (A.A.) - all in Canada; the Division of Critical Care, Tufts Medical Center, Boston (J.A.M.); the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (T.S.); and Hôpital Cardiologique du Haut Lévêque, Centre Hospitalier Universitaire Bordeaux (F.D.R.), and LIRYC (L'Institut de Rythmologie et Modélisation Cardiaque) (F.D.R.) - both in Bordeaux-Pessac, France
| | - Juan J Russo
- From the CAPITAL Research Group, Division of Cardiology (R.M., P.D.S., R.G.J., J.A.M., T.S., F.D.R., D.T.H., O.A.-R., M.F., M.L., M.R.L.M., J.J.R., B.H.), the Cardiovascular Research Methods Centre (J.B., G.A.W.), and the Division of Cardiac Surgery (V.C.), University of Ottawa Heart Institute, and the Faculty of Medicine (R.M., P.D.S., R.G.J., J.H., D.T.H., W.W., O.A.-R., S.M.F., K.K., M.F., M.L., M.R.L.M., J.J.R., B.H.), the Division of Critical Care, Department of Medicine (R.M., J.H., S.M.F., K.K.), the School of Epidemiology and Public Health (P.D.S.), and the Department of Cellular and Molecular Medicine (R.G.J., T.S., B.H.), University of Ottawa, Ottawa, the Division of Cardiology, University of Toronto, Toronto (A.M.), and the Division of Cardiology, University of British Columbia, Vancouver (A.A.) - all in Canada; the Division of Critical Care, Tufts Medical Center, Boston (J.A.M.); the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (T.S.); and Hôpital Cardiologique du Haut Lévêque, Centre Hospitalier Universitaire Bordeaux (F.D.R.), and LIRYC (L'Institut de Rythmologie et Modélisation Cardiaque) (F.D.R.) - both in Bordeaux-Pessac, France
| | - Benjamin Hibbert
- From the CAPITAL Research Group, Division of Cardiology (R.M., P.D.S., R.G.J., J.A.M., T.S., F.D.R., D.T.H., O.A.-R., M.F., M.L., M.R.L.M., J.J.R., B.H.), the Cardiovascular Research Methods Centre (J.B., G.A.W.), and the Division of Cardiac Surgery (V.C.), University of Ottawa Heart Institute, and the Faculty of Medicine (R.M., P.D.S., R.G.J., J.H., D.T.H., W.W., O.A.-R., S.M.F., K.K., M.F., M.L., M.R.L.M., J.J.R., B.H.), the Division of Critical Care, Department of Medicine (R.M., J.H., S.M.F., K.K.), the School of Epidemiology and Public Health (P.D.S.), and the Department of Cellular and Molecular Medicine (R.G.J., T.S., B.H.), University of Ottawa, Ottawa, the Division of Cardiology, University of Toronto, Toronto (A.M.), and the Division of Cardiology, University of British Columbia, Vancouver (A.A.) - all in Canada; the Division of Critical Care, Tufts Medical Center, Boston (J.A.M.); the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (T.S.); and Hôpital Cardiologique du Haut Lévêque, Centre Hospitalier Universitaire Bordeaux (F.D.R.), and LIRYC (L'Institut de Rythmologie et Modélisation Cardiaque) (F.D.R.) - both in Bordeaux-Pessac, France
| |
Collapse
|
29
|
Simard T, Jung RG, Lehenbauer K, Piayda K, Pracoń R, Jackson GG, Flores-Umanzor E, Faroux L, Korsholm K, Chun JKR, Chen S, Maarse M, Montrella K, Chaker Z, Spoon JN, Pastormerlo LE, Meincke F, Sawant AC, Moldovan CM, Qintar M, Aktas MK, Branca L, Radinovic A, Ram P, El-Zein RS, Flautt T, Ding WY, Sayegh B, Benito-González T, Lee OH, Badejoko SO, Paitazoglou C, Karim N, Zaghloul AM, Agrawal H, Kaplan RM, Alli O, Ahmed A, Suradi HS, Knight BP, Alla VM, Panaich SS, Wong T, Bergmann MW, Chothia R, Kim JS, Pérez de Prado A, Bazaz R, Gupta D, Valderrabano M, Sanchez CE, El Chami MF, Mazzone P, Adamo M, Ling F, Wang DD, O'Neill W, Wojakowski W, Pershad A, Berti S, Spoon D, Kawsara A, Jabbour G, Boersma LVA, Schmidt B, Nielsen-Kudsk JE, Rodés-Cabau J, Freixa X, Ellis CR, Fauchier L, Demkow M, Sievert H, Main ML, Hibbert B, Holmes DR, Alkhouli M. Predictors of Device-Related Thrombus Following Percutaneous Left Atrial Appendage Occlusion. J Am Coll Cardiol 2021; 78:297-313. [PMID: 34294267 DOI: 10.1016/j.jacc.2021.04.098] [Citation(s) in RCA: 92] [Impact Index Per Article: 30.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/01/2021] [Revised: 04/05/2021] [Accepted: 04/29/2021] [Indexed: 12/20/2022]
Abstract
BACKGROUND Device-related thrombus (DRT) has been considered an Achilles' heel of left atrial appendage occlusion (LAAO). However, data on DRT prediction remain limited. OBJECTIVES This study constructed a DRT registry via a multicenter collaboration aimed to assess outcomes and predictors of DRT. METHODS Thirty-seven international centers contributed LAAO cases with and without DRT (device-matched and temporally related to the DRT cases). This study described the management patterns and mid-term outcomes of DRT and assessed patient and procedural predictors of DRT. RESULTS A total of 711 patients (237 with and 474 without DRT) were included. Follow-up duration was similar in the DRT and no-DRT groups, median 1.8 years (interquartile range: 0.9-3.0 years) versus 1.6 years (interquartile range: 1.0-2.9 years), respectively (P = 0.76). DRTs were detected between days 0 to 45, 45 to 180, 180 to 365, and >365 in 24.9%, 38.8%, 16.0%, and 20.3% of patients. DRT presence was associated with a higher risk of the composite endpoint of death, ischemic stroke, or systemic embolization (HR: 2.37; 95% CI, 1.58-3.56; P < 0.001) driven by ischemic stroke (HR: 3.49; 95% CI: 1.35-9.00; P = 0.01). At last known follow-up, 25.3% of patients had DRT. Discharge medications after LAAO did not have an impact on DRT. Multivariable analysis identified 5 DRT risk factors: hypercoagulability disorder (odds ratio [OR]: 17.50; 95% CI: 3.39-90.45), pericardial effusion (OR: 13.45; 95% CI: 1.46-123.52), renal insufficiency (OR: 4.02; 95% CI: 1.22-13.25), implantation depth >10 mm from the pulmonary vein limbus (OR: 2.41; 95% CI: 1.57-3.69), and non-paroxysmal atrial fibrillation (OR: 1.90; 95% CI: 1.22-2.97). Following conversion to risk factor points, patients with ≥2 risk points for DRT had a 2.1-fold increased risk of DRT compared with those without any risk factors. CONCLUSIONS DRT after LAAO is associated with ischemic events. Patient- and procedure-specific factors are associated with the risk of DRT and may aid in risk stratification of patients referred for LAAO.
Collapse
Affiliation(s)
- Trevor Simard
- Department of Cardiovascular Diseases, Mayo Clinic School of Medicine, Rochester, Minnesota, USA. https://twitter.com/tjsimard
| | - Richard G Jung
- Capital Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Kyle Lehenbauer
- Division of Cardiology, Saint Luke's Mid America Heart Institute, Kansas City, Missouri, USA
| | - Kerstin Piayda
- CardioVascular Center Frankfurt, Frankfurt, Germany; Heinrich-Heine-University, Division of Cardiology, Pulmonology and Vascular Medicine, Düsseldorf, Germany
| | - Radoslaw Pracoń
- Coronary and Structural Heart Diseases Department, National Institute of Cardiology, Warsaw, Poland
| | | | - Eduardo Flores-Umanzor
- Department of Cardiology, Hospital Clinic of Barcelona, August Pi I Sunyer Biomedical Research Institute, University of Barcelona, Barcelona, Spain
| | - Laurent Faroux
- Quebec Heart and Lung Institute, Laval University, Quebec City, Quebec, Canada
| | - Kasper Korsholm
- Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark
| | - Julian K R Chun
- Cardioangiologisches Centrum Bethanien, Medizinische Klinik III, Markuskrankenhaus, Frankfurt, Germany
| | - Shaojie Chen
- Cardioangiologisches Centrum Bethanien, Medizinische Klinik III, Markuskrankenhaus, Frankfurt, Germany
| | - Moniek Maarse
- Cardiology, St Antonius Hospital, Nieuwegein, the Netherlands; LB Amsterdam University Medical Center, Amsterdam, the Netherlands
| | - Kristi Montrella
- University of Pittsburgh Medical Center Heart and Vascular Institute, University of Pittsburgh, Altoona, Pennsylvania, USA
| | - Zakeih Chaker
- Division of Cardiology, West Virginia School of Medicine, Morgantown, West Virginia, USA
| | - Jocelyn N Spoon
- International Heart Institute of Montana, Missoula, Montana, USA
| | - Luigi E Pastormerlo
- Fondazione Toscana Gabriele Monasterio Massa, Scuola Superiore Sant'Anna, Pisa, Italy
| | | | | | - Carmen M Moldovan
- Division of Cardiology and Structural Heart Diseases, Medical University of Silesia, Katowice, Poland
| | - Mohammed Qintar
- Division of Cardiology, Henry Ford Health System, Detroit, Michigan, USA
| | - Mehmet K Aktas
- Division of Cardiology, University of Rochester Medical Center, Rochester, New York, USA
| | - Luca Branca
- Catheterization Laboratory, Cardiothoracic Department, Spedali Civili of Brescia, Brescia, Italy
| | - Andrea Radinovic
- Arrhythmology Department, San Raffaele University Hospital, Milan, Italy
| | - Pradhum Ram
- Emory University Hospital, Atlanta, Georgia, USA
| | - Rayan S El-Zein
- Division of Cardiology, OhioHealth Doctors Hospital/OhioHealth Riverside Methodist Hospital, Columbus, Ohio, USA
| | | | - Wern Yew Ding
- Liverpool Heart and Chest Hospital, Liverpool, United Kingdom
| | - Bassel Sayegh
- Heart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA; The Heart, Lung and Vascular Institute, Excela Health, Pittsburgh, Pennsylvania, USA
| | | | - Oh-Hyun Lee
- Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea
| | - Solomon O Badejoko
- Division of Internal Medicine, St Joseph's Medical Center (Dignity Health), Stockton, California, USA
| | | | - Nabeela Karim
- Royal Brompton and Harefield Hospitals, Part of Guys' and St Thomas' National Health Service Foundation Trust, London, United Kingdom
| | - Ahmed M Zaghloul
- Division of Cardiovascular Medicine, Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, Iowa, USA
| | | | - Rachel M Kaplan
- Northwestern University, Bluhm Cardiovascular Institute, Chicago, Illinois, USA
| | - Oluseun Alli
- Division of Cardiology, Novant Health Heart and Vascular Institute, Charlotte, North Carolina, USA
| | - Aamir Ahmed
- Rush University Medical Center, Chicago, Illinois, USA
| | | | - Bradley P Knight
- Northwestern University, Bluhm Cardiovascular Institute, Chicago, Illinois, USA
| | - Venkata M Alla
- Creighton University School of Medicine, Omaha, Nebraska, USA
| | - Sidakpal S Panaich
- Division of Cardiovascular Medicine, Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, Iowa, USA
| | - Tom Wong
- Royal Brompton and Harefield Hospitals, Part of Guys' and St Thomas' National Health Service Foundation Trust, London, United Kingdom
| | | | - Rashaad Chothia
- Division of Internal Medicine, St Joseph's Medical Center (Dignity Health), Stockton, California, USA
| | - Jung-Sun Kim
- Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea
| | | | - Raveen Bazaz
- Heart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA
| | - Dhiraj Gupta
- Liverpool Heart and Chest Hospital, Liverpool, United Kingdom
| | | | - Carlos E Sanchez
- Division of Cardiology, OhioHealth Doctors Hospital/OhioHealth Riverside Methodist Hospital, Columbus, Ohio, USA
| | | | - Patrizio Mazzone
- Arrhythmology Department, San Raffaele University Hospital, Milan, Italy
| | - Marianna Adamo
- Catheterization Laboratory, Cardiothoracic Department, Spedali Civili of Brescia, Brescia, Italy
| | - Fred Ling
- Division of Cardiology, University of Rochester Medical Center, Rochester, New York, USA
| | - Dee Dee Wang
- Division of Cardiology, Henry Ford Health System, Detroit, Michigan, USA
| | - William O'Neill
- Division of Cardiology, Henry Ford Health System, Detroit, Michigan, USA
| | - Wojtek Wojakowski
- Division of Cardiology and Structural Heart Diseases, Medical University of Silesia, Katowice, Poland
| | | | - Sergio Berti
- Fondazione Toscana Gabriele Monasterio Massa, Scuola Superiore Sant'Anna, Pisa, Italy
| | - Daniel Spoon
- International Heart Institute of Montana, Missoula, Montana, USA
| | - Akram Kawsara
- Division of Cardiology, West Virginia School of Medicine, Morgantown, West Virginia, USA
| | - George Jabbour
- University of Pittsburgh Medical Center Heart and Vascular Institute, University of Pittsburgh, Altoona, Pennsylvania, USA
| | - Lucas V A Boersma
- Cardiology, St Antonius Hospital, Nieuwegein, the Netherlands; LB Amsterdam University Medical Center, Amsterdam, the Netherlands
| | - Boris Schmidt
- Cardioangiologisches Centrum Bethanien, Medizinische Klinik III, Markuskrankenhaus, Frankfurt, Germany
| | | | - Josep Rodés-Cabau
- Quebec Heart and Lung Institute, Laval University, Quebec City, Quebec, Canada
| | - Xavier Freixa
- Department of Cardiology, Hospital Clinic of Barcelona, August Pi I Sunyer Biomedical Research Institute, University of Barcelona, Barcelona, Spain
| | | | - Laurent Fauchier
- Service de Cardiologie, Centre Hospitalier Universitaire Trousseau Faculté de Médecine, Université François Rabelais, Tours, France
| | - Marcin Demkow
- Coronary and Structural Heart Diseases Department, National Institute of Cardiology, Warsaw, Poland
| | | | - Michael L Main
- Division of Cardiology, Saint Luke's Mid America Heart Institute, Kansas City, Missouri, USA
| | - Benjamin Hibbert
- Capital Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - David R Holmes
- Department of Cardiovascular Diseases, Mayo Clinic School of Medicine, Rochester, Minnesota, USA
| | - Mohamad Alkhouli
- Department of Cardiovascular Diseases, Mayo Clinic School of Medicine, Rochester, Minnesota, USA.
| |
Collapse
|
30
|
Clifford CR, Jung RG, Hibbert B, Chong AY, Lordkipanidzé M, Tanguay JF, So DYF. Dual antiplatelet therapy (PEGASUS) vs. dual pathway (COMPASS): a head-to-head in vitro comparison. Platelets 2021; 33:298-303. [PMID: 33856269 DOI: 10.1080/09537104.2021.1904134] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor is prescribed for 1-year after myocardial infarction. Two clinical strategies are considered at 1-year: continuation of DAPT or "Dual Pathway" (DP), using aspirin and rivaroxaban. No head-to-head comparative studies exist. In our in-vitro study, 24 samples of donor blood were treated with clinically proven concentrations of 5 antithrombotic regimens: aspirin, ticagrelor, rivaroxaban, DAPT, and DP. Thrombosis was analyzed using the Total Thrombus Analysis System (T-TAS) to measure both antiplatelet and anticoagulant effects. Flow cytometry was performed to quantify platelet activation. DAPT was the most potent antiplatelet regimen, delaying thrombus onset (p < .0001) and reducing thrombogenicity (p < .0001), relative to control. DP did not delay thrombus formation relative to aspirin alone (p = .69). DP was the most potent anticoagulant regimen, delaying thrombus onset (p < .0001) and reducing thrombogenicity (p < .0001), relative to control. DP showed synergistic antithrombotic effects by delaying thrombus onset (p < .0001) and reducing thrombogenicity (p = .0003), relative to rivaroxaban alone. Flow cytometry showed only DAPT (p = .0023) reduced platelet activation. DP treatment demonstrated synergistic antithrombotic effects over rivaroxaban alone, but no additional antiplatelet synergism over aspirin alone.
Collapse
Affiliation(s)
- Cole R Clifford
- Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Richard G Jung
- Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Benjamin Hibbert
- Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Aun Yeong Chong
- Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Marie Lordkipanidzé
- Montreal Heart Institute Research Center, Montreal, Qc, Canada.,Faculty of Pharmacy, Université De Montréal, Montreal, Qc, Canada
| | - Jean-Francois Tanguay
- Montreal Heart Institute Research Center, Montreal, Qc, Canada.,Faculty of Medicine, Université De Montréal, Montreal, Qc, Canada
| | - Derek Y F So
- Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| |
Collapse
|
31
|
Simard T, Motazedian P, Dhaliwal S, Di Santo P, Jung RG, Ramirez FD, Labinaz A, Short S, Parlow S, Joseph J, Rasheed A, Rockley M, Marbach J, Domecq MC, Russo JJ, Chong AY, Beanlands RS, Hibbert B. Revisiting the Evidence for Dipyridamole in Reducing Restenosis: A Systematic Review and Meta-analysis. J Cardiovasc Pharmacol 2021; 77:450-457. [PMID: 33760800 DOI: 10.1097/fjc.0000000000000976] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/11/2020] [Accepted: 11/25/2020] [Indexed: 11/26/2022]
Abstract
ABSTRACT Atherosclerosis remains a leading cause of morbidity and mortality, with revascularization remaining a cornerstone of management. Conventional revascularization modalities remain challenged by target vessel reocclusion-an event driven by mechanical, thrombotic, and proliferative processes. Despite considerable advancements, restenosis remains the focus of ongoing research. Adjunctive agents, including dipyridamole, offer a multitude of effects that may improve vascular homeostasis. We sought to quantify the potential therapeutic impact of dipyridamole on vascular occlusion. We performed a literature search (EMBASE and MEDLINE) examining studies that encompassed 3 areas: (1) one of the designated medical therapies applied in (2) the setting of a vascular intervention with (3) an outcome including vascular occlusion rates and/or quantification of neointimal proliferation/restenosis. The primary outcome was vascular occlusion rates. The secondary outcome was the degree of restenosis by neointimal quantification. Both human and animal studies were included in this translational analysis. There were 6,839 articles screened, from which 73 studies were included, encompassing 16,146 vessels followed up for a mean of 327.3 days (range 7-3650 days). Preclinical studies demonstrate that dipyridamole results in reduced vascular occlusion rates {24.9% vs. 48.8%, risk ratio 0.53 [95% confidence interval (CI) 0.40-0.70], I2 = 39%, P < 0.00001}, owing to diminished neointimal proliferation [standardized mean differences -1.13 (95% CI -1.74 to -0.53), I2 = 91%, P = 0.0002]. Clinical studies similarly demonstrated reduced occlusion rates with dipyridamole therapy [23.5% vs. 31.0%, risk ratio 0.77 (95% CI 0.67-0.88), I2 = 84%, P < 0.0001]. Dipyridamole may improve post-intervention vascular patency and mitigate restenosis. Dedicated studies are warranted to delineate its role as an adjunctive agent after revascularization.
Collapse
Affiliation(s)
- Trevor Simard
- Division of Cardiology, CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
- Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Ontario, Canada
| | - Pouya Motazedian
- Division of Cardiology, CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
- Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
| | - Shan Dhaliwal
- Division of Cardiology, CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Pietro Di Santo
- Division of Cardiology, CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Richard G Jung
- Division of Cardiology, CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
- Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Ontario, Canada
| | - Francisco Daniel Ramirez
- Division of Cardiology, CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
- Hôpital Cardiologique du Haut-Lévêque, CHU Bordeaux, Bordeaux-Pessac, France
- L'Institut de Rythmologie et Modélisation Cardiaque (LIRYC), Université de Bordeaux, Bordeaux-Pessac, France
| | - Alisha Labinaz
- Division of Cardiology, CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Spencer Short
- Division of Cardiology, CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Simon Parlow
- Division of Cardiology, CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Joanne Joseph
- Division of Cardiology, CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Adil Rasheed
- Division of Cardiology, CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Mark Rockley
- Division of Vascular Surgery, the Ottawa Hospital, Ottawa, Ontario, Canada ; and
| | - Jeffrey Marbach
- Division of Cardiology, CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | | | - Juan J Russo
- Division of Cardiology, CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Aun-Yeong Chong
- Division of Cardiology, CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Rob S Beanlands
- Division of Cardiology, CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
- Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Ontario, Canada
| | - Benjamin Hibbert
- Division of Cardiology, CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
- Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Ontario, Canada
| |
Collapse
|
32
|
Di Santo P, Simard T, Wells GA, Jung RG, Ramirez FD, Boland P, Marbach JA, Parlow S, Kyeremanteng K, Coyle D, Fergusson D, Russo JJ, Chong AY, Froeschl M, So DY, Dick A, Glover C, Labinaz M, Hibbert B, Le May M. Transradial Versus Transfemoral Access for Percutaneous Coronary Intervention in ST-Segment-Elevation Myocardial Infarction: A Systematic Review and Meta-Analysis. Circ Cardiovasc Interv 2021; 14:e009994. [PMID: 33685220 DOI: 10.1161/circinterventions.120.009994] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
[Figure: see text].
Collapse
Affiliation(s)
- Pietro Di Santo
- CAPITAL Research Group, Division of Cardiology, Department of Medicine (P.D.S., T.S., R.G.J., F.D.R., P.B., J.A.M., S.P., J.J.R., A.-Y.C., M.F., D.Y.S., A.D., C.G., M.L., B.H., M.L.M.), University of Ottawa Heart Institute, Ottawa, Canada.,School of Epidemiology and Public Health (P.D.S., D.C., D.F., G.A.W.), University of Ottawa, Canada.,Faculty of Medicine (P.D.S., T.S., G.A.W., R.G.J., P.B., J.A.M., S.P., K.K., D.C., J.J.R., A.-Y.C., M.F., D.Y.S., A.D., C.G., M.L., B.H., M.L.M.), University of Ottawa, Canada
| | - Trevor Simard
- CAPITAL Research Group, Division of Cardiology, Department of Medicine (P.D.S., T.S., R.G.J., F.D.R., P.B., J.A.M., S.P., J.J.R., A.-Y.C., M.F., D.Y.S., A.D., C.G., M.L., B.H., M.L.M.), University of Ottawa Heart Institute, Ottawa, Canada.,Faculty of Medicine (P.D.S., T.S., G.A.W., R.G.J., P.B., J.A.M., S.P., K.K., D.C., J.J.R., A.-Y.C., M.F., D.Y.S., A.D., C.G., M.L., B.H., M.L.M.), University of Ottawa, Canada.,Department of Cellular and Molecular Medicine (T.S., R.G.J., B.H.), University of Ottawa, Canada
| | - George A Wells
- Cardiovascular Research Methods Centre (G.A.W.), University of Ottawa Heart Institute, Ottawa, Canada.,School of Epidemiology and Public Health (P.D.S., D.C., D.F., G.A.W.), University of Ottawa, Canada.,Faculty of Medicine (P.D.S., T.S., G.A.W., R.G.J., P.B., J.A.M., S.P., K.K., D.C., J.J.R., A.-Y.C., M.F., D.Y.S., A.D., C.G., M.L., B.H., M.L.M.), University of Ottawa, Canada
| | - Richard G Jung
- CAPITAL Research Group, Division of Cardiology, Department of Medicine (P.D.S., T.S., R.G.J., F.D.R., P.B., J.A.M., S.P., J.J.R., A.-Y.C., M.F., D.Y.S., A.D., C.G., M.L., B.H., M.L.M.), University of Ottawa Heart Institute, Ottawa, Canada.,Faculty of Medicine (P.D.S., T.S., G.A.W., R.G.J., P.B., J.A.M., S.P., K.K., D.C., J.J.R., A.-Y.C., M.F., D.Y.S., A.D., C.G., M.L., B.H., M.L.M.), University of Ottawa, Canada.,Department of Cellular and Molecular Medicine (T.S., R.G.J., B.H.), University of Ottawa, Canada
| | - F Daniel Ramirez
- CAPITAL Research Group, Division of Cardiology, Department of Medicine (P.D.S., T.S., R.G.J., F.D.R., P.B., J.A.M., S.P., J.J.R., A.-Y.C., M.F., D.Y.S., A.D., C.G., M.L., B.H., M.L.M.), University of Ottawa Heart Institute, Ottawa, Canada.,Hôpital Cardiologique du Haut Lévêque, CHU Bordeaux, France (F.D.R.).,LIRYC (L'Institut de Rythmologie et Modélisation Cardiaque), Bordeaux-Pessac, France (F.D.R.)
| | - Paul Boland
- CAPITAL Research Group, Division of Cardiology, Department of Medicine (P.D.S., T.S., R.G.J., F.D.R., P.B., J.A.M., S.P., J.J.R., A.-Y.C., M.F., D.Y.S., A.D., C.G., M.L., B.H., M.L.M.), University of Ottawa Heart Institute, Ottawa, Canada.,Faculty of Medicine (P.D.S., T.S., G.A.W., R.G.J., P.B., J.A.M., S.P., K.K., D.C., J.J.R., A.-Y.C., M.F., D.Y.S., A.D., C.G., M.L., B.H., M.L.M.), University of Ottawa, Canada
| | - Jeffrey A Marbach
- CAPITAL Research Group, Division of Cardiology, Department of Medicine (P.D.S., T.S., R.G.J., F.D.R., P.B., J.A.M., S.P., J.J.R., A.-Y.C., M.F., D.Y.S., A.D., C.G., M.L., B.H., M.L.M.), University of Ottawa Heart Institute, Ottawa, Canada.,Faculty of Medicine (P.D.S., T.S., G.A.W., R.G.J., P.B., J.A.M., S.P., K.K., D.C., J.J.R., A.-Y.C., M.F., D.Y.S., A.D., C.G., M.L., B.H., M.L.M.), University of Ottawa, Canada
| | - Simon Parlow
- CAPITAL Research Group, Division of Cardiology, Department of Medicine (P.D.S., T.S., R.G.J., F.D.R., P.B., J.A.M., S.P., J.J.R., A.-Y.C., M.F., D.Y.S., A.D., C.G., M.L., B.H., M.L.M.), University of Ottawa Heart Institute, Ottawa, Canada.,Faculty of Medicine (P.D.S., T.S., G.A.W., R.G.J., P.B., J.A.M., S.P., K.K., D.C., J.J.R., A.-Y.C., M.F., D.Y.S., A.D., C.G., M.L., B.H., M.L.M.), University of Ottawa, Canada
| | - Kwadwo Kyeremanteng
- Faculty of Medicine (P.D.S., T.S., G.A.W., R.G.J., P.B., J.A.M., S.P., K.K., D.C., J.J.R., A.-Y.C., M.F., D.Y.S., A.D., C.G., M.L., B.H., M.L.M.), University of Ottawa, Canada.,Division of Critical Care, Department of Medicine (K.K.), University of Ottawa, Canada
| | - Doug Coyle
- School of Epidemiology and Public Health (P.D.S., D.C., D.F., G.A.W.), University of Ottawa, Canada.,Faculty of Medicine (P.D.S., T.S., G.A.W., R.G.J., P.B., J.A.M., S.P., K.K., D.C., J.J.R., A.-Y.C., M.F., D.Y.S., A.D., C.G., M.L., B.H., M.L.M.), University of Ottawa, Canada
| | - Dean Fergusson
- School of Epidemiology and Public Health (P.D.S., D.C., D.F., G.A.W.), University of Ottawa, Canada
| | - Juan J Russo
- CAPITAL Research Group, Division of Cardiology, Department of Medicine (P.D.S., T.S., R.G.J., F.D.R., P.B., J.A.M., S.P., J.J.R., A.-Y.C., M.F., D.Y.S., A.D., C.G., M.L., B.H., M.L.M.), University of Ottawa Heart Institute, Ottawa, Canada.,Faculty of Medicine (P.D.S., T.S., G.A.W., R.G.J., P.B., J.A.M., S.P., K.K., D.C., J.J.R., A.-Y.C., M.F., D.Y.S., A.D., C.G., M.L., B.H., M.L.M.), University of Ottawa, Canada
| | - Aun-Yeong Chong
- CAPITAL Research Group, Division of Cardiology, Department of Medicine (P.D.S., T.S., R.G.J., F.D.R., P.B., J.A.M., S.P., J.J.R., A.-Y.C., M.F., D.Y.S., A.D., C.G., M.L., B.H., M.L.M.), University of Ottawa Heart Institute, Ottawa, Canada.,Faculty of Medicine (P.D.S., T.S., G.A.W., R.G.J., P.B., J.A.M., S.P., K.K., D.C., J.J.R., A.-Y.C., M.F., D.Y.S., A.D., C.G., M.L., B.H., M.L.M.), University of Ottawa, Canada
| | - Michael Froeschl
- CAPITAL Research Group, Division of Cardiology, Department of Medicine (P.D.S., T.S., R.G.J., F.D.R., P.B., J.A.M., S.P., J.J.R., A.-Y.C., M.F., D.Y.S., A.D., C.G., M.L., B.H., M.L.M.), University of Ottawa Heart Institute, Ottawa, Canada.,Faculty of Medicine (P.D.S., T.S., G.A.W., R.G.J., P.B., J.A.M., S.P., K.K., D.C., J.J.R., A.-Y.C., M.F., D.Y.S., A.D., C.G., M.L., B.H., M.L.M.), University of Ottawa, Canada
| | - Derek Y So
- CAPITAL Research Group, Division of Cardiology, Department of Medicine (P.D.S., T.S., R.G.J., F.D.R., P.B., J.A.M., S.P., J.J.R., A.-Y.C., M.F., D.Y.S., A.D., C.G., M.L., B.H., M.L.M.), University of Ottawa Heart Institute, Ottawa, Canada.,Faculty of Medicine (P.D.S., T.S., G.A.W., R.G.J., P.B., J.A.M., S.P., K.K., D.C., J.J.R., A.-Y.C., M.F., D.Y.S., A.D., C.G., M.L., B.H., M.L.M.), University of Ottawa, Canada
| | - Alexander Dick
- CAPITAL Research Group, Division of Cardiology, Department of Medicine (P.D.S., T.S., R.G.J., F.D.R., P.B., J.A.M., S.P., J.J.R., A.-Y.C., M.F., D.Y.S., A.D., C.G., M.L., B.H., M.L.M.), University of Ottawa Heart Institute, Ottawa, Canada.,Faculty of Medicine (P.D.S., T.S., G.A.W., R.G.J., P.B., J.A.M., S.P., K.K., D.C., J.J.R., A.-Y.C., M.F., D.Y.S., A.D., C.G., M.L., B.H., M.L.M.), University of Ottawa, Canada
| | - Christopher Glover
- CAPITAL Research Group, Division of Cardiology, Department of Medicine (P.D.S., T.S., R.G.J., F.D.R., P.B., J.A.M., S.P., J.J.R., A.-Y.C., M.F., D.Y.S., A.D., C.G., M.L., B.H., M.L.M.), University of Ottawa Heart Institute, Ottawa, Canada.,Faculty of Medicine (P.D.S., T.S., G.A.W., R.G.J., P.B., J.A.M., S.P., K.K., D.C., J.J.R., A.-Y.C., M.F., D.Y.S., A.D., C.G., M.L., B.H., M.L.M.), University of Ottawa, Canada
| | - Marino Labinaz
- CAPITAL Research Group, Division of Cardiology, Department of Medicine (P.D.S., T.S., R.G.J., F.D.R., P.B., J.A.M., S.P., J.J.R., A.-Y.C., M.F., D.Y.S., A.D., C.G., M.L., B.H., M.L.M.), University of Ottawa Heart Institute, Ottawa, Canada.,Faculty of Medicine (P.D.S., T.S., G.A.W., R.G.J., P.B., J.A.M., S.P., K.K., D.C., J.J.R., A.-Y.C., M.F., D.Y.S., A.D., C.G., M.L., B.H., M.L.M.), University of Ottawa, Canada
| | - Benjamin Hibbert
- CAPITAL Research Group, Division of Cardiology, Department of Medicine (P.D.S., T.S., R.G.J., F.D.R., P.B., J.A.M., S.P., J.J.R., A.-Y.C., M.F., D.Y.S., A.D., C.G., M.L., B.H., M.L.M.), University of Ottawa Heart Institute, Ottawa, Canada.,Faculty of Medicine (P.D.S., T.S., G.A.W., R.G.J., P.B., J.A.M., S.P., K.K., D.C., J.J.R., A.-Y.C., M.F., D.Y.S., A.D., C.G., M.L., B.H., M.L.M.), University of Ottawa, Canada.,Department of Cellular and Molecular Medicine (T.S., R.G.J., B.H.), University of Ottawa, Canada
| | - Michel Le May
- CAPITAL Research Group, Division of Cardiology, Department of Medicine (P.D.S., T.S., R.G.J., F.D.R., P.B., J.A.M., S.P., J.J.R., A.-Y.C., M.F., D.Y.S., A.D., C.G., M.L., B.H., M.L.M.), University of Ottawa Heart Institute, Ottawa, Canada.,Faculty of Medicine (P.D.S., T.S., G.A.W., R.G.J., P.B., J.A.M., S.P., K.K., D.C., J.J.R., A.-Y.C., M.F., D.Y.S., A.D., C.G., M.L., B.H., M.L.M.), University of Ottawa, Canada
| |
Collapse
|
33
|
Jung RG, Di Santo P, Clifford C, Prosperi-Porta G, Skanes S, Hung A, Parlow S, Visintini S, Ramirez FD, Simard T, Hibbert B. Methodological quality of COVID-19 clinical research. Nat Commun 2021; 12:943. [PMID: 33574258 PMCID: PMC7878793 DOI: 10.1038/s41467-021-21220-5] [Citation(s) in RCA: 78] [Impact Index Per Article: 26.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2020] [Accepted: 01/13/2021] [Indexed: 12/15/2022] Open
Abstract
The COVID-19 pandemic began in early 2020 with major health consequences. While a need to disseminate information to the medical community and general public was paramount, concerns have been raised regarding the scientific rigor in published reports. We performed a systematic review to evaluate the methodological quality of currently available COVID-19 studies compared to historical controls. A total of 9895 titles and abstracts were screened and 686 COVID-19 articles were included in the final analysis. Comparative analysis of COVID-19 to historical articles reveals a shorter time to acceptance (13.0[IQR, 5.0–25.0] days vs. 110.0[IQR, 71.0–156.0] days in COVID-19 and control articles, respectively; p < 0.0001). Furthermore, methodological quality scores are lower in COVID-19 articles across all study designs. COVID-19 clinical studies have a shorter time to publication and have lower methodological quality scores than control studies in the same journal. These studies should be revisited with the emergence of stronger evidence. During the early phase of the COVID-19 pandemic there was a need for rapid dissemination of clinical findings. Here, Jung, Di Santo et al. perform a systematic review and cohort study providing evidence for lower methodological quality scores and faster time to publication of clinical studies related to COVID-19 than comparable studies.
Collapse
Affiliation(s)
- Richard G Jung
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.,Vascular Biology and Experimental Medicine Laboratory, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.,Department of Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada
| | - Pietro Di Santo
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.,Vascular Biology and Experimental Medicine Laboratory, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.,Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.,School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada
| | - Cole Clifford
- Faculty of Medicine, University of Ottawa, Ontario, Canada
| | | | | | - Annie Hung
- Division of Internal Medicine, The Ottawa Hospital, Ottawa, Ontario, Canada
| | - Simon Parlow
- Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Sarah Visintini
- Berkman Library, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - F Daniel Ramirez
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.,Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.,Hôpital Cardiologique du Haut-Lévêque, CHU Bordeaux, Bordeaux-Pessac, France.,L'Institut de Rythmologie et Modélisation Cardiaque (LIRYC), University of Bordeaux, Bordeaux, France
| | - Trevor Simard
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.,Vascular Biology and Experimental Medicine Laboratory, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.,Department of Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada.,Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.,Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA
| | - Benjamin Hibbert
- Vascular Biology and Experimental Medicine Laboratory, University of Ottawa Heart Institute, Ottawa, Ontario, Canada. .,Department of Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada. .,Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.
| |
Collapse
|
34
|
Simard T, Jung RG, Di Santo P, Ramirez FD, Labinaz A, Gaudet C, Motazedian P, Parlow S, Joseph J, Moreland R, Marbach J, Boland P, Promislow S, Russo JJ, Chong AY, So D, Froeschl M, Le May M, Hibbert B. Performance of Plasma Adenosine as a Biomarker for Predicting Cardiovascular Risk. Clin Transl Sci 2020; 14:354-361. [PMID: 33264483 PMCID: PMC7877863 DOI: 10.1111/cts.12886] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2020] [Accepted: 07/23/2020] [Indexed: 11/29/2022] Open
Abstract
Adenosine boasts promising preclinical and clinical data supporting a vital role in modulating vascular homeostasis. Its widespread use as a diagnostic and therapeutic agent have been limited by its short half-life and complex biology, though adenosine-modulators have shown promise in improving vascular healing. Moreover, circulating adenosine has shown promise in predicting cardiovascular (CV) events. We sought to delineate whether circulating plasma adenosine levels predict CV events in patients undergoing invasive assessment for coronary artery disease. Patients undergoing invasive angiography had clinical data prospectively recorded in the Cardiovascular and Percutaneous ClInical TriALs (CAPITAL) revascularization registry and blood samples collected in the CAPITAL Biobank from which adenosine levels were quantified. Tertile-based analysis was used to assess prediction of major adverse cardiovascular events (MACE; composite of death, myocardial infarction, unplanned revascularization, and cerebrovascular accident). Secondary analyses included MACE subgroups, clinical subgroups and adenosine levels. There were 1,815 patients undergoing angiography who had blood collected with adenosine quantified in 1,323. Of those quantified, 51.0% were revascularized and 7.3% experienced MACE in 12 months of follow-up. Tertile-based analysis failed to demonstrate any stratification of MACE rates (log rank, P = 0.83), when comparing low-to-middle (hazard ratio (HR) 1.10, 95% confidence interval (CI) 0.68-1.78, P = 0.70) or low-to-high adenosine tertiles (HR 0.95, 95% CI 0.56-1.57, P = 0.84). In adjusted analysis, adenosine similarly failed to predict MACE. Finally, adenosine did not predict outcomes in patients with acute coronary syndrome nor in those revascularized or treated medically. Plasma adenosine levels do not predict subsequent CV outcomes or aid in patient risk stratification.
Collapse
Affiliation(s)
- Trevor Simard
- CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.,Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Ontario, Canada.,Division of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA
| | - Richard G Jung
- CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.,Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Ontario, Canada
| | - Pietro Di Santo
- CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - F Daniel Ramirez
- CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.,Hôpital Cardiologique du Haut-Lévêque, CHU Bordeaux, Bordeaux-Pessac, France.,L'Institut de Rythmologie et Modélisation Cardiaque (LIRYC), Université de Bordeaux, Bordeaux-Pessac, France
| | - Alisha Labinaz
- CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Chantal Gaudet
- CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Pouya Motazedian
- CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.,Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
| | - Simon Parlow
- CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Joanne Joseph
- CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Robert Moreland
- CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Jeffrey Marbach
- CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Paul Boland
- CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Steven Promislow
- CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Juan J Russo
- CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Aun-Yeong Chong
- CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Derek So
- CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Michael Froeschl
- CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Michel Le May
- CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Benjamin Hibbert
- CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.,Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Ontario, Canada
| |
Collapse
|
35
|
Rasheed A, Shawky SA, Tsai R, Jung RG, Simard T, Saikali MF, Hibbert B, Rayner KJ, Cummins CL. The secretome of liver X receptor agonist-treated early outgrowth cells decreases atherosclerosis in Ldlr-/- mice. Stem Cells Transl Med 2020; 10:479-491. [PMID: 33231376 PMCID: PMC7900590 DOI: 10.1002/sctm.19-0390] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2019] [Revised: 09/11/2020] [Accepted: 09/26/2020] [Indexed: 12/14/2022] Open
Abstract
Endothelial progenitor cells (EPCs) promote the maintenance of the endothelium by secreting vasoreparative factors. A population of EPCs known as early outgrowth cells (EOCs) is being investigated as novel cell‐based therapies for the treatment of cardiovascular disease. We previously demonstrated that the absence of liver X receptors (LXRs) is detrimental to the formation and function of EOCs under hypercholesterolemic conditions. Here, we investigate whether LXR activation in EOCs is beneficial for the treatment of atherosclerosis. EOCs were differentiated from the bone marrow of wild‐type (WT) and LXR‐knockout (Lxrαβ−/−) mice in the presence of vehicle or LXR agonist (GW3965). WT EOCs treated with GW3965 throughout differentiation showed reduced mRNA expression of endothelial lineage markers (Cd144, Vegfr2) compared with WT vehicle and Lxrαβ−/− EOCs. GW3965‐treated EOCs produced secreted factors that reduced monocyte adhesion to activated endothelial cells in culture. When injected into atherosclerosis‐prone Ldlr−/− mice, GW3965‐treated EOCs, or their corresponding conditioned media (CM) were both able to reduce aortic sinus plaque burden compared with controls. Furthermore, when human EOCs (obtained from patients with established CAD) were treated with GW3965 and the CM applied to endothelial cells, monocyte adhesion was decreased, indicating that our results in mice could be translated to patients. Ex vivo LXR agonist treatment of EOCs therefore produces a secretome that decreases early atherosclerosis in Ldlr−/− mice, and additionally, CM from human EOCs significantly inhibits monocyte to endothelial adhesion. Thus, active factor(s) within the GW3965‐treated EOC secretome may have the potential to be useful for the treatment of atherosclerosis.
Collapse
Affiliation(s)
- Adil Rasheed
- Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada
| | - Sarah A Shawky
- Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada
| | - Ricky Tsai
- Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada
| | - Richard G Jung
- Capital Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.,Department of Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada.,University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Trevor Simard
- Capital Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.,Department of Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada.,University of Ottawa Heart Institute, Ottawa, Ontario, Canada.,Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Michael F Saikali
- Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada
| | - Benjamin Hibbert
- Capital Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.,Department of Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada.,University of Ottawa Heart Institute, Ottawa, Ontario, Canada.,Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Katey J Rayner
- University of Ottawa Heart Institute, Ottawa, Ontario, Canada.,Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Ontario, Canada
| | - Carolyn L Cummins
- Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada.,Banting and Best Diabetes Centre, Toronto, Ontario, Canada.,The Heart and Stroke Richard Lewar Centre of Excellence in Cardiovascular Research, Toronto, Ontario, Canada
| |
Collapse
|
36
|
Jung RG, Simard T, Kovach C, Flint K, Don C, Di Santo P, Adamo M, Branca L, Valentini F, Benito-González T, Fernández-Vázquez F, Estévez-Loureiro R, Berardini A, Conti N, Rapezzi C, Biagini E, Parlow S, Shorr R, Levi A, Manovel A, Cardenal-Piris R, Diaz Fernandez J, Shuvy M, Haberman D, Sala A, Alkhouli MA, Marini C, Bargagna M, Schiavi D, Denti P, Markovic S, Buzzatti N, Chan V, Hynes M, Mesana T, Labinaz M, Pappalardo F, Taramasso M, Hibbert B. Transcatheter Mitral Valve Repair in Cardiogenic Shock and Mitral Regurgitation: A Patient-Level, Multicenter Analysis. JACC Cardiovasc Interv 2020; 14:1-11. [PMID: 33069653 DOI: 10.1016/j.jcin.2020.08.037] [Citation(s) in RCA: 46] [Impact Index Per Article: 11.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/25/2020] [Revised: 08/12/2020] [Accepted: 08/25/2020] [Indexed: 12/27/2022]
Abstract
OBJECTIVES The aim of this study was to evaluate the outcome of transcatheter mitral valve repair (TMVr) in patients with cardiogenic shock and significant mitral regurgitation (MR). BACKGROUND Patients in cardiogenic shock with severe MR have a poor prognosis in the setting of conventional medical therapy. Because of its favorable safety profile, TMVr is being increasingly used as an acute therapy in this population, though its efficacy remains unknown. METHODS A multicenter, collaborative, patient-level analysis was conducted. Patients with cardiogenic shock and moderate to severe (3+) or severe (4+) MR who were not surgical candidates were treated with TMVr. The primary outcome was in-hospital mortality. Secondary outcomes included 90-day mortality, heart failure (HF) hospitalization, and the combined event rate of 90-day mortality and HF hospitalization following dichotomization by TMVr device success. RESULTS Between January 2011 and February 2019, 141 patients across 14 institutions met the inclusion criteria. In-hospital mortality occurred in 22 patients (15.6%), at 90 days in 38 patients (29.5%), and at one year in 55 patients (42.6%). Median length of hospital stay following TMVr was 10 days (interquartile range: 6 to 20 days). HF hospitalization occurred in 26 patients (18.4%) at a median of 73 days (interquartile range: 26 to 546 days). When stratified by TMVr procedural results, successful TMVr reduced rates of in-hospital mortality (hazard ratio [HR]: 0.36; 95% confidence interval [CI]: 0.13 to 0.98; p = 0.04), 90-day mortality (HR: 0.36; 95% CI: 0.16 to 0.78; p = 0.01), and the composite of 90-day mortality and HF hospitalization (HR: 0.41; 95% CI: 0.19 to 0.90; p = 0.03). CONCLUSIONS TMVr may improve short- and intermediate-term mortality in high-risk patients with cardiogenic shock and moderate to severe MR. Randomized studies are needed to definitively establish MR as a therapeutic target in patients with cardiogenic shock.
Collapse
Affiliation(s)
- Richard G Jung
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Ontario, Canada
| | - Trevor Simard
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Ontario, Canada; Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Christopher Kovach
- Division of Cardiology, University of Colorado School of Medicine, Aurora, Colorado; Division of Cardiology, University of Washington, Seattle, Washington, USA
| | - Kelsey Flint
- Division of Cardiology, University of Colorado School of Medicine, Aurora, Colorado; Rocky Mountain Regional VA Medical Center, Medicine Services, Cardiology, Aurora, Colorado, USA
| | - Creighton Don
- Division of Cardiology, University of Washington, Seattle, Washington, USA
| | - Pietro Di Santo
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Marianna Adamo
- Catheterization Laboratory, Cardiothoracic Department, Spedali Civili, Brescia, Italy
| | - Luca Branca
- Catheterization Laboratory, Cardiothoracic Department, Spedali Civili, Brescia, Italy
| | - Francesca Valentini
- Catheterization Laboratory, Cardiothoracic Department, Spedali Civili, Brescia, Italy
| | | | | | | | - Alessandra Berardini
- Cardiology Unit, Cardio-Thoracic-Vascular Department, Sant'Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy
| | - Nicolina Conti
- Cardiology Unit, Cardio-Thoracic-Vascular Department, Sant'Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy
| | - Claudio Rapezzi
- Cardiological Center, Universitario di Ferrara, University of Ferrara, Italy; Maria Cecilia Hospital, GVM Care & Research, Cotignola, Italy
| | - Elena Biagini
- Cardiology Unit, Cardio-Thoracic-Vascular Department, Sant'Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy
| | - Simon Parlow
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Risa Shorr
- University of Ottawa Health Sciences Library, Ottawa, Ontario, Canada
| | - Amos Levi
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Ana Manovel
- Juan Ramon Jimenez University Hospital, Huelva, Spain
| | | | | | - Mony Shuvy
- Cardiovascular Research Centre, Heart Institute, Hadassah-Hebrew University Medical Centre, Jerusalem, Israel
| | - Dan Haberman
- Heart Center, Kaplan Medical Center, Hebrew University of Jerusalem, Jerusalem, Israel
| | - Alessandra Sala
- Department of Cardiovascular Anesthesia and Intensive Care, San Raffaele Scientific Institute, Milan, Italy
| | - Mohamad A Alkhouli
- Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA
| | - Claudia Marini
- Department of Cardiac Surgery, San Raffaele Scientific Institute, Milan, Italy
| | - Marta Bargagna
- Department of Cardiac Surgery, San Raffaele Scientific Institute, Milan, Italy
| | | | - Paolo Denti
- Department of Cardiac Surgery, San Raffaele Scientific Institute, Milan, Italy
| | - Sinisa Markovic
- Department of Internal Medicine II, University of Ulm, Ulm, Germany
| | - Nicola Buzzatti
- Department of Cardiac Surgery, San Raffaele Scientific Institute, Milan, Italy
| | - Vincent Chan
- Division of Cardiac Surgery, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Mark Hynes
- Department of Anesthesiology, University of Ottawa Heart Institute, Ottawa, Ontario
| | - Thierry Mesana
- Division of Cardiac Surgery, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Marino Labinaz
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | | | - Maurizio Taramasso
- Department of Cardiac Surgery, San Raffaele Scientific Institute, Milan, Italy; University Heart Center Zurich, University Hospital of Zurich, Zurich, Switzerland
| | - Benjamin Hibbert
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Ontario, Canada; Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.
| |
Collapse
|
37
|
Jung RG, Di Santo P, Hibbert B. Commentary: Geographic variation in the statin trials - underrepresentation of Asian populations. Int J Cardiol 2020; 316:47-48. [PMID: 32710987 DOI: 10.1016/j.ijcard.2020.07.023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/10/2020] [Accepted: 07/15/2020] [Indexed: 11/25/2022]
Affiliation(s)
- Richard G Jung
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; Vascular Biology and Experimental Medicine Laboratory, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; Department of Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada
| | - Pietro Di Santo
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; Vascular Biology and Experimental Medicine Laboratory, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; Department of Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada; Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Benjamin Hibbert
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; Vascular Biology and Experimental Medicine Laboratory, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; Department of Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada; Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.
| |
Collapse
|
38
|
Simard T, Motazedian P, Majeed K, Sarathy K, Jung RG, Feder J, Ramirez FD, Di Santo P, Marbach J, Dhaliwal S, Short S, Labinaz A, Schultz C, Russo JJ, So D, Chong AY, Le May M, Hibbert B. Contrast-free optical coherence tomography:Systematic evaluation of non-contrast media for intravascular assessment. PLoS One 2020; 15:e0237588. [PMID: 32817672 PMCID: PMC7446899 DOI: 10.1371/journal.pone.0237588] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2020] [Accepted: 07/29/2020] [Indexed: 11/18/2022] Open
Abstract
Background Coronary revascularization using imaging guidance is rapidly becoming the standard of care. Intravascular optical coherence tomography uses near-infrared light to obtain high resolution intravascular images. Standard optical coherence tomography imaging technique employs iodinated contrast dye to achieve the required blood clearance during acquisition. We sought to systematically evaluate the technical performance of saline as an alternative to iodinated contrast for intravascular optical coherence tomography assessment. Methods and results We performed bench top optical coherence tomography analysis on nylon tubing with sequential contrast/saline dilutions to empirically derive adjustment coefficients. We then applied these coefficients in vivo in an established rabbit abdominal stenting model with both saline and contrast optical coherence tomography imaging. In this model, we assessed the impact of saline on both quantitative and qualitative vessel assessment. Nylon tubing assessment demonstrated a linear relationship between saline and contrast for both area and diameter. We then derived adjustment coefficients, allowing for accurate calculation of area and diameter when converting saline into both contrast and reference dimensions. In vivo studies confirmed reduced area with saline versus contrast [7.43 (5.67–8.36) mm2 versus 8.2 (6.34–9.39) mm2, p = 0.001] and diameter [3.08 mm versus 3.23 mm, p = 0.001]. Following correction, a strong relationship was achieved in vivo between saline and contrast in both area and diameter without compromising image quality, artefact, or strut assessment. Conclusion Saline generates reduced dimensions compared to contrast during intravascular optical coherence tomography imaging. The relationship across physiologic coronary diameters is linear and can be corrected with high fidelity. Saline does not adversely impact image quality, artefact, or strut assessment.
Collapse
Affiliation(s)
- Trevor Simard
- CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
- Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Ontario, Canada
| | - Pouya Motazedian
- CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
- Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
| | - Kamran Majeed
- Department of Cardiology, Royal Perth Hospital, Perth, Western Australia, Australia
- School of Medicine, University of Western Australia, Perth, Western Australia, Australia
| | - Kiran Sarathy
- CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Richard G. Jung
- CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
- Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Ontario, Canada
| | - Joshua Feder
- CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - F. Daniel Ramirez
- CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
- Hôpital Cardiologique du Haut-Lévêque, CHU Bordeaux, Bordeaux-Pessac, France
- L’Institut de Rythmologie et Modélisation Cardiaque (LIRYC), Université de Bordeaux, Bordeaux-Pessac, France
| | - Pietro Di Santo
- CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Jeffrey Marbach
- CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Shan Dhaliwal
- CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Spencer Short
- CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Alisha Labinaz
- CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Carl Schultz
- Department of Cardiology, Royal Perth Hospital, Perth, Western Australia, Australia
- School of Medicine, University of Western Australia, Perth, Western Australia, Australia
| | - Juan J. Russo
- CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Derek So
- CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Aun-Yeong Chong
- CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Michel Le May
- CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Benjamin Hibbert
- CAPITAL Research Group, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
- Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Ontario, Canada
- * E-mail:
| |
Collapse
|
39
|
Jung RG, Simard T, Di Santo P, Dhaliwal S, Sypkes C, Duchez AC, Moreland R, Taylor K, Parlow S, Visintini S, Labinaz A, Marbach J, Sarathy K, Bernick J, Joseph J, Boland P, Abdel-Razek O, Harnett DT, Ramirez FD, Hibbert B. Evaluation of plasminogen activator inhibitor-1 as a biomarker of unplanned revascularization and major adverse cardiac events in coronary angiography and percutaneous coronary intervention. Thromb Res 2020; 191:125-133. [PMID: 32447094 DOI: 10.1016/j.thromres.2020.04.025] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2020] [Revised: 03/30/2020] [Accepted: 04/20/2020] [Indexed: 10/24/2022]
Abstract
BACKGROUND The stented coronary artery remains at high-risk of complications, particularly in the form of stent thrombosis and in-stent restenosis. Improving our ability to identify patients at high-risk for these complications may provide opportunities for intervention. PAI-1 has been implicated in the pathophysiology of stent complications in preclinical studies, suggesting it may be a clinically valuable biomarker to predict adverse events following percutaneous coronary intervention. METHODS Plasma PAI-1 levels were measured in 910 subjects immediately after coronary angiography between 2015 and 2019. The primary outcome was the incidence of unplanned revascularization (UR) at 12 months. The secondary outcome was the incidence of major adverse cardiac events (MACE). RESULTS UR and MACE occurred in 49 and 103 patients in 12 months. Reduced plasma PAI-1 levels were associated with UR (4386.1 pg/mL [IQR, 2778.7-6664.6], n = 49, vs. 5247.6 pg/mL [IQR, 3414.1-7836.1], n = 861; p = 0.04). Tertile PAI-1 levels were predictive of UR after adjustment for known clinical risk factors associated with adverse outcomes. In post-hoc landmark analysis, UR was enhanced with low plasma PAI-1 levels for late complications (beyond 30 days). Finally, an updated systematic review and meta-analysis did not reveal an association between plasma PAI-1 and MACE. CONCLUSION PAI-1 levels are not independently associated with UR nor MACE in patients undergoing angiography but associated with UR following adjustment with known clinical factors. In our landmark analysis, low PAI-1 levels were associated with UR for late stent complications. As such, future studies should focus on the mediatory role of PAI-1 in the pathogenesis of stent complications.
Collapse
Affiliation(s)
- Richard G Jung
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; Vascular Biology and Experimental Medicine Laboratory, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; Department of Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada
| | - Trevor Simard
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; Vascular Biology and Experimental Medicine Laboratory, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; Department of Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada; Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Pietro Di Santo
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; Vascular Biology and Experimental Medicine Laboratory, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada
| | - Shan Dhaliwal
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; Vascular Biology and Experimental Medicine Laboratory, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; Department of Biochemistry, Microbiology, and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada
| | - Caleb Sypkes
- Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada
| | | | - Robert Moreland
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
| | - Katlyn Taylor
- Department of Pharmacy, The Ottawa Hospital, Ottawa, Ontario, Canada
| | - Simon Parlow
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; Vascular Biology and Experimental Medicine Laboratory, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; Division of Internal Medicine, The Ottawa Hospital, Ottawa, Ontario, Canada
| | - Sarah Visintini
- Berkman Library, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Alisha Labinaz
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; Vascular Biology and Experimental Medicine Laboratory, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Jeffrey Marbach
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Kiran Sarathy
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Jordan Bernick
- Ottawa Cardiovascular Research Methods Center, Ottawa, Ontario, Canada
| | - Joanne Joseph
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; Division of Internal Medicine, The Ottawa Hospital, Ottawa, Ontario, Canada
| | - Paul Boland
- Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Omar Abdel-Razek
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - David T Harnett
- Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - F Daniel Ramirez
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; Hôpital Cardiologique du Haut-Lévêque, CHU Bordeaux, Bordeaux-Pessac, France; L'Institut de Rythmologie et Modélisation Cardiaque (LIRYC), University of Bordeaux, France
| | - Benjamin Hibbert
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; Vascular Biology and Experimental Medicine Laboratory, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; Department of Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada; Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.
| |
Collapse
|
40
|
Ramirez FD, Jung RG, Motazedian P, Perry-Nguyen D, Di Santo P, MacDonald Z, Clancy AA, Labinaz A, Promislow S, Simard T, Provencher S, Bonnet S, Graham ID, Wells GA, Hibbert B. Journal Initiatives to Enhance Preclinical Research: Analyses of Stroke, Nature Medicine, Science Translational Medicine. Stroke 2020; 51:291-299. [PMID: 31718504 PMCID: PMC6924942 DOI: 10.1161/strokeaha.119.026564] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2019] [Revised: 08/08/2019] [Accepted: 08/28/2019] [Indexed: 01/01/2023]
Abstract
Background and Purpose- Preclinical research using animals often informs clinical trials. However, its value is dependent on its scientific validity and reproducibility, which are, in turn, dependent on rigorous study design and reporting. In 2011, Stroke introduced a Basic Science Checklist to enhance the reporting and methodology of its preclinical studies. Except for Nature and Science journals, few others have implemented similar initiatives. We sought to estimate the impact of these journal interventions on the quality of their published reports. Methods- All articles published in Stroke, Nature Medicine, and Science Translational Medicine over 9 to 18 years and in 2 control journals without analogous interventions over a corresponding 11.5 years were reviewed to identify reports of experiments in nonhuman mammals with proposed clinical relevance. The effect of journal interventions on the reporting and use of key study design elements was estimated via interrupted time-series analyses. Results- Of 33 009 articles screened, 4162 studies met inclusion criteria. In the 3.5 to 12 years preceding each journal's intervention, the proportions of studies reporting and using key study design elements were stable except for blinding in Stroke and randomization in Science Translational Medicine, which were both increasing. Post-intervention, abrupt and often marked increases were seen in the reporting of randomization status (level change: +17% to +44%, P≤0.005), blinding (level change: +20% to +40%, P≤0.008), and sample size estimation (level change: 0% to +40%, P≤0.002 in 2 journals). Significant but more modest improvements in the use of these study design elements were also observed. These improvements were not seen in control journals. Conclusions- Journal interventions such as Stroke's author submission checklist can meaningfully improve the quality of published preclinical research and should be considered to enhance study transparency and design. However, such interventions are alone insufficient to fully address widespread shortcomings in preclinical research practices.
Collapse
Affiliation(s)
- F. Daniel Ramirez
- From the Division of Cardiology (F.D.R., P.D.S., S. Promislow, T.S., B.H.), University of Ottawa Heart Institute, ON, Canada
- CAPITAL Research Group (F.D.R., R.G.J., P.M., D.P.-N., P.D.S., A.L., S. Promislow, T.S., B.H.), University of Ottawa Heart Institute, ON, Canada
- School of Epidemiology and Public Health (F.D.R., P.D.S., I.D.G., G.A.W.), University of Ottawa, ON, Canada
- Electrophysiology and Ablation Unit, Hôpital cardiologique du Haut-Lévêque, Centre hospitalier universitaire (CHU) de Bordeaux, Bordeaux-Pessac, France (F.D.R.)
- L’Institut de rythmologie et modélisation cardiaque (LIRYC), Université de Bordeaux, Bordeaux-Pessac, France (F.D.R.)
| | - Richard G. Jung
- CAPITAL Research Group (F.D.R., R.G.J., P.M., D.P.-N., P.D.S., A.L., S. Promislow, T.S., B.H.), University of Ottawa Heart Institute, ON, Canada
- Vascular Biology and Experimental Medicine Laboratory (R.G.J., P.M., D.P.-N., A.L., T.S., B.H.), University of Ottawa Heart Institute, ON, Canada
- Department of Cellular and Molecular Medicine (R.G.J., T.S., B.H.), University of Ottawa, ON, Canada
- Faculty of Medicine (R.G.J., P.M., D.P.-N., Z.M.), University of Ottawa, ON, Canada
| | - Pouya Motazedian
- CAPITAL Research Group (F.D.R., R.G.J., P.M., D.P.-N., P.D.S., A.L., S. Promislow, T.S., B.H.), University of Ottawa Heart Institute, ON, Canada
- Vascular Biology and Experimental Medicine Laboratory (R.G.J., P.M., D.P.-N., A.L., T.S., B.H.), University of Ottawa Heart Institute, ON, Canada
- Faculty of Medicine (R.G.J., P.M., D.P.-N., Z.M.), University of Ottawa, ON, Canada
- Department of Medicine, University of Calgary Cumming School of Medicine, AB, Canada (P.M.)
| | - Dylan Perry-Nguyen
- CAPITAL Research Group (F.D.R., R.G.J., P.M., D.P.-N., P.D.S., A.L., S. Promislow, T.S., B.H.), University of Ottawa Heart Institute, ON, Canada
- Vascular Biology and Experimental Medicine Laboratory (R.G.J., P.M., D.P.-N., A.L., T.S., B.H.), University of Ottawa Heart Institute, ON, Canada
- Faculty of Medicine (R.G.J., P.M., D.P.-N., Z.M.), University of Ottawa, ON, Canada
| | - Pietro Di Santo
- From the Division of Cardiology (F.D.R., P.D.S., S. Promislow, T.S., B.H.), University of Ottawa Heart Institute, ON, Canada
- CAPITAL Research Group (F.D.R., R.G.J., P.M., D.P.-N., P.D.S., A.L., S. Promislow, T.S., B.H.), University of Ottawa Heart Institute, ON, Canada
- School of Epidemiology and Public Health (F.D.R., P.D.S., I.D.G., G.A.W.), University of Ottawa, ON, Canada
| | - Zachary MacDonald
- Faculty of Medicine (R.G.J., P.M., D.P.-N., Z.M.), University of Ottawa, ON, Canada
- Department of Emergency Medicine (Z.M.), University of Ottawa, ON, Canada
| | - Aisling A. Clancy
- Department of Obstetrics and Gynecology (A.A.C.), University of Ottawa, ON, Canada
- Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA (A.A.C.)
| | - Alisha Labinaz
- CAPITAL Research Group (F.D.R., R.G.J., P.M., D.P.-N., P.D.S., A.L., S. Promislow, T.S., B.H.), University of Ottawa Heart Institute, ON, Canada
- Vascular Biology and Experimental Medicine Laboratory (R.G.J., P.M., D.P.-N., A.L., T.S., B.H.), University of Ottawa Heart Institute, ON, Canada
- Faculty of Science (A.L.), University of Ottawa, ON, Canada
| | - Steven Promislow
- From the Division of Cardiology (F.D.R., P.D.S., S. Promislow, T.S., B.H.), University of Ottawa Heart Institute, ON, Canada
- CAPITAL Research Group (F.D.R., R.G.J., P.M., D.P.-N., P.D.S., A.L., S. Promislow, T.S., B.H.), University of Ottawa Heart Institute, ON, Canada
| | - Trevor Simard
- From the Division of Cardiology (F.D.R., P.D.S., S. Promislow, T.S., B.H.), University of Ottawa Heart Institute, ON, Canada
- CAPITAL Research Group (F.D.R., R.G.J., P.M., D.P.-N., P.D.S., A.L., S. Promislow, T.S., B.H.), University of Ottawa Heart Institute, ON, Canada
- Vascular Biology and Experimental Medicine Laboratory (R.G.J., P.M., D.P.-N., A.L., T.S., B.H.), University of Ottawa Heart Institute, ON, Canada
- Department of Cellular and Molecular Medicine (R.G.J., T.S., B.H.), University of Ottawa, ON, Canada
| | - Steeve Provencher
- Pulmonary Hypertension Research Group, Centre de recherche de l’Institut universitaire de cardiologie et de pneumologie de Québec (S. Provencher, S.B.), Université Laval, Québec City, Canada
- Department of Medicine (S. Provencher, S.B.), Université Laval, Québec City, Canada
| | - Sébastien Bonnet
- Pulmonary Hypertension Research Group, Centre de recherche de l’Institut universitaire de cardiologie et de pneumologie de Québec (S. Provencher, S.B.), Université Laval, Québec City, Canada
- Department of Medicine (S. Provencher, S.B.), Université Laval, Québec City, Canada
| | - Ian D. Graham
- School of Epidemiology and Public Health (F.D.R., P.D.S., I.D.G., G.A.W.), University of Ottawa, ON, Canada
- Clinical Epidemiology Program, Ottawa Hospital Research Institute, ON, Canada (I.D.G.)
| | - George A. Wells
- Cardiovascular Research Methods Centre (G.A.W.), University of Ottawa Heart Institute, ON, Canada
- School of Epidemiology and Public Health (F.D.R., P.D.S., I.D.G., G.A.W.), University of Ottawa, ON, Canada
| | - Benjamin Hibbert
- From the Division of Cardiology (F.D.R., P.D.S., S. Promislow, T.S., B.H.), University of Ottawa Heart Institute, ON, Canada
- CAPITAL Research Group (F.D.R., R.G.J., P.M., D.P.-N., P.D.S., A.L., S. Promislow, T.S., B.H.), University of Ottawa Heart Institute, ON, Canada
- Vascular Biology and Experimental Medicine Laboratory (R.G.J., P.M., D.P.-N., A.L., T.S., B.H.), University of Ottawa Heart Institute, ON, Canada
- Department of Cellular and Molecular Medicine (R.G.J., T.S., B.H.), University of Ottawa, ON, Canada
| |
Collapse
|
41
|
Di Santo P, Harnett DT, Simard T, Ramirez FD, Pourdjabbar A, Yousef A, Moreland R, Bernick J, Wells G, Dick A, Le May M, Labinaz M, So D, Motazedian P, Jung RG, Chandrasekhar J, Mehran R, Chong AY, Hibbert B. Photoplethysmography using a smartphone application for assessment of ulnar artery patency: a randomized clinical trial. CMAJ 2019; 190:E380-E388. [PMID: 29615421 DOI: 10.1503/cmaj.170432] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/06/2017] [Indexed: 11/01/2022] Open
Abstract
BACKGROUND Radial artery access is commonly performed for coronary angiography and invasive hemodynamic monitoring. Despite limitations in diagnostic accuracy, the modified Allen test (manual occlusion of radial and ulnar arteries followed by release of the latter and assessment of palmar blush) is used routinely to evaluate the collateral circulation to the hand and, therefore, to determine patient eligibility for radial artery access. We sought to evaluate whether a smartphone application may provide a superior alternative to the modified Allen test. METHODS We compared the modified Allen test with a smartphone heart rate-monitoring application (photoplethysmography readings detected using a smartphone camera lens placed on the patient's index finger) in patients undergoing a planned cardiac catheterization. Test order was randomly assigned in a 1:1 fashion. All patients then underwent conventional plethysmography of the index finger, followed by Doppler ultrasonography of the radial and ulnar arteries (the diagnostic standard). The primary outcome was diagnostic accuracy of the heart rate-monitoring application. RESULTS Among 438 patients who were included in the study, we found that the heart rate-monitoring application had a superior diagnostic accuracy compared with the modified Allen test (91.8% v. 81.7%, p = 0.002), attributable to its greater specificity (93.0% v. 82.8%, p = 0.001). We also found that this application had greater diagnostic accuracy for assessment of radial or ulnar artery patency in the ipsilateral and contralateral wrist (94.0% v. 84.0%, p < 0.001). INTERPRETATION A smartphone application used at the bedside was diagnostically superior to traditional physical examination for confirming ulnar patency before radial artery access. This study highlights the potential for smartphone-based diagnostics to aid in clinical decision-making at the patient's bedside. Trial registration: Clinicaltrials.gov, no. NCT02519491.
Collapse
Affiliation(s)
- Pietro Di Santo
- Division of Cardiology (Di Santo, Harnett, Simard, Ramirez Pourdjabbar, Youssef, Dick, Le May, Labinaz, So, Chong, Hibbert); CAPITAL Research Group (Di Santo, Harnett, Simard, Ramirez, Youssef, Moreland, Dick, Le May, Labinaz, So, Motazedian, Jung, Chong, Hibbert); Vascular Biology and Experimental Medicine Laboratory (Simard, Jung, Hibbert); Cardiovascular Research Methods Centre (Bernick, Wells), University of Ottawa Heart Institute; Department of Cellular and Molecular Medicine (Simard, Hibbert); Department of Radiology (Moreland); School of Epidemiology, Public Health and Preventive Medicine (Ramirez, Wells), University of Ottawa, Ottawa, Ont.; Division of Cardiovascular Medicine (Pourdjabbar), Sulpizio Cardiovascular Center, University of California, San Diego, CA; Icahn School of Medicine at Mount Sinai ( Chandrasekhar, Mehran), New York, NY
| | - David T Harnett
- Division of Cardiology (Di Santo, Harnett, Simard, Ramirez Pourdjabbar, Youssef, Dick, Le May, Labinaz, So, Chong, Hibbert); CAPITAL Research Group (Di Santo, Harnett, Simard, Ramirez, Youssef, Moreland, Dick, Le May, Labinaz, So, Motazedian, Jung, Chong, Hibbert); Vascular Biology and Experimental Medicine Laboratory (Simard, Jung, Hibbert); Cardiovascular Research Methods Centre (Bernick, Wells), University of Ottawa Heart Institute; Department of Cellular and Molecular Medicine (Simard, Hibbert); Department of Radiology (Moreland); School of Epidemiology, Public Health and Preventive Medicine (Ramirez, Wells), University of Ottawa, Ottawa, Ont.; Division of Cardiovascular Medicine (Pourdjabbar), Sulpizio Cardiovascular Center, University of California, San Diego, CA; Icahn School of Medicine at Mount Sinai ( Chandrasekhar, Mehran), New York, NY
| | - Trevor Simard
- Division of Cardiology (Di Santo, Harnett, Simard, Ramirez Pourdjabbar, Youssef, Dick, Le May, Labinaz, So, Chong, Hibbert); CAPITAL Research Group (Di Santo, Harnett, Simard, Ramirez, Youssef, Moreland, Dick, Le May, Labinaz, So, Motazedian, Jung, Chong, Hibbert); Vascular Biology and Experimental Medicine Laboratory (Simard, Jung, Hibbert); Cardiovascular Research Methods Centre (Bernick, Wells), University of Ottawa Heart Institute; Department of Cellular and Molecular Medicine (Simard, Hibbert); Department of Radiology (Moreland); School of Epidemiology, Public Health and Preventive Medicine (Ramirez, Wells), University of Ottawa, Ottawa, Ont.; Division of Cardiovascular Medicine (Pourdjabbar), Sulpizio Cardiovascular Center, University of California, San Diego, CA; Icahn School of Medicine at Mount Sinai ( Chandrasekhar, Mehran), New York, NY
| | - F Daniel Ramirez
- Division of Cardiology (Di Santo, Harnett, Simard, Ramirez Pourdjabbar, Youssef, Dick, Le May, Labinaz, So, Chong, Hibbert); CAPITAL Research Group (Di Santo, Harnett, Simard, Ramirez, Youssef, Moreland, Dick, Le May, Labinaz, So, Motazedian, Jung, Chong, Hibbert); Vascular Biology and Experimental Medicine Laboratory (Simard, Jung, Hibbert); Cardiovascular Research Methods Centre (Bernick, Wells), University of Ottawa Heart Institute; Department of Cellular and Molecular Medicine (Simard, Hibbert); Department of Radiology (Moreland); School of Epidemiology, Public Health and Preventive Medicine (Ramirez, Wells), University of Ottawa, Ottawa, Ont.; Division of Cardiovascular Medicine (Pourdjabbar), Sulpizio Cardiovascular Center, University of California, San Diego, CA; Icahn School of Medicine at Mount Sinai ( Chandrasekhar, Mehran), New York, NY
| | - Ali Pourdjabbar
- Division of Cardiology (Di Santo, Harnett, Simard, Ramirez Pourdjabbar, Youssef, Dick, Le May, Labinaz, So, Chong, Hibbert); CAPITAL Research Group (Di Santo, Harnett, Simard, Ramirez, Youssef, Moreland, Dick, Le May, Labinaz, So, Motazedian, Jung, Chong, Hibbert); Vascular Biology and Experimental Medicine Laboratory (Simard, Jung, Hibbert); Cardiovascular Research Methods Centre (Bernick, Wells), University of Ottawa Heart Institute; Department of Cellular and Molecular Medicine (Simard, Hibbert); Department of Radiology (Moreland); School of Epidemiology, Public Health and Preventive Medicine (Ramirez, Wells), University of Ottawa, Ottawa, Ont.; Division of Cardiovascular Medicine (Pourdjabbar), Sulpizio Cardiovascular Center, University of California, San Diego, CA; Icahn School of Medicine at Mount Sinai ( Chandrasekhar, Mehran), New York, NY
| | - Altayyeb Yousef
- Division of Cardiology (Di Santo, Harnett, Simard, Ramirez Pourdjabbar, Youssef, Dick, Le May, Labinaz, So, Chong, Hibbert); CAPITAL Research Group (Di Santo, Harnett, Simard, Ramirez, Youssef, Moreland, Dick, Le May, Labinaz, So, Motazedian, Jung, Chong, Hibbert); Vascular Biology and Experimental Medicine Laboratory (Simard, Jung, Hibbert); Cardiovascular Research Methods Centre (Bernick, Wells), University of Ottawa Heart Institute; Department of Cellular and Molecular Medicine (Simard, Hibbert); Department of Radiology (Moreland); School of Epidemiology, Public Health and Preventive Medicine (Ramirez, Wells), University of Ottawa, Ottawa, Ont.; Division of Cardiovascular Medicine (Pourdjabbar), Sulpizio Cardiovascular Center, University of California, San Diego, CA; Icahn School of Medicine at Mount Sinai ( Chandrasekhar, Mehran), New York, NY
| | - Robert Moreland
- Division of Cardiology (Di Santo, Harnett, Simard, Ramirez Pourdjabbar, Youssef, Dick, Le May, Labinaz, So, Chong, Hibbert); CAPITAL Research Group (Di Santo, Harnett, Simard, Ramirez, Youssef, Moreland, Dick, Le May, Labinaz, So, Motazedian, Jung, Chong, Hibbert); Vascular Biology and Experimental Medicine Laboratory (Simard, Jung, Hibbert); Cardiovascular Research Methods Centre (Bernick, Wells), University of Ottawa Heart Institute; Department of Cellular and Molecular Medicine (Simard, Hibbert); Department of Radiology (Moreland); School of Epidemiology, Public Health and Preventive Medicine (Ramirez, Wells), University of Ottawa, Ottawa, Ont.; Division of Cardiovascular Medicine (Pourdjabbar), Sulpizio Cardiovascular Center, University of California, San Diego, CA; Icahn School of Medicine at Mount Sinai ( Chandrasekhar, Mehran), New York, NY
| | - Jordan Bernick
- Division of Cardiology (Di Santo, Harnett, Simard, Ramirez Pourdjabbar, Youssef, Dick, Le May, Labinaz, So, Chong, Hibbert); CAPITAL Research Group (Di Santo, Harnett, Simard, Ramirez, Youssef, Moreland, Dick, Le May, Labinaz, So, Motazedian, Jung, Chong, Hibbert); Vascular Biology and Experimental Medicine Laboratory (Simard, Jung, Hibbert); Cardiovascular Research Methods Centre (Bernick, Wells), University of Ottawa Heart Institute; Department of Cellular and Molecular Medicine (Simard, Hibbert); Department of Radiology (Moreland); School of Epidemiology, Public Health and Preventive Medicine (Ramirez, Wells), University of Ottawa, Ottawa, Ont.; Division of Cardiovascular Medicine (Pourdjabbar), Sulpizio Cardiovascular Center, University of California, San Diego, CA; Icahn School of Medicine at Mount Sinai ( Chandrasekhar, Mehran), New York, NY
| | - George Wells
- Division of Cardiology (Di Santo, Harnett, Simard, Ramirez Pourdjabbar, Youssef, Dick, Le May, Labinaz, So, Chong, Hibbert); CAPITAL Research Group (Di Santo, Harnett, Simard, Ramirez, Youssef, Moreland, Dick, Le May, Labinaz, So, Motazedian, Jung, Chong, Hibbert); Vascular Biology and Experimental Medicine Laboratory (Simard, Jung, Hibbert); Cardiovascular Research Methods Centre (Bernick, Wells), University of Ottawa Heart Institute; Department of Cellular and Molecular Medicine (Simard, Hibbert); Department of Radiology (Moreland); School of Epidemiology, Public Health and Preventive Medicine (Ramirez, Wells), University of Ottawa, Ottawa, Ont.; Division of Cardiovascular Medicine (Pourdjabbar), Sulpizio Cardiovascular Center, University of California, San Diego, CA; Icahn School of Medicine at Mount Sinai ( Chandrasekhar, Mehran), New York, NY
| | - Alexander Dick
- Division of Cardiology (Di Santo, Harnett, Simard, Ramirez Pourdjabbar, Youssef, Dick, Le May, Labinaz, So, Chong, Hibbert); CAPITAL Research Group (Di Santo, Harnett, Simard, Ramirez, Youssef, Moreland, Dick, Le May, Labinaz, So, Motazedian, Jung, Chong, Hibbert); Vascular Biology and Experimental Medicine Laboratory (Simard, Jung, Hibbert); Cardiovascular Research Methods Centre (Bernick, Wells), University of Ottawa Heart Institute; Department of Cellular and Molecular Medicine (Simard, Hibbert); Department of Radiology (Moreland); School of Epidemiology, Public Health and Preventive Medicine (Ramirez, Wells), University of Ottawa, Ottawa, Ont.; Division of Cardiovascular Medicine (Pourdjabbar), Sulpizio Cardiovascular Center, University of California, San Diego, CA; Icahn School of Medicine at Mount Sinai ( Chandrasekhar, Mehran), New York, NY
| | - Michel Le May
- Division of Cardiology (Di Santo, Harnett, Simard, Ramirez Pourdjabbar, Youssef, Dick, Le May, Labinaz, So, Chong, Hibbert); CAPITAL Research Group (Di Santo, Harnett, Simard, Ramirez, Youssef, Moreland, Dick, Le May, Labinaz, So, Motazedian, Jung, Chong, Hibbert); Vascular Biology and Experimental Medicine Laboratory (Simard, Jung, Hibbert); Cardiovascular Research Methods Centre (Bernick, Wells), University of Ottawa Heart Institute; Department of Cellular and Molecular Medicine (Simard, Hibbert); Department of Radiology (Moreland); School of Epidemiology, Public Health and Preventive Medicine (Ramirez, Wells), University of Ottawa, Ottawa, Ont.; Division of Cardiovascular Medicine (Pourdjabbar), Sulpizio Cardiovascular Center, University of California, San Diego, CA; Icahn School of Medicine at Mount Sinai ( Chandrasekhar, Mehran), New York, NY
| | - Marino Labinaz
- Division of Cardiology (Di Santo, Harnett, Simard, Ramirez Pourdjabbar, Youssef, Dick, Le May, Labinaz, So, Chong, Hibbert); CAPITAL Research Group (Di Santo, Harnett, Simard, Ramirez, Youssef, Moreland, Dick, Le May, Labinaz, So, Motazedian, Jung, Chong, Hibbert); Vascular Biology and Experimental Medicine Laboratory (Simard, Jung, Hibbert); Cardiovascular Research Methods Centre (Bernick, Wells), University of Ottawa Heart Institute; Department of Cellular and Molecular Medicine (Simard, Hibbert); Department of Radiology (Moreland); School of Epidemiology, Public Health and Preventive Medicine (Ramirez, Wells), University of Ottawa, Ottawa, Ont.; Division of Cardiovascular Medicine (Pourdjabbar), Sulpizio Cardiovascular Center, University of California, San Diego, CA; Icahn School of Medicine at Mount Sinai ( Chandrasekhar, Mehran), New York, NY
| | - Derek So
- Division of Cardiology (Di Santo, Harnett, Simard, Ramirez Pourdjabbar, Youssef, Dick, Le May, Labinaz, So, Chong, Hibbert); CAPITAL Research Group (Di Santo, Harnett, Simard, Ramirez, Youssef, Moreland, Dick, Le May, Labinaz, So, Motazedian, Jung, Chong, Hibbert); Vascular Biology and Experimental Medicine Laboratory (Simard, Jung, Hibbert); Cardiovascular Research Methods Centre (Bernick, Wells), University of Ottawa Heart Institute; Department of Cellular and Molecular Medicine (Simard, Hibbert); Department of Radiology (Moreland); School of Epidemiology, Public Health and Preventive Medicine (Ramirez, Wells), University of Ottawa, Ottawa, Ont.; Division of Cardiovascular Medicine (Pourdjabbar), Sulpizio Cardiovascular Center, University of California, San Diego, CA; Icahn School of Medicine at Mount Sinai ( Chandrasekhar, Mehran), New York, NY
| | - Pouya Motazedian
- Division of Cardiology (Di Santo, Harnett, Simard, Ramirez Pourdjabbar, Youssef, Dick, Le May, Labinaz, So, Chong, Hibbert); CAPITAL Research Group (Di Santo, Harnett, Simard, Ramirez, Youssef, Moreland, Dick, Le May, Labinaz, So, Motazedian, Jung, Chong, Hibbert); Vascular Biology and Experimental Medicine Laboratory (Simard, Jung, Hibbert); Cardiovascular Research Methods Centre (Bernick, Wells), University of Ottawa Heart Institute; Department of Cellular and Molecular Medicine (Simard, Hibbert); Department of Radiology (Moreland); School of Epidemiology, Public Health and Preventive Medicine (Ramirez, Wells), University of Ottawa, Ottawa, Ont.; Division of Cardiovascular Medicine (Pourdjabbar), Sulpizio Cardiovascular Center, University of California, San Diego, CA; Icahn School of Medicine at Mount Sinai ( Chandrasekhar, Mehran), New York, NY
| | - Richard G Jung
- Division of Cardiology (Di Santo, Harnett, Simard, Ramirez Pourdjabbar, Youssef, Dick, Le May, Labinaz, So, Chong, Hibbert); CAPITAL Research Group (Di Santo, Harnett, Simard, Ramirez, Youssef, Moreland, Dick, Le May, Labinaz, So, Motazedian, Jung, Chong, Hibbert); Vascular Biology and Experimental Medicine Laboratory (Simard, Jung, Hibbert); Cardiovascular Research Methods Centre (Bernick, Wells), University of Ottawa Heart Institute; Department of Cellular and Molecular Medicine (Simard, Hibbert); Department of Radiology (Moreland); School of Epidemiology, Public Health and Preventive Medicine (Ramirez, Wells), University of Ottawa, Ottawa, Ont.; Division of Cardiovascular Medicine (Pourdjabbar), Sulpizio Cardiovascular Center, University of California, San Diego, CA; Icahn School of Medicine at Mount Sinai ( Chandrasekhar, Mehran), New York, NY
| | - Jaya Chandrasekhar
- Division of Cardiology (Di Santo, Harnett, Simard, Ramirez Pourdjabbar, Youssef, Dick, Le May, Labinaz, So, Chong, Hibbert); CAPITAL Research Group (Di Santo, Harnett, Simard, Ramirez, Youssef, Moreland, Dick, Le May, Labinaz, So, Motazedian, Jung, Chong, Hibbert); Vascular Biology and Experimental Medicine Laboratory (Simard, Jung, Hibbert); Cardiovascular Research Methods Centre (Bernick, Wells), University of Ottawa Heart Institute; Department of Cellular and Molecular Medicine (Simard, Hibbert); Department of Radiology (Moreland); School of Epidemiology, Public Health and Preventive Medicine (Ramirez, Wells), University of Ottawa, Ottawa, Ont.; Division of Cardiovascular Medicine (Pourdjabbar), Sulpizio Cardiovascular Center, University of California, San Diego, CA; Icahn School of Medicine at Mount Sinai ( Chandrasekhar, Mehran), New York, NY
| | - Roxana Mehran
- Division of Cardiology (Di Santo, Harnett, Simard, Ramirez Pourdjabbar, Youssef, Dick, Le May, Labinaz, So, Chong, Hibbert); CAPITAL Research Group (Di Santo, Harnett, Simard, Ramirez, Youssef, Moreland, Dick, Le May, Labinaz, So, Motazedian, Jung, Chong, Hibbert); Vascular Biology and Experimental Medicine Laboratory (Simard, Jung, Hibbert); Cardiovascular Research Methods Centre (Bernick, Wells), University of Ottawa Heart Institute; Department of Cellular and Molecular Medicine (Simard, Hibbert); Department of Radiology (Moreland); School of Epidemiology, Public Health and Preventive Medicine (Ramirez, Wells), University of Ottawa, Ottawa, Ont.; Division of Cardiovascular Medicine (Pourdjabbar), Sulpizio Cardiovascular Center, University of California, San Diego, CA; Icahn School of Medicine at Mount Sinai ( Chandrasekhar, Mehran), New York, NY
| | - Aun-Yeong Chong
- Division of Cardiology (Di Santo, Harnett, Simard, Ramirez Pourdjabbar, Youssef, Dick, Le May, Labinaz, So, Chong, Hibbert); CAPITAL Research Group (Di Santo, Harnett, Simard, Ramirez, Youssef, Moreland, Dick, Le May, Labinaz, So, Motazedian, Jung, Chong, Hibbert); Vascular Biology and Experimental Medicine Laboratory (Simard, Jung, Hibbert); Cardiovascular Research Methods Centre (Bernick, Wells), University of Ottawa Heart Institute; Department of Cellular and Molecular Medicine (Simard, Hibbert); Department of Radiology (Moreland); School of Epidemiology, Public Health and Preventive Medicine (Ramirez, Wells), University of Ottawa, Ottawa, Ont.; Division of Cardiovascular Medicine (Pourdjabbar), Sulpizio Cardiovascular Center, University of California, San Diego, CA; Icahn School of Medicine at Mount Sinai ( Chandrasekhar, Mehran), New York, NY
| | - Benjamin Hibbert
- Division of Cardiology (Di Santo, Harnett, Simard, Ramirez Pourdjabbar, Youssef, Dick, Le May, Labinaz, So, Chong, Hibbert); CAPITAL Research Group (Di Santo, Harnett, Simard, Ramirez, Youssef, Moreland, Dick, Le May, Labinaz, So, Motazedian, Jung, Chong, Hibbert); Vascular Biology and Experimental Medicine Laboratory (Simard, Jung, Hibbert); Cardiovascular Research Methods Centre (Bernick, Wells), University of Ottawa Heart Institute; Department of Cellular and Molecular Medicine (Simard, Hibbert); Department of Radiology (Moreland); School of Epidemiology, Public Health and Preventive Medicine (Ramirez, Wells), University of Ottawa, Ottawa, Ont.; Division of Cardiovascular Medicine (Pourdjabbar), Sulpizio Cardiovascular Center, University of California, San Diego, CA; Icahn School of Medicine at Mount Sinai ( Chandrasekhar, Mehran), New York, NY
| |
Collapse
|
42
|
Jung RG, Simard T, Di Santo P, Labinaz A, Moreland R, Duchez AC, Majeed K, Motazedian P, Rochman R, Jung Y, Hibbert B. Performance of plasminogen activator inhibitor-1 as a biomarker in patients undergoing coronary angiography: Analytical and biological considerations. Diab Vasc Dis Res 2019; 16:478-482. [PMID: 31064214 DOI: 10.1177/1479164119845123] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
Abstract
INTRODUCTION AND OBJECTIVE Target lesion failure continues to limit the efficacy of percutaneous coronary intervention despite advancements in stent design and medical therapy. Identification of biomarkers to risk stratify patients after percutaneous coronary intervention has the potential to focus therapies on cohorts with increased benefits. Plasminogen activator inhibitor-1 has been identified as a candidate biomarker. Herein, we evaluate biological variables which impact plasminogen activator inhibitor-1 levels and analytical characteristics which impact its utility as a biomarker in humans. METHODS Plasma plasminogen activator inhibitor-1 was measured in 689 patients undergoing coronary angiography. Plasminogen activator inhibitor-1 levels were measured. Clinical and procedural characteristics were collected in a prospective registry. RESULTS Plasma plasminogen activator inhibitor-1 analytical (CVa = 4.1%), intra-individual (CVi = 44.0%) and inter-individual (CVg = 118.6%) variations with reference change value of 122.3% were calculated. Plasminogen activator inhibitor-1 levels were elevated in patients with cardiovascular risk factors, including type 2 diabetes, pre-diabetes, smokers, obesity, hypertension, and daytime variation in procedure and blood draw. CONCLUSION Variation in plasma plasminogen activator inhibitor-1 levels is influenced by multiple biological and procedural characteristics. The performance of plasma plasminogen activator inhibitor-1 is consistent with biomarkers in clinical use (N-terminal pro-B-type natriuretic peptide and C-reactive protein) and its applicability is promising.
Collapse
Affiliation(s)
- Richard G Jung
- 1 CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, ON, Canada
- 2 Vascular Biology and Experimental Medicine Laboratory, University of Ottawa Heart Institute, Ottawa, ON, Canada
- 3 Department of Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada
| | - Trevor Simard
- 1 CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, ON, Canada
- 2 Vascular Biology and Experimental Medicine Laboratory, University of Ottawa Heart Institute, Ottawa, ON, Canada
- 3 Department of Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada
- 4 Division of Cardiology, University of Ottawa Heart Institute, Ottawa, ON, Canada
| | - Pietro Di Santo
- 1 CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, ON, Canada
- 2 Vascular Biology and Experimental Medicine Laboratory, University of Ottawa Heart Institute, Ottawa, ON, Canada
- 4 Division of Cardiology, University of Ottawa Heart Institute, Ottawa, ON, Canada
- 5 School of Epidemiology and Public Health, University of Ottawa, Ottawa, ON, Canada
| | - Alisha Labinaz
- 1 CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, ON, Canada
- 2 Vascular Biology and Experimental Medicine Laboratory, University of Ottawa Heart Institute, Ottawa, ON, Canada
| | - Robert Moreland
- 1 CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, ON, Canada
- 6 Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
| | - Anne-Claire Duchez
- 7 Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada
| | - Kamran Majeed
- 1 CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, ON, Canada
- 2 Vascular Biology and Experimental Medicine Laboratory, University of Ottawa Heart Institute, Ottawa, ON, Canada
- 4 Division of Cardiology, University of Ottawa Heart Institute, Ottawa, ON, Canada
- 8 University of Western Australia, Perth, WA, Australia
| | - Pouya Motazedian
- 1 CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, ON, Canada
- 9 Department of Medicine, Cumming School of Medicine, Calgary, AB, Canada
| | - Rebecca Rochman
- 1 CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, ON, Canada
- 2 Vascular Biology and Experimental Medicine Laboratory, University of Ottawa Heart Institute, Ottawa, ON, Canada
| | - Young Jung
- 10 Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada
| | - Benjamin Hibbert
- 1 CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, ON, Canada
- 2 Vascular Biology and Experimental Medicine Laboratory, University of Ottawa Heart Institute, Ottawa, ON, Canada
- 3 Department of Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada
- 4 Division of Cardiology, University of Ottawa Heart Institute, Ottawa, ON, Canada
| |
Collapse
|
43
|
Labinaz A, Marbach JA, Jung RG, Moreland R, Motazedian P, Di Santo P, Clancy AA, MacDonald Z, Simard T, Hibbert B, Ramirez FD. Female Authorship in Preclinical Cardiovascular Research: Temporal Trends and Influence on Experimental Design. ACTA ACUST UNITED AC 2019; 4:471-477. [PMID: 31468001 PMCID: PMC6712050 DOI: 10.1016/j.jacbts.2019.04.004] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2019] [Revised: 04/22/2019] [Accepted: 04/27/2019] [Indexed: 11/28/2022]
Abstract
In this analysis of 3,396 preclinical studies published in 5 leading cardiovascular journals over a 10-year period, women accounted for 24 ± 17% of authors per manuscript. Female authorship is increasing in preclinical cardiovascular science, but the proportions of articles with first and senior authors of different sex have remained unchanged, which suggests that segregation by sex in mentorship relationships exists and persists. In preclinical studies that reported the sex of the animals used, female authorship was positively associated with studying female animals, using animals of both sexes, and reporting sex-specific results, which are findings that persisted in adjusted and sensitivity analyses. Author sex was not associated with other measures of methodological rigor or with 60-month citation counts.
In this analysis of 3,396 preclinical cardiovascular studies, women were first, senior, and both first and senior authors in 41.3%, 20.7%, and 11.0% of the studies, respectively. Female authorship increased over a 10-year period. However, the proportion of studies with first and senior authors of differing sex was low and stable, suggesting that segregation by sex in mentorship relationships exists and persists. Female authors were more likely to consider sex as a biological variable, but author sex was not associated with other measures of experimental rigor or research impact, indicating that women’s underrepresentation was not due to differences in research capacity or impact.
Collapse
Affiliation(s)
- Alisha Labinaz
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.,Vascular Biology and Experimental Medicine Laboratory, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.,Faculty of Science, University of Ottawa, Ottawa, Ontario, Canada
| | - Jeffrey A Marbach
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.,Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Richard G Jung
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.,Vascular Biology and Experimental Medicine Laboratory, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.,Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Ontario, Canada.,Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada
| | - Robert Moreland
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.,Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
| | - Pouya Motazedian
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.,Department of Medicine, University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada
| | - Pietro Di Santo
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.,Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.,School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada
| | - Aisling A Clancy
- Department of Obstetrics and Gynecology, University of Ottawa, Ottawa, Ontario, Canada.,Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts
| | - Zachary MacDonald
- Department of Emergency Medicine, University of Ottawa, Ottawa, Ontario, Canada
| | - Trevor Simard
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.,Vascular Biology and Experimental Medicine Laboratory, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.,Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.,Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Ontario, Canada
| | - Benjamin Hibbert
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.,Vascular Biology and Experimental Medicine Laboratory, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.,Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.,Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Ontario, Canada
| | - F Daniel Ramirez
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.,Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.,School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada
| |
Collapse
|
44
|
Perry-Nguyen D, Jung RG, Labinaz A, Duchez AC, Dewidar O, Simard T, Karunakaran D, Majeed K, Sarathy K, Li R, Ramirez FD, Di Santo P, Rochman R, So D, Foin N, Hibbert B. Evaluation of an in vitro coronary stent thrombosis model for preclinical assessment. Platelets 2019; 31:167-173. [PMID: 30973035 DOI: 10.1080/09537104.2019.1595564] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
Stent thrombosis remains an infrequent but significant complication following percutaneous coronary intervention. Preclinical models to rapidly screen and validate therapeutic compounds for efficacy are lacking. Herein, we describe a reproducible, high throughput and cost-effective method to evaluate candidate therapeutics and devices for either treatment or propensity to develop stent thrombosis in an in vitro bench-top model. Increasing degree of stent malapposition (0.00 mm, 0.10 mm, 0.25 mm and 0.50 mm) was associated with increasing thrombosis and luminal area occlusion (4.1 ± 0.5%, 6.3 ± 0.5%, 19.7 ± 4.5%, and 92.6 ± 7.4%, p < 0.0001, respectively). Differences in stent design in the form of bare-metal, drug-eluting, and bioresorbable vascular scaffolds demonstrated differences in stent thrombus burden (14.7 ± 3.8% vs. 20.5 ± 3.1% vs. 86.8 ± 5.3%, p < 0.01, respectively). Finally, thrombus burden was significantly reduced when healthy blood samples were incubated with Heparin, ASA/Ticagrelor (DAPT), and Heparin+DAPT compared to control (DMSO) at 4.1 ± 0.6%, 6.9 ± 1.7%, 4.5 ± 1.2%, and 12.1 ± 1.8%, respectively (p < 0.01). The reported model produces high throughput reproducible thrombosis results across a spectrum of antithrombotic agents, stent design, and degrees of apposition. Importantly, performance recapitulates clinical observations of antiplatelet/antithrombotic regimens as well as device and deployment characteristics. Accordingly, this model may serve as a screening tool for candidate therapies in preclinical evaluation.
Collapse
Affiliation(s)
- Dylan Perry-Nguyen
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.,Vascular Biology and Experimental Medicine Laboratory, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.,Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada
| | - Richard G Jung
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.,Vascular Biology and Experimental Medicine Laboratory, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.,Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada.,Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Ontario, Canada
| | - Alisha Labinaz
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.,Vascular Biology and Experimental Medicine Laboratory, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.,Faculty of Science, University of Ottawa, Ottawa, Ontario, Canada
| | - Anne-Claire Duchez
- Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada
| | - Omar Dewidar
- Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada
| | - Trevor Simard
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.,Vascular Biology and Experimental Medicine Laboratory, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.,Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Ontario, Canada.,Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Denuja Karunakaran
- Vascular Biology and Experimental Medicine Laboratory, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Kamran Majeed
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.,Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Kiran Sarathy
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.,Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Ruonan Li
- School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, China
| | - F Daniel Ramirez
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.,Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.,School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada
| | - Pietro Di Santo
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.,Vascular Biology and Experimental Medicine Laboratory, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.,Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.,School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada
| | - Rebecca Rochman
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.,Vascular Biology and Experimental Medicine Laboratory, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Derek So
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.,Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Nicolas Foin
- National Heart Research Institute Singapore, National Heart Centre Singapore, Singapore
| | - Benjamin Hibbert
- CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.,Vascular Biology and Experimental Medicine Laboratory, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.,Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Ontario, Canada.,Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| |
Collapse
|
45
|
Jung RG, Motazedian P, Ramirez FD, Simard T, Di Santo P, Visintini S, Faraz MA, Labinaz A, Jung Y, Hibbert B. Association between plasminogen activator inhibitor-1 and cardiovascular events: a systematic review and meta-analysis. Thromb J 2018; 16:12. [PMID: 29991926 PMCID: PMC5987541 DOI: 10.1186/s12959-018-0166-4] [Citation(s) in RCA: 65] [Impact Index Per Article: 10.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2017] [Accepted: 03/05/2018] [Indexed: 12/17/2022] Open
Abstract
Background Small studies have implicated plasminogen activator inhibitor-1 (PAI-1) as a predictor of cardiovascular events; however, these findings have been inconsistent. We sought out to examine the potential role of PAI-1 as a marker for major adverse cardiovascular events (MACE). Methods We systematically reviewed all indexed studies examining the association between PAI-1 and MACE (defined as death, myocardial infarction, or cerebrovascular accident) or restenosis. EMBASE, Web of Science, Medline, and the Cochrane Library were searched through October 2016 to identify relevant studies, supplemented by letters to authors and review of citations. Studies reporting the results of PAI-1 antigen and/or activity levels in association with MACE in human subjects were included. Results Of 5961 articles screened, we identified 38 articles published between 1991 to 2016 that reported PAI-1 levels in 11,557 patients. In studies that examined PAI-1 antigen and activity levels, 15.1% and 29.6% of patients experienced MACE, respectively. Patients with MACE had higher PAI-1 antigen levels with a mean difference of 6.11 ng/mL (95% CI, 3.27-8.96). This finding was similar among patients with and without known coronary artery disease. Comparatively, studies that stratified by PAI-1 activity levels were not associated with MACE. In contrast, studies of coronary restenosis suggest PAI-1 antigen and activity levels are negatively associated with MACE. Conclusions Elevated plasma PAI-1 antigen levels are associated with MACE. Definitive studies are needed to ascertain if PAI-1 acts simply as a marker of risk or if it is indeed a bona fide therapeutic target. Electronic supplementary material The online version of this article (10.1186/s12959-018-0166-4) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Richard G Jung
- 1CAPITAL Research Group, University of Ottawa Heart Institute, 40 Ruskin Street, H-4238, Ottawa, ON K1Y 4W7 Canada.,2Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, ON Canada.,3Vascular Biology and Experimental Medicine Laboratory, University of Ottawa Heart Institute, Ottawa, ON Canada
| | - Pouya Motazedian
- 1CAPITAL Research Group, University of Ottawa Heart Institute, 40 Ruskin Street, H-4238, Ottawa, ON K1Y 4W7 Canada
| | - F Daniel Ramirez
- 1CAPITAL Research Group, University of Ottawa Heart Institute, 40 Ruskin Street, H-4238, Ottawa, ON K1Y 4W7 Canada.,4Division of Cardiology, University of Ottawa Heart Institute, Ottawa, ON Canada.,5School of Epidemiology, Public Health and Preventive Medicine, University of Ottawa, Ottawa, ON Canada
| | - Trevor Simard
- 1CAPITAL Research Group, University of Ottawa Heart Institute, 40 Ruskin Street, H-4238, Ottawa, ON K1Y 4W7 Canada.,2Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, ON Canada.,3Vascular Biology and Experimental Medicine Laboratory, University of Ottawa Heart Institute, Ottawa, ON Canada.,4Division of Cardiology, University of Ottawa Heart Institute, Ottawa, ON Canada
| | - Pietro Di Santo
- 1CAPITAL Research Group, University of Ottawa Heart Institute, 40 Ruskin Street, H-4238, Ottawa, ON K1Y 4W7 Canada.,4Division of Cardiology, University of Ottawa Heart Institute, Ottawa, ON Canada
| | - Sarah Visintini
- 6Berkman Library, University of Ottawa Heart Institute, Ottawa, ON Canada
| | - Mohammad Ali Faraz
- 1CAPITAL Research Group, University of Ottawa Heart Institute, 40 Ruskin Street, H-4238, Ottawa, ON K1Y 4W7 Canada
| | - Alisha Labinaz
- 1CAPITAL Research Group, University of Ottawa Heart Institute, 40 Ruskin Street, H-4238, Ottawa, ON K1Y 4W7 Canada
| | - Young Jung
- 7Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON Canada
| | - Benjamin Hibbert
- 1CAPITAL Research Group, University of Ottawa Heart Institute, 40 Ruskin Street, H-4238, Ottawa, ON K1Y 4W7 Canada.,2Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, ON Canada.,3Vascular Biology and Experimental Medicine Laboratory, University of Ottawa Heart Institute, Ottawa, ON Canada.,4Division of Cardiology, University of Ottawa Heart Institute, Ottawa, ON Canada
| |
Collapse
|
46
|
Di Santo P, Motazedian P, Jung RG, Simard T, Ramirez FD, Chong AY, Glover C, Hibbert B, Dwivedi G. Evaluation of Cobalt and Chromium Levels Following Implantation of Cobalt Chromium Coronary Stents: A Pilot Study. Heart Lung Circ 2018; 27:763-766. [DOI: 10.1016/j.hlc.2017.12.002] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2017] [Accepted: 12/03/2017] [Indexed: 10/18/2022]
|
47
|
Jung RG, Simard T, Labinaz A, Ramirez FD, Di Santo P, Motazedian P, Rochman R, Gaudet C, Faraz MA, Beanlands RS, Hibbert B. Role of plasminogen activator inhibitor-1 in coronary pathophysiology. Thromb Res 2018; 164:54-62. [DOI: 10.1016/j.thromres.2018.02.135] [Citation(s) in RCA: 25] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2017] [Revised: 02/03/2018] [Accepted: 02/15/2018] [Indexed: 01/13/2023]
|
48
|
Ramirez FD, Motazedian P, Jung RG, Di Santo P, MacDonald ZD, Moreland R, Simard T, Clancy AA, Russo JJ, Welch VA, Wells GA, Hibbert B. Methodological Rigor in Preclinical Cardiovascular Studies: Targets to Enhance Reproducibility and Promote Research Translation. Circ Res 2017; 120:1916-1926. [PMID: 28373349 PMCID: PMC5466021 DOI: 10.1161/circresaha.117.310628] [Citation(s) in RCA: 105] [Impact Index Per Article: 15.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/12/2017] [Revised: 03/11/2017] [Accepted: 03/31/2017] [Indexed: 01/13/2023]
Abstract
RATIONALE Methodological sources of bias and suboptimal reporting contribute to irreproducibility in preclinical science and may negatively affect research translation. Randomization, blinding, sample size estimation, and considering sex as a biological variable are deemed crucial study design elements to maximize the quality and predictive value of preclinical experiments. OBJECTIVE To examine the prevalence and temporal patterns of recommended study design element implementation in preclinical cardiovascular research. METHODS AND RESULTS All articles published over a 10-year period in 5 leading cardiovascular journals were reviewed. Reports of in vivo experiments in nonhuman mammals describing pathophysiology, genetics, or therapeutic interventions relevant to specific cardiovascular disorders were identified. Data on study design and animal model use were collected. Citations at 60 months were additionally examined as a surrogate measure of research impact in a prespecified subset of studies, stratified by individual and cumulative study design elements. Of 28 636 articles screened, 3396 met inclusion criteria. Randomization was reported in 21.8%, blinding in 32.7%, and sample size estimation in 2.3%. Temporal and disease-specific analyses show that the implementation of these study design elements has overall not appreciably increased over the past decade, except in preclinical stroke research, which has uniquely demonstrated significant improvements in methodological rigor. In a subset of 1681 preclinical studies, randomization, blinding, sample size estimation, and inclusion of both sexes were not associated with increased citations at 60 months. CONCLUSIONS Methodological shortcomings are prevalent in preclinical cardiovascular research, have not substantially improved over the past 10 years, and may be overlooked when basing subsequent studies. Resultant risks of bias and threats to study validity have the potential to hinder progress in cardiovascular medicine as preclinical research often precedes and informs clinical trials. Stroke research quality has uniquely improved in recent years, warranting a closer examination for interventions to model in other cardiovascular fields.
Collapse
Affiliation(s)
- F Daniel Ramirez
- From the Division of Cardiology (F.D.R., P.M., R.G.J., P.D.S., T.S., J.J.R., B.H.), CAPITAL Research Group (F.D.R., P.M., R.G.J., P.D.S., Z.D.M.D., R.M., T.S., J.J.R., B.H.), Vascular Biology and Experimental Medicine Laboratory (R.G.J., T.S., B.H.), and Cardiovascular Research Methods Centre (G.A.W.), University of Ottawa Heart Institute, Ontario, Canada; and School of Epidemiology, Public Health and Preventive Medicine (F.D.R., V.A.W., G.A.W.), Department of Cellular and Molecular Medicine (R.G.J., T.S., B.H.), Department of Radiology (R.M.), Department of Obstetrics and Gynecology (A.A.C.), Bruyère Research Institute (V.A.W.), and Centre for Global Health (V.A.W.), University of Ottawa, Ontario, Canada
| | - Pouya Motazedian
- From the Division of Cardiology (F.D.R., P.M., R.G.J., P.D.S., T.S., J.J.R., B.H.), CAPITAL Research Group (F.D.R., P.M., R.G.J., P.D.S., Z.D.M.D., R.M., T.S., J.J.R., B.H.), Vascular Biology and Experimental Medicine Laboratory (R.G.J., T.S., B.H.), and Cardiovascular Research Methods Centre (G.A.W.), University of Ottawa Heart Institute, Ontario, Canada; and School of Epidemiology, Public Health and Preventive Medicine (F.D.R., V.A.W., G.A.W.), Department of Cellular and Molecular Medicine (R.G.J., T.S., B.H.), Department of Radiology (R.M.), Department of Obstetrics and Gynecology (A.A.C.), Bruyère Research Institute (V.A.W.), and Centre for Global Health (V.A.W.), University of Ottawa, Ontario, Canada
| | - Richard G Jung
- From the Division of Cardiology (F.D.R., P.M., R.G.J., P.D.S., T.S., J.J.R., B.H.), CAPITAL Research Group (F.D.R., P.M., R.G.J., P.D.S., Z.D.M.D., R.M., T.S., J.J.R., B.H.), Vascular Biology and Experimental Medicine Laboratory (R.G.J., T.S., B.H.), and Cardiovascular Research Methods Centre (G.A.W.), University of Ottawa Heart Institute, Ontario, Canada; and School of Epidemiology, Public Health and Preventive Medicine (F.D.R., V.A.W., G.A.W.), Department of Cellular and Molecular Medicine (R.G.J., T.S., B.H.), Department of Radiology (R.M.), Department of Obstetrics and Gynecology (A.A.C.), Bruyère Research Institute (V.A.W.), and Centre for Global Health (V.A.W.), University of Ottawa, Ontario, Canada
| | - Pietro Di Santo
- From the Division of Cardiology (F.D.R., P.M., R.G.J., P.D.S., T.S., J.J.R., B.H.), CAPITAL Research Group (F.D.R., P.M., R.G.J., P.D.S., Z.D.M.D., R.M., T.S., J.J.R., B.H.), Vascular Biology and Experimental Medicine Laboratory (R.G.J., T.S., B.H.), and Cardiovascular Research Methods Centre (G.A.W.), University of Ottawa Heart Institute, Ontario, Canada; and School of Epidemiology, Public Health and Preventive Medicine (F.D.R., V.A.W., G.A.W.), Department of Cellular and Molecular Medicine (R.G.J., T.S., B.H.), Department of Radiology (R.M.), Department of Obstetrics and Gynecology (A.A.C.), Bruyère Research Institute (V.A.W.), and Centre for Global Health (V.A.W.), University of Ottawa, Ontario, Canada
| | - Zachary D MacDonald
- From the Division of Cardiology (F.D.R., P.M., R.G.J., P.D.S., T.S., J.J.R., B.H.), CAPITAL Research Group (F.D.R., P.M., R.G.J., P.D.S., Z.D.M.D., R.M., T.S., J.J.R., B.H.), Vascular Biology and Experimental Medicine Laboratory (R.G.J., T.S., B.H.), and Cardiovascular Research Methods Centre (G.A.W.), University of Ottawa Heart Institute, Ontario, Canada; and School of Epidemiology, Public Health and Preventive Medicine (F.D.R., V.A.W., G.A.W.), Department of Cellular and Molecular Medicine (R.G.J., T.S., B.H.), Department of Radiology (R.M.), Department of Obstetrics and Gynecology (A.A.C.), Bruyère Research Institute (V.A.W.), and Centre for Global Health (V.A.W.), University of Ottawa, Ontario, Canada
| | - Robert Moreland
- From the Division of Cardiology (F.D.R., P.M., R.G.J., P.D.S., T.S., J.J.R., B.H.), CAPITAL Research Group (F.D.R., P.M., R.G.J., P.D.S., Z.D.M.D., R.M., T.S., J.J.R., B.H.), Vascular Biology and Experimental Medicine Laboratory (R.G.J., T.S., B.H.), and Cardiovascular Research Methods Centre (G.A.W.), University of Ottawa Heart Institute, Ontario, Canada; and School of Epidemiology, Public Health and Preventive Medicine (F.D.R., V.A.W., G.A.W.), Department of Cellular and Molecular Medicine (R.G.J., T.S., B.H.), Department of Radiology (R.M.), Department of Obstetrics and Gynecology (A.A.C.), Bruyère Research Institute (V.A.W.), and Centre for Global Health (V.A.W.), University of Ottawa, Ontario, Canada
| | - Trevor Simard
- From the Division of Cardiology (F.D.R., P.M., R.G.J., P.D.S., T.S., J.J.R., B.H.), CAPITAL Research Group (F.D.R., P.M., R.G.J., P.D.S., Z.D.M.D., R.M., T.S., J.J.R., B.H.), Vascular Biology and Experimental Medicine Laboratory (R.G.J., T.S., B.H.), and Cardiovascular Research Methods Centre (G.A.W.), University of Ottawa Heart Institute, Ontario, Canada; and School of Epidemiology, Public Health and Preventive Medicine (F.D.R., V.A.W., G.A.W.), Department of Cellular and Molecular Medicine (R.G.J., T.S., B.H.), Department of Radiology (R.M.), Department of Obstetrics and Gynecology (A.A.C.), Bruyère Research Institute (V.A.W.), and Centre for Global Health (V.A.W.), University of Ottawa, Ontario, Canada
| | - Aisling A Clancy
- From the Division of Cardiology (F.D.R., P.M., R.G.J., P.D.S., T.S., J.J.R., B.H.), CAPITAL Research Group (F.D.R., P.M., R.G.J., P.D.S., Z.D.M.D., R.M., T.S., J.J.R., B.H.), Vascular Biology and Experimental Medicine Laboratory (R.G.J., T.S., B.H.), and Cardiovascular Research Methods Centre (G.A.W.), University of Ottawa Heart Institute, Ontario, Canada; and School of Epidemiology, Public Health and Preventive Medicine (F.D.R., V.A.W., G.A.W.), Department of Cellular and Molecular Medicine (R.G.J., T.S., B.H.), Department of Radiology (R.M.), Department of Obstetrics and Gynecology (A.A.C.), Bruyère Research Institute (V.A.W.), and Centre for Global Health (V.A.W.), University of Ottawa, Ontario, Canada
| | - Juan J Russo
- From the Division of Cardiology (F.D.R., P.M., R.G.J., P.D.S., T.S., J.J.R., B.H.), CAPITAL Research Group (F.D.R., P.M., R.G.J., P.D.S., Z.D.M.D., R.M., T.S., J.J.R., B.H.), Vascular Biology and Experimental Medicine Laboratory (R.G.J., T.S., B.H.), and Cardiovascular Research Methods Centre (G.A.W.), University of Ottawa Heart Institute, Ontario, Canada; and School of Epidemiology, Public Health and Preventive Medicine (F.D.R., V.A.W., G.A.W.), Department of Cellular and Molecular Medicine (R.G.J., T.S., B.H.), Department of Radiology (R.M.), Department of Obstetrics and Gynecology (A.A.C.), Bruyère Research Institute (V.A.W.), and Centre for Global Health (V.A.W.), University of Ottawa, Ontario, Canada
| | - Vivian A Welch
- From the Division of Cardiology (F.D.R., P.M., R.G.J., P.D.S., T.S., J.J.R., B.H.), CAPITAL Research Group (F.D.R., P.M., R.G.J., P.D.S., Z.D.M.D., R.M., T.S., J.J.R., B.H.), Vascular Biology and Experimental Medicine Laboratory (R.G.J., T.S., B.H.), and Cardiovascular Research Methods Centre (G.A.W.), University of Ottawa Heart Institute, Ontario, Canada; and School of Epidemiology, Public Health and Preventive Medicine (F.D.R., V.A.W., G.A.W.), Department of Cellular and Molecular Medicine (R.G.J., T.S., B.H.), Department of Radiology (R.M.), Department of Obstetrics and Gynecology (A.A.C.), Bruyère Research Institute (V.A.W.), and Centre for Global Health (V.A.W.), University of Ottawa, Ontario, Canada
| | - George A Wells
- From the Division of Cardiology (F.D.R., P.M., R.G.J., P.D.S., T.S., J.J.R., B.H.), CAPITAL Research Group (F.D.R., P.M., R.G.J., P.D.S., Z.D.M.D., R.M., T.S., J.J.R., B.H.), Vascular Biology and Experimental Medicine Laboratory (R.G.J., T.S., B.H.), and Cardiovascular Research Methods Centre (G.A.W.), University of Ottawa Heart Institute, Ontario, Canada; and School of Epidemiology, Public Health and Preventive Medicine (F.D.R., V.A.W., G.A.W.), Department of Cellular and Molecular Medicine (R.G.J., T.S., B.H.), Department of Radiology (R.M.), Department of Obstetrics and Gynecology (A.A.C.), Bruyère Research Institute (V.A.W.), and Centre for Global Health (V.A.W.), University of Ottawa, Ontario, Canada
| | - Benjamin Hibbert
- From the Division of Cardiology (F.D.R., P.M., R.G.J., P.D.S., T.S., J.J.R., B.H.), CAPITAL Research Group (F.D.R., P.M., R.G.J., P.D.S., Z.D.M.D., R.M., T.S., J.J.R., B.H.), Vascular Biology and Experimental Medicine Laboratory (R.G.J., T.S., B.H.), and Cardiovascular Research Methods Centre (G.A.W.), University of Ottawa Heart Institute, Ontario, Canada; and School of Epidemiology, Public Health and Preventive Medicine (F.D.R., V.A.W., G.A.W.), Department of Cellular and Molecular Medicine (R.G.J., T.S., B.H.), Department of Radiology (R.M.), Department of Obstetrics and Gynecology (A.A.C.), Bruyère Research Institute (V.A.W.), and Centre for Global Health (V.A.W.), University of Ottawa, Ontario, Canada.
| |
Collapse
|
49
|
Ramirez FD, Motazedian P, Jung RG, Di Santo P, MacDonald Z, Simard T, Clancy AA, Russo JJ, Welch V, Wells GA, Hibbert B. Sex Bias Is Increasingly Prevalent in Preclinical Cardiovascular Research: Implications for Translational Medicine and Health Equity for Women. Circulation 2017; 135:625-626. [DOI: 10.1161/circulationaha.116.026668] [Citation(s) in RCA: 38] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Affiliation(s)
- F. Daniel Ramirez
- From Division of Cardiology, University of Ottawa Heart Institute, ON, Canada (F.D.R., P.D.S., T.S., J.J.R., B.H.); CAPITAL Research Group, University of Ottawa Heart Institute, ONT, Canada (F.D.R., P.M., R.G.J., P.D.S., Z.M., T.S., J.J.R., B.H.); School of Epidemiology, Public Health and Preventive Medicine, University of Ottawa, ONT, Canada (F.D.R., V.W., G.A.W.); Vascular Biology and Experimental Medicine Laboratory, University of Ottawa Heart Institute, ONT, Canada (R.G.J., T.S., B.H.)
| | - Pouya Motazedian
- From Division of Cardiology, University of Ottawa Heart Institute, ON, Canada (F.D.R., P.D.S., T.S., J.J.R., B.H.); CAPITAL Research Group, University of Ottawa Heart Institute, ONT, Canada (F.D.R., P.M., R.G.J., P.D.S., Z.M., T.S., J.J.R., B.H.); School of Epidemiology, Public Health and Preventive Medicine, University of Ottawa, ONT, Canada (F.D.R., V.W., G.A.W.); Vascular Biology and Experimental Medicine Laboratory, University of Ottawa Heart Institute, ONT, Canada (R.G.J., T.S., B.H.)
| | - Richard G. Jung
- From Division of Cardiology, University of Ottawa Heart Institute, ON, Canada (F.D.R., P.D.S., T.S., J.J.R., B.H.); CAPITAL Research Group, University of Ottawa Heart Institute, ONT, Canada (F.D.R., P.M., R.G.J., P.D.S., Z.M., T.S., J.J.R., B.H.); School of Epidemiology, Public Health and Preventive Medicine, University of Ottawa, ONT, Canada (F.D.R., V.W., G.A.W.); Vascular Biology and Experimental Medicine Laboratory, University of Ottawa Heart Institute, ONT, Canada (R.G.J., T.S., B.H.)
| | - Pietro Di Santo
- From Division of Cardiology, University of Ottawa Heart Institute, ON, Canada (F.D.R., P.D.S., T.S., J.J.R., B.H.); CAPITAL Research Group, University of Ottawa Heart Institute, ONT, Canada (F.D.R., P.M., R.G.J., P.D.S., Z.M., T.S., J.J.R., B.H.); School of Epidemiology, Public Health and Preventive Medicine, University of Ottawa, ONT, Canada (F.D.R., V.W., G.A.W.); Vascular Biology and Experimental Medicine Laboratory, University of Ottawa Heart Institute, ONT, Canada (R.G.J., T.S., B.H.)
| | - Zachary MacDonald
- From Division of Cardiology, University of Ottawa Heart Institute, ON, Canada (F.D.R., P.D.S., T.S., J.J.R., B.H.); CAPITAL Research Group, University of Ottawa Heart Institute, ONT, Canada (F.D.R., P.M., R.G.J., P.D.S., Z.M., T.S., J.J.R., B.H.); School of Epidemiology, Public Health and Preventive Medicine, University of Ottawa, ONT, Canada (F.D.R., V.W., G.A.W.); Vascular Biology and Experimental Medicine Laboratory, University of Ottawa Heart Institute, ONT, Canada (R.G.J., T.S., B.H.)
| | - Trevor Simard
- From Division of Cardiology, University of Ottawa Heart Institute, ON, Canada (F.D.R., P.D.S., T.S., J.J.R., B.H.); CAPITAL Research Group, University of Ottawa Heart Institute, ONT, Canada (F.D.R., P.M., R.G.J., P.D.S., Z.M., T.S., J.J.R., B.H.); School of Epidemiology, Public Health and Preventive Medicine, University of Ottawa, ONT, Canada (F.D.R., V.W., G.A.W.); Vascular Biology and Experimental Medicine Laboratory, University of Ottawa Heart Institute, ONT, Canada (R.G.J., T.S., B.H.)
| | - Aisling A. Clancy
- From Division of Cardiology, University of Ottawa Heart Institute, ON, Canada (F.D.R., P.D.S., T.S., J.J.R., B.H.); CAPITAL Research Group, University of Ottawa Heart Institute, ONT, Canada (F.D.R., P.M., R.G.J., P.D.S., Z.M., T.S., J.J.R., B.H.); School of Epidemiology, Public Health and Preventive Medicine, University of Ottawa, ONT, Canada (F.D.R., V.W., G.A.W.); Vascular Biology and Experimental Medicine Laboratory, University of Ottawa Heart Institute, ONT, Canada (R.G.J., T.S., B.H.)
| | - Juan J. Russo
- From Division of Cardiology, University of Ottawa Heart Institute, ON, Canada (F.D.R., P.D.S., T.S., J.J.R., B.H.); CAPITAL Research Group, University of Ottawa Heart Institute, ONT, Canada (F.D.R., P.M., R.G.J., P.D.S., Z.M., T.S., J.J.R., B.H.); School of Epidemiology, Public Health and Preventive Medicine, University of Ottawa, ONT, Canada (F.D.R., V.W., G.A.W.); Vascular Biology and Experimental Medicine Laboratory, University of Ottawa Heart Institute, ONT, Canada (R.G.J., T.S., B.H.)
| | - Vivian Welch
- From Division of Cardiology, University of Ottawa Heart Institute, ON, Canada (F.D.R., P.D.S., T.S., J.J.R., B.H.); CAPITAL Research Group, University of Ottawa Heart Institute, ONT, Canada (F.D.R., P.M., R.G.J., P.D.S., Z.M., T.S., J.J.R., B.H.); School of Epidemiology, Public Health and Preventive Medicine, University of Ottawa, ONT, Canada (F.D.R., V.W., G.A.W.); Vascular Biology and Experimental Medicine Laboratory, University of Ottawa Heart Institute, ONT, Canada (R.G.J., T.S., B.H.)
| | - George A. Wells
- From Division of Cardiology, University of Ottawa Heart Institute, ON, Canada (F.D.R., P.D.S., T.S., J.J.R., B.H.); CAPITAL Research Group, University of Ottawa Heart Institute, ONT, Canada (F.D.R., P.M., R.G.J., P.D.S., Z.M., T.S., J.J.R., B.H.); School of Epidemiology, Public Health and Preventive Medicine, University of Ottawa, ONT, Canada (F.D.R., V.W., G.A.W.); Vascular Biology and Experimental Medicine Laboratory, University of Ottawa Heart Institute, ONT, Canada (R.G.J., T.S., B.H.)
| | - Benjamin Hibbert
- From Division of Cardiology, University of Ottawa Heart Institute, ON, Canada (F.D.R., P.D.S., T.S., J.J.R., B.H.); CAPITAL Research Group, University of Ottawa Heart Institute, ONT, Canada (F.D.R., P.M., R.G.J., P.D.S., Z.M., T.S., J.J.R., B.H.); School of Epidemiology, Public Health and Preventive Medicine, University of Ottawa, ONT, Canada (F.D.R., V.W., G.A.W.); Vascular Biology and Experimental Medicine Laboratory, University of Ottawa Heart Institute, ONT, Canada (R.G.J., T.S., B.H.)
| |
Collapse
|
50
|
Mallozzi PJ, Epstein HM, Jung RG, Applebaum DC, Fairand BP, Gallagher WJ, Campbell BE. Current status of laser fusion research at Battelle. Ann N Y Acad Sci 1976; 267:126-34. [PMID: 1064348 DOI: 10.1111/j.1749-6632.1976.tb41603.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
|